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 i 
 
Abstract 
 
The complement system provides an essential role in the orchestration of an 
effective immune response against microbial infection.  Activation leads to the 
generation of C5a which activates receptors expressed on immune cells promoting 
microbial clearance.  Dysregulation of the complement system that results in the 
excessive production of C5a can lead to host tissue damage.  This has fuelled drug 
discovery efforts to therapeutically block the actions of C5a to treat diseases 
associated with dysregulation of the complement system.  C5a is rapidly degraded to 
C5a des Arg, a mechanism which is considered to inactivate its effector functions, 
however, there is incomplete understanding of precise functions of C5a and C5a des 
Arg on the cognate C5a receptors, C5a1 and C5a2. The research conducted here 
attempted to improve upon this understanding as well as fuel future drug discovery 
efforts that target this component of the complement system. 
Functional assays using human isolated neutrophils or engineered cell lines along 
with C5a1 and C5a2 receptor selective antagonists were employed to assess the 
contribution of each C5a receptor to functional responses elicited by human purified 
C5a and C5a des Arg.  For each functional endpoint investigated, the relative activity 
of C5a des Arg was compared with C5a using the Log(Emax/EC50) transformation.  
Single point mutagenesis was performed on the C5a1 receptor to relate differences in 
agonist functional activity to mode of agonist binding. 
The data presented here supports the hypothesis that C5a des Arg behaves as a 
biased agonist in relation to C5a.  Via the C5a1 receptor, C5a des Arg produces 
neutrophil phenotypes that are involved in the orchestration of immune cell 
recruitment to sites of infection.  However, unlike C5a, C5a des Arg does not induce a 
respiratory burst response that leads to the generation of hypochlorous acid.  The 
biased agonism of C5a des Arg appears to be brought about by its inability to interact 
with amino acid residues within the seventh transmembrane domain of the C5a1 
receptor, which prevents the receptor recruitment of -arrestins.  Furthermore, data 
presented here also show that the C5a2 receptor does not directly contribute to C5a 
 ii 
 
or C5a des Arg mediated activation of the human isolated neutrophil.  Taken 
together, the data support a hypothesis whereby the generation of C5a des Arg, 
through C5a1 receptor, limits the ability of C5a to promote the production of 
potentially damaging respiratory burst while still enabling immune cell extravasation. 
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1. Introduction 
 
Multicellular organisms have developed highly sophisticated defence mechanisms to 
combat the effects of pathogens and microbial infection that threaten normal 
homeostasis.  These defence mechanisms are collectively known as the immune 
system and consist of a complex network of cells and chemical mediators, each with 
a specialized role to defend against microbial infection (Delves et al., 2000). 
For an infection to occur, a microbe must first breach the organism’s anatomical 
barriers that face the external environment and subsequently evade destruction by 
host derived antimicrobial substances located on or within these physical surfaces.  If 
entry is successful, the microbe will encounter the next level of defence, the immune 
system which can be broadly divided into two components depending on the speed 
and specificity of the response that is launched (Parkin et al., 2001).  The rapidly 
responding innate immune system launches an immediate assault through the 
recognition of generic microbial patterns.  In contrast, the adaptive immune system, 
although slower to respond, delivers a tailored response to specific microbial 
antigens, a response which becomes imprinted within the memory of the immune 
system (figure 1.1). 
The innate immune system consists of cells of myeloid origin which possess 
germline-encoded receptors which detect highly conserved molecular patterns that 
are shared by a broad set of pathogenic microbes.  Activation of these pattern 
recognition receptors (PRRs) by pathogen associated molecular patterns (PAMPs) 
orchestrates microbial clearance by promoting an inflammatory response.  Basophils, 
mast cells and eosinophils release inflammatory mediators, including cytokines, 
which promote the activation and recruitment of effector cells including 
macrophages, monocytes, neutrophils and natural killer cells which phagocytose and 
destroy the microbe, restoring sterility (Janeway et al., 2002).   
The adaptive immune system consists of cells of lymphoid origin including T and B 
lymphocytes. Unlike the cells of the innate immune system, lymphocytes are not 
preprogramed to respond to generic pathogen associated molecular patterns.  
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Instead each lymphocyte expresses a unique antigen specific receptor which was 
somatically generated by the random rearrangement of genes encoding the variable 
region of these receptors.  B cells are responsible for the humoral adaptive response 
involving the production of highly specific antibodies while T cells are responsible for 
the cell-mediated adaptive response.  Although this random generation of receptors 
leads to the detection of an almost infinite number of antigens, these receptors 
alone, unlike those of the innate immune system, are unable to determine the origin 
of their ligands.  This biological context is provided by antigen presenting cells 
(dendritic cells and macrophages) which present self and non-self antigens to T cells 
using the major histocompatibility complex (MHC) class of proteins along with either 
co-stimulatory or co-inhibitory signal.  T-cell activation leads to the clonal expansion 
of that T-cell, orchestration of antigen specific antibody production from B-cells and 
results in long term immunological memory to that antigen (Janeway, 2001). 
The key attributes of an effective immune response are discrimination between 
foreign and self surfaces and the speed of the response, so that an infection is 
adequately contained. Although the cellular components of the immune system 
produce an antimicrobial response within minutes to hours of an infection occurring, 
there is a component of the innate immune system which has the ability to respond 
within seconds.  This immediately acting element is known as the complement 
system.  An evolutionary conserved stalwart of the innate immune system, its routes 
can be traced as far back as echinoderms with origins over 600 million years ago 
(Smith et al., 1996).  This facet of the innate immune system consists of a tightly 
regulated network of proteins that orchestrate the rapid clearance of pathogens by 
opsonisation, recruiting phagocytic cells to the site of infection and inducing the 
rapid lysis of microbes through the complement derived membrane attack complex 
(MAC) (Patel et al., 1987). 
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Figure 1.1. Components of the innate and adaptive immune responses 
The immune system can be broken down into two components based on the speed and specificity of 
the response that is launched.  The rapid and generic innate immune response is orchestrated by cells 
of myeloid origin which include monocytes, macrophages, dendritic cells, basophils, eosinophils, 
neutrophils and natural killer cells.  The innate immune response also includes the complement 
system which consists of a network of soluble and membrane bound proteins that facilitate the 
actions of the innate immune response.  The adaptive immune response, which is slower to respond, 
launches a tailored, specific immune response with memory.  It consists of cells of lymphoid origin 
including B cells which release antigen specific antibodies and CD4
+
 and CD8
+
 T cells which possess 
antigen specific receptors.  Natural killer T cells, which share properties of both natural killer cells and 
T cells, contribute to both innate and adaptive immune responses.  Figure recreated from Dranoff 
(2004). 
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1.1. Overview of the complement system 
 
The discovery of the complement system is attributed to a Belgian scientist, Jules 
Bordet, who, while working at the Pasteur Institute in the late 1890’s, demonstrated 
that bacteriolysis only occurred in the presence of two serum factors.  A thermo-
stable factor present in the serum of immunized animals (antibodies), and a thermo-
labile factor that had been earlier discovered and named Alexin (Greek - ‘to ward 
off’) by Hans Buchner (Morrison, 1922).  Later the term Komplement, originally 
coined by Paul Ehrlich, the renowned German physician scientist, gained greater 
traction among research scientists and has survived to this day in its anglicized form, 
complement (Kaufmann, 2008).  Nonetheless, it would be several decades before 
scientists realized that complement exists as a complex mixture of labile and stable 
constituents that act in succession to induce an immune response. 
The complement system is now recognized to comprise more than 30 soluble plasma 
proteins and glycoproteins as well as membrane bound receptors and regulatory 
proteins (Walport, 2001).  A number of these proteins exhibit protease activity but 
are secreted as inactive zymogens that are activated locally, at sites of infection.  
These, in turn, cleave and activate other complement zymogens to trigger a series of 
potent pro-inflammatory events.  This triggered response, which is initiated by the 
activation of a small number of complement proteins at the start of the pathway, 
leads to an amplification of enzymatic activity at each successive stage, resulting in 
the rapid generation of a disproportionately large inflammatory response.  
Ultimately, a set of complement effector proteins are produced that can 1) opsonize 
pathogens for uptake by phagocytes, 2) cause direct lysis of cells through the 
assembly of a membrane attack complex (MAC) or 3) recruit additional phagocytic 
cells to the site of infection through the chemoattractant properties of certain 
liberated complement peptides (McCaughan et al., 2013). 
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1.2. The pathways of complement activation 
 
The complement system consists of a set of inactive proteins that are sequentially 
linked in a cascading manner.  Upon stimulation of the complement system, 
zymogens become active, causing the cleavage of substrates which yield effector 
molecules and opsonisation factors, leading to the activation of the next enzyme in 
the cascade.  Activation of the complement system occurs through three main 
pathways: 1) the classical pathway activated by antigen-antibody complexes and so 
named because it was the first complement activation pathway to be described in 
detail (Dodds, 2002), 2) the lectin-binding pathway, initially described in the 1980’s 
by Kawakami et al. (1982) that is initiated by soluble carbohydrate-binding proteins 
and 3) the alternative pathway, that is initiated by spontaneous hydrolysis and 
activation of the complement component C3 (Pillemer et al., 1954) (figure 1.2).  Since 
complement activation occurs in a sequential manner, involving proteins that are 
secreted as inactive zymogens, the system is finely tuned to rapidly and selectively 
activate at sites of pathogen invasion (Sarma et al., 2011).  This sequential manner of 
complement system activation can be divided into 4 main steps: 1) initiation of 
complement activation, 2) generation of C3 convertase and system amplification, 3) 
generation of C5 convertase leading to the production of C5a and 4) terminal 
pathway activity producing the MAC (Zipfel et al., 2009).  Although activation of the 
complement system leads to the indiscriminate delivery of effector molecules to 
both host and microbial surfaces, system amplification is tightly controlled by a series 
of regulatory and inhibitory proteins (figure 1.2). 
While the initial activation of each pathway occurs via a different mechanism, all 
three pathways converge at the point of C3 convertase as highlighted below. 
 
1.2.1. The Classical pathway 
 
The classical activation pathway, so named because it was the first complement 
pathway to be discovered, is built upon nine central components, C1-9 which were 
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numbered in the order in which they were discovered and not the order in which 
they feature in the system.  It is primarily activated through the binding of the C1q 
protein to a pathogen surface or to antigen bound immunoglobulin (Ig) IgG or IgM.  
The tail of the C1q protein binds two copies of the serine proteases C1r and C1s 
which, together, form the C1 complex.  Binding to antigen bound antibody induces a 
conformational change in C1q which activates C1r.  C1r then cleaves C1s to generate 
an active serine protease which splits C4 into a smaller C4a fragment and a larger 
C4b fragment (Lorincz et al., 2000).  C4b, which contains a labile thioester bond, 
subsequently attaches to the pathogen surface (Law et al., 1997).  The C2 protein 
binds to C4b and is split by the C1 complex.  The smaller fragment, C2b, dissociates 
leaving C2a bound to C4b generating the classical pathway C3 convertase, C4bC2a. 
The nomenclature of the proteins that make up the classical pathway C3 convertase 
can often cause confusion.  This comes from the inconsistency in the designation of 
the fragments of the C2 protein.  The smaller of the two fragments generated from 
the cleavage of C3, C4 and C5 is typically given the designation ‘a’ and the larger ‘b’ 
however this nomenclature is not maintained in the naming of the C2 fragments.   
The cleavage of C2 by activated C1s was first demonstrated by Stroud et al. (1966) 
with guinea pig C2 and Muller-Eberhard et al. (1967) with human C2.  Since their 
initial attempts failed to detect the smaller C2 fragment, the designation of C2a was 
given to the detected cleaved protein.  Further work by Nagasawa et al. (1977) and 
Kerr et al. (1978) saw the successful identification of both large and small fragments 
of the cleaved C2 protein with apparent molecular weights of 74,000 and 34,000 Da 
respectively.  Remaining consistent with the previous nomenclature of C2a, the 
smaller identified fragment was referred to as C2b.  However, both C4bC2a and 
C4bC2b are frequently used to refer to the classical C3 convertase and there does 
not seem to be correlation between naming convention and the author’s 
geographical location. Throughout the remainder of this thesis I will use the original 
nomenclature for the classical complement system C3 convertase of C4bC2a. 
C3 convertase cleaves C3 into two fragments.  The smaller fragment, C3a, acts as a 
potent anaphylatoxin via activating the cell surface C3a receptor, while the larger 
C3b fragment acts as an opsonin.  Through the transient exposure of a reactive 
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thioester bond, C3b covalently binds to hydroxyl groups present on cell surfaces, 
immune complexes and complex carbohydrates.  Microorganisms decorated with 
C3b are detected by phagocytic cells via the complement receptors, engulfed and 
then destroyed.  If no covalent bond is formed, the thioester is rapidly hydrolysed 
resulting in the inactivation of C3b (Sahu et al., 2001). 
As well as its opsonisation function, C3b also complexes with the previously formed 
C3 convertase to produce the multimeric complex, C5 convertase (C4bC2aC3b) 
(Pangburn et al., 2002).  C5 convertase cleaves C5 to yield the small peptide 
fragment, C5a and the large fragment C5b.  Like C3a, C5a is a potent anaphylatoxin 
which mediates an inflammatory response through binding and activating C5a 
receptors expressed on structural cells and cells of the immune system.  C5b initiates 
the late events of complement activation by complexing with complement proteins 
C6 and C7.  The C5bC6C7 scaffold contains hydrophobic phospholipid-binding sites 
and upon attachment to cellular membranes acts as a receptor for the subsequent 
binding of C8.  The tetramolecular complex containing C5bC6C7C8 induces the 
binding of several C9 monomers which polymerize to form the lytic pore known as 
the MAC.  The function of the MAC is to promote rapid microbial lysis. (Podack et al., 
1982; Muller-Eberhard, 1985). 
 
1.2.2. The Lectin pathway 
 
The lectin pathway is functionally similar to the classical pathway.  It is activated 
when conserved carbohydrates on the surfaces of pathogens are detected by a set of 
soluble pattern recognition molecules (PRMs).  These include members of the 
collectin family, such as mannose-binding lectin (MBL) and the ficolin family, 
including H-ficolin, L-ficolin and M-ficolin (Kjaer et al., 2013).  Collectins are 
characterized by a collagen-like region and a C-type carbohydrate recognition 
domain (CRD) in their C-terminus that specifically recognizes monosaccharides 
exposing OH groups, present in mannose.  Likewise, the polypeptide chain of ficolins 
contains a short N-terminal and a collagen-like domain, but in this case, the C-
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terminal recognition domain is a fibrinogen-like domain (FBG) instead of the CRD.  
The FBG has affinity for N-acetylated carbohydrate structures as seen in N-acetyl-D-
glucosamine (GlcNAc), but will also bind other acetylated molecules, such as 
acetylated-albumin or acetylated glycine (Lu et al., 2002).   
These PRMs associate with mannose binding lectin associated serine protease 
(MASP) family members, MASP-1, MASP-2 and MASP-3.  MASPs are secreted as 
inactive zymogens and bind to collectins and ficolins at which point they become 
activated.  Although MASP-1 cannot initiate the lectin pathway on its own, it plays a 
crucial role in the activation of MASP-2 which, in turn cleaves C4 into C4a and C4b 
facilitating exposure of the C4b thioester bond.  As a result C4b covalently binds to 
surfaces within the immediate vicinity where it then binds one molecule of C2.  C2 is 
in turn cleaved by MASP-2, producing C2a, which remains bound to C4b, forming the 
lectin mediated C3 convertase, C4bC2a.  As a consequence, the C3 convertase of the 
lectin pathway is identical to that generated by the classical pathway (Matsushita et 
al., 2001). 
 
1.2.3. The Alternative pathway 
 
The alternative pathway is evolutionally the oldest facet of the mammalian 
complement system (Nonaka et al., 2006).  It was first discovered by Pillemer et al. 
(1954) who named it the Properdin system, after one of the fundamental proteins 
that makes up this part of the complement system.  However, it later became known 
as the alternative system due to the alternative activation mechanism that initiates 
this pathway compared with the classical pathway.  This pathway exhibits two 
unique features; its ability to be spontaneously activated and its distinct C3 
convertase.  It also contains some components that are not found in the classical and 
lectin pathways such as factor B (FB), factor D (FD) and properdin (factor P, FP).  
The alternative pathway is capable of auto-activation due to a low level of 
constitutive generation of a hydrolysed C3 product, C3(H2O), a process that is 
referred to as ‘tick over’ (Lachmann et al., 1975).  The hydrolysis of the thioester  
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Figure 1.2. The pathways of the complement system 
Activation of the Classical pathway occurs via the detection of antibody bound antigen complexes by 
the C1-complex of proteins.  Similarly, the Lectin pathway is activated upon the detection of 
conserved carbohydrates on the surfaces of pathogens by mannose binding lectin (MBL) and 
associated serine protease (MASP) complex. This results in the cleavage of C4 and C2 to form C3 
convertase.  The Alternative pathway is activated by a spontaneous ‘tick-over’ mechanism which leads 
to the generation of C3(H2O).  Factor B (FB), factor D (FD) and properdin (FP) promote the generation 
of the alternative pathway C3 convertase which cleaves C3 into C3a and C3b.  C3a binds the C3a 
receptor while C3b binds to C3 convertase to form C5 convertase which cleaves C5 into C5a and C5b.  
C5a binds to and activates C5a receptors while C5b initiates the formation of the membrane attach 
complex (MAC).  Proteases of the coagulation and fibrinolysis systems and those release by cells can 
cleave C3 and C5 and represent an Extrinsic pathway.  Regulatory proteins (shown in blue) direct the 
activation of the complement system to microbial and damaged host cell surfaces; (C1 inhibitor - 
C1INH, C4 binding protein - C4BP, CD59 - protectin, complement factor H - CFH, factor I - FI, 
membrane cofactor protein - MCP, decay accelerating factor - DAF, carboxypeptidase - CP). 
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within C3 promotes the recruitment of FB, in a Mg2+-dependent manner, which 
consequently becomes susceptible to cleavage by the serine protease, FD.  This 
causes the release of the peptide fragment Ba and the generation of the fluid phase 
C3 convertase, C3(H2O)Bb (Williams et al., 1994).  This fluid phase C3 convertase 
splits C3 into C3a and C3b, the latter of which covalently binds to adjacent cells 
surfaces though its exposed thioester bond.  Surface bound C3b again recruits FB 
which is also cleaved by FD generating the surface bound alternative pathway C3 
convertase, C3bBb.  On its own this alternative pathway C3 convertase is very short 
lived.  However, it can be stabilized by binding to FP, a plasma protein that is 
synthesized and stored in the granules of neutrophils and released upon their 
activation (Wirthmueller et al., 1997).  Stabilized C3 convertase is able to cleave 
more C3, leading to further surface accumulation of C3b and the production of more 
C3 convertase.  This positive feedback cycle involving the exponential production of 
C3 convertase is known as the ‘amplification loop’ of the complement system 
(Lachmann, 2009).  Excess production of C3b gradually leads to the formation of the 
alternative pathway C5 convertase (C3bBbC3b) and shifts the substrate specificity 
away from C3 and towards C5.  As with the classical and lectin pathways, C5 
convertase cleaves C5, yielding the potent anaphylatoxin C5a and C5b which initiates 
the formation of the MAC. 
This remarkable amplification of the complement system involving proteins for the 
alternative pathway has been shown to account for 80-90% of C5 activation even 
when the initial activation is highly specific for the classical pathway (Harboe et al., 
2008). 
 
1.2.4. The Extrinsic mechanism of complement activation 
 
The intrinsic mechanisms of complement system activation via the classical, lectin 
and alternative pathways are considered to be the main biochemical routes leading 
to the release of amplification and effector molecules from C3 and C5.  However, in 
recent years it has become apparent that non-complement serine proteases residing 
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in the plasma or released from cells, are able to directly cleave these proteins and 
contribute to the so called extrinsic complement pathway.  Huber-Lang et al. (2002), 
demonstrated that activated phagocytic cells (human neutrophils or rat alveolar 
macrophages), in the presence of exogenous C5, were able to generate a biologically 
active C5a.  With the use of specific protease inhibitors (soybean trypsin inhibitor and 
secretory leukocyte protease inhibitor), they determined that serine proteases, 
released from these cells, were responsible for the cleavage of C5.  Work performed 
by others suggests that the enzyme released from leukocytes responsible for the 
cleavage of C5 is human leukocyte elastase (Ward et al., 1970; Wetsel et al., 1983). 
There is a reasonable amount of evidence to suggest that serine proteases of the 
coagulation and fibrinolysis systems are also able to induce the local complement 
activation.  In the absence of C3, Huber-Lang et al. (2006) demonstrated that 
thrombin, the coagulation pathway serine protease responsible for fibrin production 
and thrombus formation, is able to generate a biologically active C5a in the presence 
of C5.  Similarly Amara et al. (2010) found that plasmin, the serine protease of the 
fibrinolysis pathway, responsible for breaking down the thrombus fibrin matrix, is 
also able to generate biologically active anaphylatoxins in the presence of C3 and C5.  
This apparent cross talk between the complement, coagulation and fibrinolysis 
pathways is thought to be critical in regulating thrombus formation.  The localized 
production of complement by thrombin and plasmin provides a role in both 
thrombus formation and thrombus resolution.  Neutrophils and monocytes recruited 
to the site of tissue damage by C5a release mediators such as proteases and 
nucleosomes which provide a scaffold for platelet aggregation and thrombus 
stabilization.  C5a also promotes the release of other chemotactic factors that recruit 
phagocytic cells to assist in thrombus breakdown and clearance (Foley et al., 2016).  
In the thrombotic microangiopathy disorder, atypical hemolytic uremic syndrome 
(aHUS), the production of C5a appears to be out of balance leading to excessive renal 
capillary and arteriole inflammation.  This over production of C5a may be due, in 
part, to the actions of thrombin and plasmin but may also be exacerbated by 
plasmin’s ability to locally generate C3b.  Failure to regulate C3b, which is also 
generated from the tick-over of the alternative pathway, is a genetic phenotype of 
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many aHUS patients and contributes to excessive C5a production, leading to extreme 
capillary and arteriole inflammation which often results in acute renal failure (Noris 
et al., 2015). 
 
1.3. Regulatory proteins of the complement system 
 
Activation of the complement system leads to the potentially deleterious, non-
specific deposition of effector molecules onto local surfaces.  To discriminate 
between self and non-self surfaces, the complement system also consists of 
numerous regulatory proteins.  Regulation of the complement system occurs at 
different stages of activation by molecules that are present in both the fluid phase 
and on the surface of cells.  These regulators work in a tight balance to precisely 
control the location and degree of complement activation.  Changes in the function 
or expression of any one of the regulatory components can lead to complement 
dysregulation and disease. 
With the exception of properdin, which is the only known positive regulator of the 
complement system, all regulatory proteins reduce complement system propagation 
and potency of effector molecules.  Starting at the activation stage of the 
complement system, C1-inhibitor (C1INH), an acute phase protein, limits pathway 
initiation by binding to the serine proteases C1r and C1s of the classical pathway and 
MASP-1 and MASP-2 of the lectin pathway (Hansen et al., 2015).  If pathway 
activation progresses beyond this point, the formation of C3 convertase can be 
inhibited by C4-binding protein (C4BP).  This soluble protein binds to C4b and 
facilitates its cleavage by acting as a cofactor for the serine protease, factor I (FI) 
(Blom et al., 2004). 
A similar brake is applied to the functions of C3b of the alternative pathway by 
complement factor H (CFH) family of proteins.  This group of soluble plasma proteins 
includes CFH, CFH-like protein 1 (CFHL1) and the complement factor H related 
proteins (CFHR1-5).  A common feature of these proteins is their composition of 
individual domains called short consensus repeat domains (SCR), with the C-terminal 
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domains recognizing and anchoring to host surfaces, and the N-terminal domains 
recognizing C3b, promoting its destabilization.  All proteins contain heparin binding 
regions (Skerka et al., 2013).  CFH and CFHL1 are the only two proteins to possess a 
four SCR regulatory region at their N-terminus.  This regulatory region provides two 
functions; to act as a co-factor for FI, which cleaves C3b to the inactive iC3b, C3dg or 
C3d, and to promote the destabilization and decay of C3 convertase. 
The five CFHR proteins lack this regulatory region and based on their sequence 
homology are divided into two groups.  Group one contains CFHR1, 2 and 5 which 
display a highly conserved N-terminus and circulate as dimers, and group two 
includes CFRH3 and 4, which lack the ability to form dimers, yet share sequence 
homology with CFH in a heparin binding region of the protein (Skerka et al., 2013).  
CFHR1 can not only bind to C3b of C5 convertase and prevent the cleavage of C5, but 
it can also disrupt the formation of the MAC. CFHR2 binds to C3b and prevents the 
formation or C3 convertase and inhibits the amplification loop.  The complete actions 
of CFHR5 are not fully understood but it appears to bind to C3b and iC3b in a similar 
fashion to CFH and provide cofactor activities to FI (Goicoechea de Jorge et al., 2013).  
Similarly, the complete actions of CFHR3 and CFHR4 are not fully characterized.  They 
are believed to bind both C3b and C3d and provide cofactor activity to FI and CFH 
(Hellwage et al., 1999).  Interestingly, CRHR1, 3 and 5 have been shown to bind C3b 
in a competitive manner to CFH promoting its displacement from C3b (Fritsche et al., 
2010). 
Two other proteins can also regulate the actions of the complement system at the 
level of C3b.  Membrane cofactor protein (MCP, CD46) binds to C3b and C4b 
providing cofactor activity to FI facilitating their cleavage and inactivation (Liszewski 
et al., 1991).  Similarly decay accelerating factor (DAF, CD55), binds to both C3b and 
C4b preventing the formation of new and accelerates the decay of preformed C3 and 
C5 convertases (Lublin et al., 1989). 
There are four cell surface bound regulatory receptors that, upon recognition of cell 
deposited complement products, induce responses by effector cells.  Complement 
receptor 1 (CR1, CD35) expressed on erythrocytes and phagocytic cell promotes the 
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clearance of C3b opsonized immune complexes.  Activation of CR1 expressed on 
lymphocytes has been shown to regulate their proliferation and differentiation (Jozsi 
et al., 2002; Wagner et al., 2006).  Complement receptor 2 (CR2, CD21) is expressed 
primarily on B cells where it forms a complex with CD19 and CD81.  Activation of CR2 
by fragments of C3 which include iC3b, C3dg and C3d, enhances B cell receptor 
activation (Asokan et al., 2013).  Both CR3 (CD11b/CD18) and CR4 (CD11c/CD18) 
belong to the 2 integrin family of adhesion molecules and are expressed on the 
surface of monocytes and many other phagocytic cells.  Activation by iC3b or C3dg 
mediates the binding and phagocytosis of complement bound cells (Vik et al., 1987; 
Law, 1988). 
Finally, two other proteins that can regulate the effects of the complement system 
are Protectin (CD59) and carboxypeptidases (CP).  Protectin is expressed on the 
surface of many host cells including erythrocytes and epithelial cells where it 
prevents the formation of the MAC, inhibiting its lytic activity (Meri et al., 1990).  
CPs, specifically CPN, hydrolyse a bond at the carboxy-terminal of C3a and C5a that 
leads to the removal of the terminal arginine resulting in their inactivation (Skidgel et 
al., 2007). 
The majority of the soluble components of the complement system are synthesized 
and secreted into the bloodstream by hepatocytes (Morris et al., 1982).  However, 
hepatocytes are not the only source of complement protein production.  Figure 1.3 
highlights some of the cellular and tissue gene expression patterns of many soluble 
and membrane bound proteins of the complement system. 
 
1.4. Disorders associated with the complement system 
 
The extensive set of regulatory proteins ensures that the complement system 
focuses its actions on invading pathogens or damaged host cells.  However, if the 
expression or function of any of these proteins is altered in any way, the effector 
functions of the complement system may damage host cells and lead to disease  
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Figure 1.3. Cellular and tissue gene expression of complement proteins 
Table represent mRNA expression values of proteins of the complement system.   Normal tissue 
expression is derived from BioGPS (Wu et al., 2009).  Normal human hematopotic cell expression is 
derived from the DMAP database (Huang et al., 2015).  Scale represents log2 gene expression values. 
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(Morgan et al., 2015).  A dysfunctional complement response can occur due to 
inherited genetic mutations, that alter complement protein expression or function, 
or because of acquired auto-antibodies, that either neutralize or stabilize 
complement proteins.  In some instances, the genetic deficiency of non-complement 
proteins, that provide a supporting role to complement system proteins, can also 
lead to disease.  This is evident from the genetic mutation of the 
glycosylphosphatidylinositol anchor in hematopoietic stem cells which leads to 
paroxysmal nocturnal hemoglobinuria (PNH).  Mutations in this protein prevent the 
attachment of protectin and DAF to the surface of erythrocytes, resulting in the 
failure to regulate MAC formation which leads to their lysis (Rother et al., 2007).  
There are many examples in the literature of inherited or acquired alterations of 
complement proteins that cause disease (Morgan et al., 2015), some of which are 
outlined in table 1.1. 
There is a great deal of evidence to suggest that over activation or dysregulation of 
the complement systems is involved in the pathogenesis of rheumatoid arthritis (RA) 
and the syndrome of sepsis.  These two disorders have received a great deal of 
attention from the pharmaceutical industry and the role of the complement system 
in driving these disorders is outlined below. 
 
1.4.1. Complement and rheumatoid arthritis 
 
RA is a chronic autoimmune disease which is characterized by synovial inflammation, 
autoantibody production, cartilage and bone destruction leading to joint deformity, 
and systemic features, including cardiovascular, pulmonary, psychological, and 
skeletal disorders.  Affecting over 1% of the western population (Alamanos et al., 
2006) RA is regarded as a common multi-factorial chronic inflammatory disorder that 
involves an interaction between genetic and environmental factors (McInnes et al., 
2011).  Over activation of the complement system and excessing joint recruitment of 
neutrophils is implicated in the pathogenesis of RA. 
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Several studies investigating the presence of complement activation products in the 
joint fluid of RA patients have observed significant increases in C5a concentrations 
compared with fluid taken from healthy volunteers and osteoarthritis patients (Jose 
et al., 1990; Hogasen et al., 1995b).  Production of C5a enhances the recruitment of 
neutrophils into the joint space where they propagate the inflammatory response 
and exacerbate joint destruction.  This is achieved through the release of degrading 
enzymes, reactive oxygen species, cytokines and chemokines which enhances the 
recruitment of other immune cells (Wright et al., 2014).  Evidence for the role of the 
complement system driving the pathogenesis of RA also comes from experimental 
models of arthritis.  Antibodies to either C5 or C5a1 receptor both produce disease 
amelioration in mouse, collagen induced arthritis models (Wang et al., 1995; 
Andersson et al., 2014). 
There are several genetic variations in complement proteins which appear to 
predispose patients to RA.  Single nucleotide polymorphisms (SNP) of the C1q gene 
are associated with increased protein levels and appear to be linked to a greater 
susceptibility for developing RA (Trouw et al., 2013).  From genome wide association 
studies, identification of a TRAF1-C5 locus on chromosome 9 has been associated 
with an increased risk for RA (Plenge et al., 2007).  Focusing on a coding SNP within 
this locus, which causes a mutation at V802I in C5, Giles et al. (2015) noted this 
mutant C5 was more susceptible to cleavage by elastases found within the joints of 
RA patients.  This in turn would lead to enhanced joint C5a levels and lead to greater 
neutrophil recruitment maintaining joint inflammation. 
 
1.4.2. Complement and sepsis 
 
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host 
response to infection (Singer et al., 2016).  Sepsis is a syndrome where patients can 
present with a constellation of different physiological, pathological, and biochemical 
symptoms.  If unregulated and allowed to progress, the syndrome can develop from 
initial systemic inflammation to septic shock and on to organ dysfunction, eventually 
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leading to death.  With around 600,000 cases of sepsis in the US each year, this 
syndrome places a huge burden on the health care system and accounted for more 
than $20 billion of total US hospital costs in 2011 (Singer et al., 2016).  There have 
been more than 100 clinical trials conducted to test the efficacy of agents designed 
to modify systemic inflammation, many of which have targeted microbial endotoxin, 
their innate receptors or the slew of cytokines that are released during sepsis (TNF, 
IL-1).  However, none of these trials have resulted in new treatments for this 
devastating syndrome (Marshall, 2014). 
There is a large body of evidence from human investigations and experimental 
models suggesting that over activation of the complement system is implicated in the 
pathophysiology of sepsis.  The excessive systemic production of C5a rapidly 
activates neutrophils resulting in tissue damage and subsequent paralysis immune 
system.  In preclinical models of sepsis, systemic C5a concentrations have been 
shown to increase, which correlates with a loss in in C5a1 receptor expression on 
neutrophils (Riedemann et al., 2002a; Guo et al., 2003).  Prophylactic administration 
of neutralizing antibodies to either C5a or C5a1 receptor, or C5a1 receptor small 
molecule antagonist have all improved animal survival in these models (Czermak et 
al., 1999; Huber-Lang et al., 2002b). 
Activation of the complement system during sepsis has also been demonstrated in a 
clinical setting.  Circulating concentrations of C5a in septic patients have been 
reported to be as high as 5 nM (Younger et al., 2010).  Similar to preclinical 
observations, Unnewehr et al. (2013) noted that in a clinical setting, circulating 
concentrations of C5a increased 5 fold during severe sepsis, which correlated with a 
loss of neutrophil C5a1 receptor expression.  Interestingly, these authors noted that 
the degree of C5a1 receptor loss from neutrophils correlated with mortality, 
suggesting that over stimulation of the C5a-C5a1 receptor axis on neutrophils 
promotes immune system paralysis and results in death.  These experimental model 
and clinical data provide a strong body of evidence suggesting that modulators of the 
C5-C5a1 receptor axis could provide benefit to patients who develop sepsis. 
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Table 1.1. Inherited and acquired dysfunctions of complement system proteins 
Examples of inherited and acquired alterations on complement system proteins.  In many incidences, the gain or loss of complement system protein function is associated 
with the pathogenesis of disease. (Complement system – CS, Classical pathway – CP, Lectin pathway – LP Alternative pathway – AP, Hereditary angioedema – HAE, Age 
related macular degeneration – AMD, Systemic lupus erythematosus – SLE, Lupus nephritis – LN, Rheumatoid arthritis – RA, C3 glomerulonephritis – C3GN, Dense deposit 
disease – DDD, IgA nephropathy – IgAN, Atypical hemolytic uremic syndrome – aHUS). 
Complement component Abnormality Complement system consequence Associated disorders Reference 
Loss of function 
C1INH Genetic deficiency Failure to regulate CS and coagulation pathways preventing 
vascular homeostasis. 
HAE/AMD (Carugati et al., 2001; 
Ennis et al., 2008) 
C1q/r/s Genetic deficiency Failure to activate CP and clear immune complex SLE (Pickering et al., 2000) 
Anti-C1q antibody Failure to activate CP and clear immune complex SLE/LN (Orbai et al., 2015) 
C2 Genetic deficiency Failure to activate CP and clear immune complex SLE/RA/Infection (Glass et al., 1976; 
Hussain et al., 2007) 
C4 Genetic 
insufficiency 
Failure to activate CP and clear immune complex SLE (Yih Chen et al., 2016) 
MBL Genetic deficiency Failure to activate LP and opsonize microbes Infection (Super et al., 1989) 
FH Genetic deficiency Loss of FH mediated C3b regulation – excessive activation of 
AP leading to inflammation 
C3GN, DDD,  AMD, IgAN (Hageman et al., 
2005; Maillard et al., 
2015; Zhu et al., 
2015) 
Anti-FH antibody Neutralization of FH preventing C3b regulation – excessive 
activation of AP leading to inflammation 
aHUS (Blanc et al., 2012) 
FI Genetic deficiency 
/ insufficiency 
Failure to inactivate C3b – excessive CS activation leading to 
inflammation 
aHUS (Bienaime et al., 
2010) 
MCP Genetic 
insufficiency 
Reduced affinity for C4b and C3b - excessive CS activation 
leading to inflammation 
aHUS (Liszewski et al., 
2015) 
FP Genetic deficiency Failure to activate AP and opsonize microbes Infection (Linton et al., 1999) 
Gain of function 
C3bBb (C3 convertase) Anti-C3 convertase 
(C3 nephritic 
factor) 
Stabilization of C3 convertase – excessive AP activation DDD (Servais et al., 2012) 
FB Genetic gain of 
function 
Stabilization of C3 convertase – excessive AP activation DDD, aHUS (Goicoechea de Jorge 
et al., 2007) 
Anti-FB antibody Stabilization of C3 convertase – excessive AP activation DDD (Strobel et al., 2010) 
C3 Genetic gain of 
function 
Reduced regulation by MCP – excessive CS activation aHUS (Lhotta et al., 2009) 
 21 
 
1.5. C5a and the cleaved isoform C5a des Arg 
 
As described above, all three complement pathways lead to the generation of C5 
convertase (Rawal et al., 2001).  Proteolytic cleavage of an arginine-leucine bond at 
position 74-75 in the -chain of C5 leads to the generation of the potent 
anaphylatoxin C5a and C5b, which initiates the formation of MAC. (DiScipio et al., 
1983).  C5a consists of four alpha helices linked by peptide loops and contains three 
disulphide bridges between cysteine residues at positions 21-47, 22-54 and 34-55. 
(Manthey et al., 2009).  The C-terminal residues 69-74, are considered to contain all 
of the agonist properties of C5a (Ember et al., 1992).  C5a binds to and activates two 
members of the G protein-coupled receptor (GPCR) family of cell surface proteins, 
the C5a1 and C5a2 (Alexander et al., 2013).  Activation of C5a receptors orchestrates 
a plethora of leukocyte actions which contribute to the immune response.  These 
include; integrin up regulation (Weber et al., 1996), chemotaxis (Snyderman et al., 
1971), respiratory burst (Sacks et al., 1978b), NETosis (Martinelli et al., 2004), 
enhanced cytokine release (Riedemann et al., 2002), phagocytosis (Mollnes et al., 
2002) and cell degranulation leading histamine release, the latter of which 
contributes to the anaphylactic properties of C5a (Regal et al., 1983). 
The potent inflammatory effects of C5a are regulated as described earlier, by 
members of the CP family of enzymes, specifically CPB and CPN, which remove the C-
terminal arginine by hydrolysis, generating C5a des Arg.  The inactivation of C5a is 
very rapid and has been reported to be complete within two minutes in human 
serum (Bokisch et al., 1970).  With this in mind, although the majority of analytical 
methods used to quantify concentrations of the peptide fragments of C5 are unable 
to distinguish between C5a and C5a des Arg, the vast majority of C5a in the 
circulation is considered to be that of the des arginated isoform (Fernandez et al., 
1976; Mueller-Ortiz et al., 2009).  Removal of C5a and C5a des Arg from the 
circulation is believed to be mediated through binding to C5a receptors expressed on 
leukocytes (Oppermann et al., 1994). 
Original methods employed to assess the functional activity of C5a and C5a des Arg, 
focused on the contraction of guinea pig ileum, release of histamine from mast cells 
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and the wheal and flare response (Vogt et al., 1969; Vallota et al., 1973).  It was not 
until researchers directly compared the activity of these two C5 derived peptides in 
other cell based assay systems, that it became apparent that C5a des Arg retains a 
significant degree of activity.  Fernandez et al. (1978b) demonstrated that C5a des 
Arg, although approximately 10 fold weaker than C5a at inducing a chemotactic 
response of human isolated neutrophils, was able promote the migration of a larger 
number of cells.  Using an in vitro assay to measure the adhesion of human isolated 
neutrophils to human umbilical vein endothelial cells, Tonnesen et al. (1984) 
discovered that C5a des Arg was able to promote a comparable response to that of 
C5a.  Interestingly, in contrast to C5a, this group also observed that C5a des Arg was 
unable to induce the release of myeloperoxidase (MPO) from human neutrophils, a 
mechanism which may be comparable with the release of histamine from mast cells. 
With these data in mind, it appears that, although the anaphylactic properties of C5a 
are lost when the C-terminal arginine is removed, C5a des Arg retains certain 
functional activities.  Given the plethora of cellular responses that have been 
described for C5a and the increasing availability of biochemical and phenotypic 
assays, an extensive investigation characterizing the full signalling potential of C5a 
des Arg in relation to C5a would be a worthwhile endeavour.  Such data would help 
the scientific community better understand the functional role of C5a des Arg and its 
contribution to the pathogenesis of diseases that are associated with over activation 
of the complement system. 
 
1.6. The two C5a receptors 
 
As previously mentioned, C5a and C5a des Arg mediate their actions through binding 
to and activating two members of the GPCR superfamily of receptors, the C5a1 
(formerly known as CD88 and C5aR) and the C5a2 (formerly known as GPR77 and 
C5a-like receptor 2, C5L2).  Both of these receptors belong to the rhodopsin-like 
(class A) sub-family and are encoded by adjacent genes in cluster q13.3 of 
chromosome 19.  The C5a1 receptor is the larger of the two consisting of 350 amino 
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acids compared with 337 for the C5a2 receptor.  Although originally considered to be 
confined to cells of myeloid lineage, including neutrophils, monocytes and mast cells, 
the expression of the C5a receptors has been demonstrated in many other cell and 
tissue types including brain, lung, heart and kidney (Monk et al., 2007).  However, 
their expression on lymphocytes still remains controversial (Dunkelberger et al., 
2010).  Although the C5a1 receptor was cloned in 1991 (Boulay et al., 1991; Gerard et 
al., 1991), it was not until 2000 that the C5a2 receptor was discovered (Ohno et al., 
2000).  Despite these two receptors sharing a low overall sequence homology of 
35%, both peptide ligands are able to bind these two receptors with relatively high 
affinity.  Researchers at the University of Sheffield (Cain et al., 2002) reported that 
the binding affinity of C5a to C5a1 and C5a2 is comparable (IC50 values of 19 and 10 
nM respectively) and while C5a des Arg has a much reduced affinity for C5a1, it 
retains high affinity for C5a2 (IC50 values of 412 and 37 nM respectively). 
One key difference between the C5a1 and C5a2 receptors is in their ability to couple 
to G-proteins.  The C5a1 receptor has been shown to couple to heterotrimeric G-
proteins leading to changes in intracellular cAMP and calcium (Buhl et al., 1993).  
However, activation of the C5a2 receptor does not lead to productive coupling of G-
proteins which is thought to be due to lack of the highly conserved aspartic acid-
arginine-tyrosine/phenylalanine (DRY/F) motif found in the third transmembrane 
domain (Okinaga et al., 2003). 
 
1.6.1. The multi domain interaction between C5a and its receptors 
 
The mechanism by which C5a and C5a des Arg interact with the C5a1 receptor has 
been revealed to be highly complex involving multiple ligand-receptor domains.  Like 
many peptidergic GPCRs, the binding of the peptide ligand to the receptor involves 
both the hydrophilic N-terminal and a binding pocket formed by the transmembrane 
domains (TM) of the receptor.  With the use of N-terminal specific antibodies 
(Oppermann et al., 1993) and receptor mutagenesis (DeMartino et al., 1994), 
researchers were able to demonstrate that this negatively charged, aspartic acid rich 
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region of the C5a1 receptor contributes to greater than 45% of the total binding 
energy for C5a.  The work also concluded that this region of the receptor did not 
control receptor activation, as truncated peptides, resembling the C-terminal of C5a, 
and a N-terminal truncated receptor were still able to promote receptor activation 
and G-protein coupling.  With the data suggesting the involvement of a second site 
on the receptor, further research focused on the interactions of C5a with the TM 
region of the receptor. 
Several residues within the TM region of the C5a1 receptor have been identified as 
being critical for the binding and functional responses associated with C5a.  Using 
hexapeptides that resemble the six terminal amino acids of C5a and both calcium 
mobilization and degranulation assays, DeMartino et al. (1995) demonstrated the 
terminal arginine of C5a contributes heavily to the binding affinity and is essential for 
receptor activation.  Using receptor mutagenesis and altering the charge of the 
hexapeptide terminal arginine, they were able to demonstrate an electrostatic 
interaction between this residue and the receptor residue Arg-206, which appears to 
control the activation state of the receptor. 
Subsequent research to map the ligand interaction sites on the C5a1 receptor 
highlighted the importance of the aspartic acid residue at position 282.  Using full 
length peptides and mutating Asp-282 to alanine, Cain et al. (2001) observed a 
reduction in receptor activation by C5a but not C5a des Arg.  Similarly, mutating the 
terminal arginine on C5a to alanine resulted in the reduction in activation of the wild 
type receptor.  These data confirm the importance of the interaction between Asp-
282 and the terminal arginine of C5a and provides an explanation for the typical 
reduction in potency observed with C5a des Arg at the C5a1 receptor. 
A more extensive study to characterize the TM binding regions of the C5a1 receptor 
was performed by Higginbottom et al. (2005).  Using both receptor-ligand binding 
and functional assays, they confirmed the importance of the C5a-arginine and C5a1-
Asp-282 interaction.  Their work also discovered important ligand interactions with 
residues Arg-175, Glu-199 and Arg-206 on the C5a1 receptor.  This cluster of residues 
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towards the top of TM 4 and 5 was demonstrated to have minimal impact on the 
affinity and function of C5a but dramatically affected C5a des Arg. 
The interactions of C5a and C5a des Arg with the C5a2 receptor are less well 
characterized.  The inability of peptides that resemble the C-terminus of C5a, to 
interact with the C5a2 receptor suggests that the core of C5a is most relevant for 
binding to this receptor.  Both mutagenesis and antibody neutralization of the N-
terminus of the C5a2 receptor has highlighted amino acid residues that are important 
for C5a des Arg binding but do not contribute to the affinity of C5a.  These data 
suggest that, similar to the C5a1 receptor, there are probably multiple domains 
involved in ligand binding to the C5a2 receptor (Klos et al., 2013). 
 
1.6.2. Functional signalling of the C5a1 receptor 
 
Upon binding, C5a induces a change in the conformation of the C5a1 receptor that 
results in the re-orientation of the transmembrane (TM) domains.  The movement of 
TM7 relieves a constraint on TM6 allowing it to move away from TM3 and the core of 
the receptor, resulting in the exposure of intracellular receptor binding sites (Gerber 
et al., 2001).  The appearance of these new binding sites promotes the recruitment 
of heterotrimeric guanine nucleotide-binding proteins (G-proteins), composed of , 
 and  subunits, leading to the activation of the G-protein cycle which comprises the 
following events.  Prior to receptor activation, the G-protein complex exists in an 
inactive state with the -subunit bound to GDP.  Upon activation, the receptor 
functions as a guanine nucleotide exchange factor, promoting the exchange of GDP 
for GTP on the -subunit.  The GTP bound -subunit dissociates from the G 
complex and both elements are able to regulate the activity of intracellular signalling 
pathways.  The G-protein cycle is terminated via intrinsic GTPase activity of the -
subunit, which hydrolyses the terminal phosphate of GTP.  The GTPase activity is 
enhanced by the regulators of G-protein signalling family of proteins promoting re-
association of GDP bound -subunit with the G complex, completing the G-protein 
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cycle.  Restoration of the inactive G-protein complex allows the cycle to undergo 
further activation upon receptor stimulation (Milligan et al., 2006). 
The C5a1 receptor displays high expression on cells of myeloid origin, including 
neutrophils, where it has been demonstrated to couple to both pertussis toxin 
sensitive Gi/o-proteins and pertussis toxin insensitive G16-proteins (Rollins et al., 
1991; Amatruda et al., 1993).  Activation of Gi/o-proteins leads to the negative 
regulation of adenylate cyclase resulting in a lowering of intracellular cAMP 
concentration and the regulation of protein kinase A activity.  The dissociated G 
complex activates phospholipase C (PLC) which cleaves phosphatidylinositol 4,5-
bisphosphate into inositol trisphosphate (IP3), which induces the release of Ca
2+ from 
intracellular stores, and diacylglycerol (DAG), which activates protein kinase C.  The 
G complex is also able to activate phosphatidylinositide 3-kinase (PI3K)/Akt (protein 
kinase B) pathway which is considered to play an important role in cell migration 
(Hirsch et al., 2000).  Both Gi/o-protein and G complex have also been shown to 
activate the mitogen-activated protein kinase pathway.  This pathway includes the 
protein kinases, Ras, Raf, MEK and eventually leads to the phosphorylation and 
activation of extracellular signal-related kinase (ERK), regulating gene transcription 
(Inglese et al., 1995; Mochizuki et al., 1999). 
Unlike the Gi/o-protein, the G16-protein, which is a Gq family member and almost 
exclusively expressed in cells of hematopoietic lineage, couples directly to PLC 
leading to the generation of IP3 and DAG (Buhl et al., 1993). 
After G-protein activation, the intracellular domain of the C5a1 receptor is 
phosphorylated by G-protein coupled receptor kinases which promote the 
recruitment of -arrestins.  The physical presence of these molecules prevents 
further G-protein association and initiates receptor internalization via clathrin-coated 
vesicles.  However, -arrestins do not only act to regulate GPCR activity and have 
been shown to activate ERK in a non G-protein manner (Ahn et al., 2004) (figure 1.4). 
As briefly mentioned above, C5a and C5a des Arg orchestrate many cellular functions 
of human leukocytes including adhesion molecule regulation and chemotaxis.  With 
the use of selective receptor antagonists, researchers have determined that most of 
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these cellular responses are mediated through the C5a1 receptor (Sumichika et al., 
2002; Brodbeck et al., 2008).  It is often reported that activation of the C5a1 receptor 
expressed on neutrophils can also lead to the respiratory burst response.  The 
purpose of the respiratory burst response is to enable phagocytic cells to destroy 
engulfed microbes and involves a multi-step process.  Once a microbe has been 
engulfed, nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) assembles 
and leads to the production of superoxide which is subsequently converted to 
hydrogen peroxide (H2O2) by super oxide dismutase.  Although H2O2 is a reactive 
oxygen species, its oxidizing capabilities are mild (Halliwell et al., 2000).  The full 
potential of the respiratory burst response is not fully realized until hypochlorous 
acid (HOCl) is produced from H2O2 and chloride anions by myeloperoxidase.  HOCl, is 
highly reactive and has the power to destroy pathogenic microbes via oxidation. 
Although the C5a1 receptor is often cited as driving the neutrophil respiratory burst 
response, the mechanism by which this is achieved is not well understood (Lee et al., 
2008).  Although receptor activation does lead to MPO release, there is little 
evidence to suggest that the C5a1 receptor couples directly to the generation of 
reactive oxygen species.  Some data in the literature point to the fact that 
neutrophils need to be primed before C5a1 receptor can induce certain effector 
functions (Bajaj et al., 1992; Brodbeck et al., 2008).  Further work to elucidate the 
exact contribution of the C5a1 receptor to the respiratory burst response would help 
scientist better understand this cellular event, which, when excessively activated can 
result in tissue damage leading to disease (Jeitner et al., 2016). 
 
1.6.3. The enigmatic role of the C5a2 receptor 
 
Although discovered over 15 years ago, the precise contribution of the C5a2 receptor 
to C5a and C5a des Arg signalling still remains unclear.  Devoid of the capacity to 
couple to G-proteins, the C5a2 receptor has been shown to be phosphorylated at 
intracellular domains after C5a activation (Okinaga et al., 2003).  Since its discovery, 
there have been numerous claims as to the precise role of this receptor with both 
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pro and anti-inflammatory functions being suggested (Li et al., 2013).  A summary of 
the proposed functions of the C5a2 receptor can be found in figure 1.5. 
There are several lines of evidence suggesting an anti-inflammatory role for the C5a2 
receptor.  Using cell lines engineered to overexpress the C5a2 receptor and human 
isolated neutrophils, Scola et al. (2009) suggested that the main function of C5a2 was 
to act as a recycling decoy receptor, sequestering C5a and preventing the pro-
inflammatory activation of the C5a1 receptor.  They observed that the majority of 
C5a2 receptors primarily reside at an intracellular location and undergoes rapid 
constitutive recycling from the membrane to the intracellular compartment of the 
cell by a clathrin-dependent mechanism which is agonist independent.  With use of a 
ligand uptake assay, using radiolabelled C5a and C5a des Arg, they observed that the 
C5a2 receptor was able to remove both ligands from the extracellular space.  This 
uptake into intracellular compartments led to ligand degradation.  The majority of 
their work was performed using engineered or differentiated HL-60 cells.  When 
switching to human isolated neutrophils they observed that although expressed at a 
very low level at the cell surface, the C5a2 receptor preferentially removed and 
degraded C5a des Arg with minimal effect on C5a. 
An alternative mechanism by which the C5a2 receptor provides an anti-inflammatory 
role was proposed by Bamberg et al. (2010).  With their research focused on human 
isolated neutrophils, they reported that the C5a2 receptor is confined to an 
intracellular location with no detectable expression at the cell surface.  In contrast to 
the work performed by (Scola et al.), they were unable to detect C5a2 receptor 
mediated ligand uptake, although they only investigated the uptake of C5a.  
Neutrophil activation by C5a led to both chemotactic activity and ERK 
phosphorylation, both of which were enhanced in the presence of C5a2 receptor 
blocking antibody.  Using confocal microscopy, they observed that when neutrophils 
were activated with C5a, the C5a1 and C5a2 receptors co-localized at an intracellular 
location and that each receptor associated with -arrestin 1.  The C5a1--arrestin 
complex promoted the phosphorylation of ERK while the C5a2--arrestin complex did 
not.  Based on these data they proposed that upon activation of the C5a1 receptor, 
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the C5a2 receptor acts as negative regulator of C5a1 receptor function by competing 
for -arrestin, with the net signal being a result of the balance of the two pathways. 
In a rat cecal ligation and puncture (CLP) sepsis model, Gao et al. (2005) observed an 
increase in neutrophil C5a2 receptor expression, which was in contrast to the 
reduction in C5a1 receptor expression.  In vivo blockade of the C5a2 receptor using a 
receptor specific antibody resulted in a fourfold increase in IL-6 levels compared with 
IgG control animals, an observation that was consistent with in vitro findings.  Similar 
results were obtained by Gerard et al. (2005) who investigated the in vivo effects of 
both C5a and C5a des Arg in a lung injury model.  They observed that the targeted 
deletion of C5a2 receptor dramatically enhanced neutrophil influx into the lung.  This 
finding was further supported with the demonstration that neutrophils from C5a2 
knock out animals displayed enhanced chemotactic activity in vitro.  
There appears to be an equal number of research efforts that have provided 
evidence for a pro-inflammatory role for the C5a2 receptor as well.  In the mouse CLP 
sepsis model, Rittirsch et al. (2008) showed that the selective antibody blockade or 
targeted deletion of either the C5a1 or C5a2 receptor improved animal survival in 
mid-grade sepsis.  The in vivo appearance of the damage associated molecular 
pattern (DAMP), high mobility group box 1 protein, in this study was solely due to the 
activation of the C5a2 receptor.  In more severe sepsis, protection was only achieved 
with the blockade of both C5a receptors. 
Chen et al. (2007) demonstrated that leukocytes obtained from mice with the 
targeted deletion of the C5a2 receptor displayed both reduced upregulation of 
surface adhesion molecules and chemotactic responsiveness to C5a.  These 
leukocytes also displayed a reduced ability to regulate LPS stimulated TNF and IL-6 
production.  Contrary to the data generated by Bamberg et al. (2010), they showed 
that the deletion of C5a2 receptor reduced C5a induced ERK activation.  In an in vivo 
model of airway hyper-sensitivity, C5a2 receptor knock out mice displayed reduced 
airway inflammation which correlated with a reduced influx of immune cell 
infiltration. 
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Figure 1.4. The mechanistic functions of the C5a1 receptor 
Activation of the C5a1 receptor inhibits adenylate cyclase (AC) via Gi-proteins resulting in a lowered 
intracellular cAMP concentration which alters protein kinase A activation and protein phosphorylation 
(A).  Receptor activation also stimulates phospholipase C (PLC) via G16-proteins and the  complex 
(B).  This results in the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) generating inositol 
1,4,5-trisphosphate (IP3) which regulates intracellular calcium and diacylglycerol (DAG) which activates 
protein kinase C (PKC).  The  complex activates the mitogen activated protein kinase pathway 
leading to the phosphorylation of extracellular signal–regulated kinases (ERK) and gene transcription.  
The  complex can also activate the phosphoinositide 3-kinase (PI3K)/Akt (protein kinase B) pathway 
which regulates cell motility.  After G-protein activation, G-protein receptor kinases (GRKs) 
phosphorylate intracellular domains of the C5a1 receptor leading to the recruitment of -arrestin and 
receptor internalization (C).  The Internalized C5a1--arrestin complex can induce ERK 
phosphorylation. 
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Figure 1.5. The proposed mechanistic functions of the C5a2 receptor 
A recycling decoy receptor (A); The C5a2 receptor binds C5a or C5a des Arg and sequesters it from the 
extracellular space via -arrestin mediated receptor internalization.  Peptide agonists dissociate from 
the receptor in the endosome, after which the C5a2 receptor recycles back to the surface.  An 
intracellular regulator of C5a1 receptor function (B); Activation of the C5a1 receptor by C5a or C5a des 
Arg promotes the activation of the C5a2 receptor.  Post activation, both receptors are phosphorylated 
and recruit -arrestin.  The C5a1--arrestin complex activates ERK whereas the C5a2--arrestin 
complex does not.  An independent signalling receptor (C); Activation of cell surface C5a2 receptor 
leads to the direct release of the nuclear damage associated molecular pattern, high mobility group 
box 1 protein (HMGB-1). 
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Finally, Hao et al. (2013) investigated the role of C5a2 receptor during C5a-priming of 
neutrophils prior to anti-neutrophil cytoplasmic antibody (ANCA) induced neutrophil 
activation.  In C5a primed neutrophils, subsequent activation with MPO-ANCA or 
mPR3-ANCA led to neutrophil degranulation and respiratory burst which was 
significantly reduced in the presence of the C5a2 receptor antibody.  With the lack of 
any inhibition of neutrophil response achieved with a C5a1 receptor antagonist, the 
authors proposed that C5a2 receptor plays a pro-inflammatory role in C5a-primed 
neutrophils for ANCA-induced activation. 
Although the data described above highlight the interesting mechanisms by which 
the C5a2 receptor can regulate the actions of the complement system, the precise 
function of this receptor still remains enigmatic.  A potential reason for the 
conflicting roles of this receptor could be due to the situation in which the receptor 
was investigated.  The majority of the data that support an anti-inflammatory role, 
were generated using either engineered cells or using quiescent systems where only 
C5a or C5a des Arg were present.  However, in more complex settings, where 
additional inflammatory mediators were present, the C5a2 receptor was described as 
having a pro-inflammatory role.  Also, the majority of the work described focused on 
the same leukocyte functions, mainly chemotaxis and cytokine release.  An 
assessment of the impact that different inflammatory mediators have on the cellular 
expression profile of the C5a2 receptor and an investigation as to the contribution of 
C5a2 receptor in different cellular events may help better define the role of the C5a2 
receptor. 
 
1.7. Therapeutically targeting the complement system 
 
Over the past 30 years there have been numerous attempts to therapeutically target 
the complement system to treat disease.  Many of these attempts have targeted the 
serine proteases of the complement system.  Ruconest®, Cinryze and Berinert are all 
human recombinant versions of nature’s own serine protease inhibitor, C1-inhibitor, 
and are approved in the US for the treatment of hereditary angioedema.  
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Lampalizumab, a monoclonal antibody from Roche/Genentech, targets FD and is 
currently in Ph3 clinical trials for age related macular degeneration (AMD).  There is 
currently a great deal of activity to demonstrate the clinical benefit of targeting the 
amplification loop of the complement system.  This is being investigated by Amyndas 
Pharmaceuticals and Apellis Pharmaceuticals with analogues of the cyclic peptide 
inhibitor of C3, Compstatin (Morgan et al., 2015). 
During this time, there has also been a large degree of activity to design therapies 
that target the distal part of the complement system, the C5-C5a-C5a1 receptor axis.  
Examples of which will be discussed below and are represented in figure 1.6.  
 
1.7.1. Preventing C5 cleavage 
 
With all pathways of the complement system signalling though C5, inhibiting the 
cleavage of this protein is an attractive therapeutic strategy as it will stop pathway 
progression regardless of the stimuli.  This is exactly what is achieved with the 
humanized anti-C5 monoclonal antibody Eculizumab.  Sold by Alexion 
Pharmaceuticals Inc, under the trade name Soliris®, this agent was approved by the 
FDA in 2007 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).  PNH 
is a rare haemolytic disease caused by somatic mutations that result in the loss of 
expression of glycosylphosphatidylinositol anchors that link complement regulator 
proteins DAF and CD59 to hematopoietic stem cells.  The absence of this protein 
allows the formation of the MAC on erythrocytes, leading to complement mediated 
hemolysis, which, if not treated becomes a progressive illness with an increased risk 
of death (Rother et al., 2007).  Eculizumab functions by binding to C5 in such a way 
that it sterically hinders C5 convertase from cleaving it.  More recently Eculizumab 
has received FDA approval for the treatment of aHUS and is currently in clinical trials 
for several other clinical indications. 
The success of Eculizumab has spurred other biotechnology companies to generate 
agents that target the C5 protein.  Ra Pharma is currently developing RA101495, a 
subcutaneous, self-administered macrocyclic peptides that binds C5 in a very 
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different location to Eculizumab.  Alynylam is attempting to silence the production of 
C5 with their liver targeted C5 RNAi, ALN-CC5.  Both agents are currently in Ph2 
clinical trials for PNH and provide hope for patients with C5 polymorphisms that 
make them resistant to Eculizumab. 
 
1.7.2. Neutralizing C5a 
 
With experimental model data suggesting blocking the actions of C5a would be 
protective in the syndrome of sepsis, InflaRx GmbH have recently completed a Ph2 
clinical trial investigating the efficacy of their anti-C5a monoclonal antibody IFX-1 in 
patients suffering from early sepsis associated organ failure.  A key advantage of 
targeting C5a is that the actions of this peptide are blocked at both C5a receptors 
while maintaining the function of the MAC.  Although the data from this clinical study 
demonstrated that IFX-1 showed positive trends in various clinically relevant 
endpoints such as organ dysfunction score, need for ventilator support and length of 
stay on the ICU, the development of this agent for sepsis associated organ failure has 
been put on hold.  The graveyard of sepsis clinical trial failures and investor fear have 
prompted InflaRx to reposition IFX-1 to other complement driven disorders including 
the debilitating systemic skin disease hidradenitis suppurativa and ANCA-vasculitis 
(www.inflarx.de).  
 
1.7.3. Antagonizing the C5a1 receptor 
 
Targeting the C5a1 receptor to treat complement system related disorders has 
received a great deal of attention since the early 1990s.  Neutralizing antibodies 
(NNC0215-0384) and several small and large molecule antagonists (MP-435, NGD 
2000-1 and PMX53) have all entered clinical trial for the treatment of RA.  However, 
all efforts with these molecules have been abandoned due to either compound 
toxicity or lack of clinical efficacy (Lee et al., 2008).  More recently ChemoCentryx has  
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Figure 1.6. Therapeutically targeting the C5-C5a1 receptor axis 
Marketed or investigational drugs that target the distal part of the complement system.  Alexion’s 
Solaris®, a C5 monoclonal antibody (mAb) is approved for the treatment of paroxysmal nocturnal 
hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) and is currently in clinical trials 
for generalized Myasthenia Gravis (gMG) and antibody mediated rejection (AMR).  Alnylam 
Pharmaceuticals and Ra Pharma are currently developing agents that neutralize C5 by other 
mechanisms.  InflaRx are developing the C5a mAb IFX-1, which recently completed a Ph2 clinical trial 
investigating its efficacy in sepsis associated organ dysfunction.  Numerous attempts have been made 
to antagonize the C5a1 receptor.  Novo Nordisk’s mAb, Neurogen’s small molecule (SM) antagonist 
and Teva Therapeutics cyclic peptide (CP) antagonist all entered clinical trials for rheumatoid arthritis 
(RA) but their development has been stopped.  ChemoCentryx are currently developing the C5a1 
receptor antagonist CCX168 for the treatment of ANCA associated vasculitis and aHUS. 
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received greater success with CCX168 (Avacopan), which has progressed to Ph3 
clinical trials for ANCA vasculitis (Bekker et al., 2016). 
One particular molecule that has received a great deal of attention since its discovery 
is the peptide antagonist, PMX53.  This cyclic hexapeptide resembles the last six 
amino acids of C5a and was generated from a culmination of work by three separate 
teams of researchers.  In 1992 researcher at Abbot Laboratories discovered that the 
analogues of the C-terminus of C5a were able to bind to and activate the C5a1 
receptor (Kawai et al., 1992).  Two years later colleagues at Merck made further 
modifications to these truncated peptides which removed all agonist properties, 
generating potent antagonists with nanomolar affinity for the C5a1 receptor 
(Konteatis et al., 1994).  Scientists at the University of Queensland continued this 
research and using NMR spectroscopy they determined that in solution these 
peptide antagonists naturally adopted a cyclic conformation.  Stabilizing the peptides 
conformation via cyclization generated AcF[OPdChaWR] (PMX53), which displays an 
IC50 of 20 nM for the C5a1 receptor (Finch et al., 1999).  This orthosteric, competitive 
receptor antagonist has been extensively characterized both in vitro and in vivo and 
has demonstrated efficacy in numerous experimental animal models (Seow et al., 
2016).  
In 2006 PMX53 entered into a double-blind, placebo controlled, orally administered 
clinical trial to assess its efficacy in patients with active RA.  Unfortunately PMX53 did 
not show any benefit in this patient population and the study sponsors (Teva 
Pharmaceuticals Ltd) concluded that antagonism of the C5a1 receptor does not result 
in reduced synovial inflammation in RA patients (Vergunst et al., 2007).  However, on 
closer inspection of the reported clinical data, it appears the clinical exposures of 
PMX53 in this study were very low and perhaps not enough to sufficiently antagonize 
the actions of C5a at the C5a1 receptor.  It is therefore a matter of a debate as to 
whether this clinical trial truly tested the hypothesis that antagonizing the C5a1 
receptor would ameliorate joint inflammation associated with RA.  Further research, 
focused on quantifying the degree of antagonist-receptor occupancy required to 
block the actions of both C5a and C5a des Arg would provide a great deal of benefit 
to future clinical studies investigating this axis in disease. 
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1.8. Rationale, aims, hypotheses and experimental strategy. 
 
Rationale 
The complement system is an integral component of the body’s immune system and 
provides an essential role in clearance of microbial infections.  Appropriate activation 
of the complement system leads to the generation of potent inflammatory 
mediators, including C5a, which through ligation of C5a receptors guide neutrophils 
to the site of infection and help orchestrate its clearance.  However, dysregulation or 
over activation of the complement system can lead to the continual and excessive 
production of these inflammatory mediators which can result in disease. 
The precise role of the C5a1 and C5a2 receptors in orchestrating neutrophil functions 
and true signalling signature of both C5a and its cleaved isoform C5a des Arg are still 
not fully understood.  A better understanding of the function and signalling 
capabilities of C5a, C5a des Arg and the role of the C5a receptors will help inform 
future drug discovery efforts that aim to treat disorders associated with this part of 
the complement system. 
With the above in mind, I plan to focus my research to address the following aims 
and hypothesis. 
 
Aims 
1. To investigate the impact of inflammatory mediators, present during states of 
disease, on the expression of neutrophil C5a receptors. 
2. To perform an extensive characterization of the signalling signatures of both 
C5a and C5a des Arg in cell base functional assays and define the contribution 
of the C5a1 and C5a2 receptors in agonist mediated neutrophil responses.   
3. At receptor and G-protein level, determine the mechanism that controls the 
biased signalling profile of C5a des Arg. 
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Hypothesis and experimental strategies: 
1. There are conflicting data as to the precise role of the C5a2 receptor 
mediating the actions of C5a and C5a des Arg.  I hypothesised that pro 
inflammatory mediators around during states of inflammation alter the 
human neutrophil surface expression of this receptor which controls C5a1 
receptor function.  Experimental strategy:  I compared the effects of 
stimulating unactivated neutrophils with LPS, TNF, C5a or C5a des Arg on 
the surface expression of C5a1, C5a2 and other innate immune receptors.  
 
2. Experimental evidence suggests that C5a des Arg retains some but not all of 
the signalling activity of C5a.  I hypothesised that C5a des Arg retains certain 
signalling properties that enable it to orchestrate the extravasation of 
neutrophils to sites of infection while minimizing damage to surrounding 
tissue.  Experimental strategy:  I compared the potency and efficacy of C5a 
and C5a des Arg in a panel of human neutrophil and engineered cell based 
assays to determine the functional signature of each peptide agonist.  Using 
receptor specific antagonists I determined the contribution of each C5a 
receptor to the agonist responses observed in human isolated neutrophils. 
 
3. Certain amino acid residues on the C5a1 receptor have been identified as 
being important for the binding and function of C5a and C5a des Arg.  I 
hypothesised that the removal of the C-terminal arginine from C5a causes C5a 
des Arg to bind the C5a1 receptor in such a way that it induces a receptor 
conformation that only allows the activation certain G-protein mediated 
pathways.  Experimental strategy:  I used receptor mutagenesis and a 
functional cell based assay to confirm the key receptor amino acid residues 
involved in C5a and C5a des Arg binding and function.  I worked with a 
collaborator, Domain Therapeutics, to determine the G-protein signalling 
signature of C5a and C5a des Arg at the C5a1 receptor. 
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Materials and methods 
 
2.1. Reagents and assay kits 
 
Unless otherwise stated, all reagents and assay kits were purchased from either 
Complement Technology, Sigma-Aldrich, PerkinElmer, Life Technologies, Thermo 
Fisher Scientific, Biolegend, BD Biosciences, R&D Systems, Tocris, Qiagen, Integrated 
DNA Technologies, Miltenyi Biotec, DiscoverX or Cisbio. 
 
2.2. Assay buffer 
 
Unless otherwise stated, all in vitro assays were conducted using the following assay 
buffer: HBSS containing CaCl2 and MgCl2 (Life Technologies, Cat. 14025) 
supplemented with 20 mM HEPES (Life Technologies, Cat. 15630) and 0.1% BSA 
(Miltenyi Biotec, Cat. 130-091-376) at pH 7.4. 
 
2.3. C5a1 and C5a2 receptor expressing cell lines 
 
To investigate the selectivity, specificity and functional responses of ligands at either 
the human C5a1 or C5a2 receptor, historical Pfizer cell lines expressing either of the 
C5a receptors were used.  CHO-K1 cells engineered to express the C5a1 receptor and 
the G16 protein were cultured in a Dulbecco's Modified Eagle Medium/F-12 growth 
media (Life Technologies Cat. 11320) containing 10% heat inactivated FBS (Sigma-
Aldrich, Cat. F4135), 1mg/mL Geneticin® (Life Technologies, Cat. 11811) and 250 
µg/mL ZeocinTM (Life Technologies, Cat. R25001).  U2OS cells engineered to express 
the C5a2 receptor and GFP tagged -arrestin 2 were cultured in Minimum Essential 
Medium (Life Technologies, Cat. 11095) containing 10% heat inactivated FBS, 400 
µg/mL Geneticin® and 400 µg/mL ZeocinTM (Life Technologies Cat. R25001).  Cells 
were cultured in humidified conditions at 37oC, 5% CO2. 
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2.3. Assessment of recombinant C5a1 and C5a2 receptor 
sequences 
 
Genomic DNA was isolated from CHO-K1 C5a1 and U2OS C5a2 receptor cells using the 
Qiagen DNAeasy kit. In brief the method was as follows:  Approximately 2 x 106 of 
each cell type was thawed and dispensed into a fresh micro-centrifuge tube and 
centrifuged at 300 x g for 5 minutes.  Cells were suspended in PBS containing 
proteinase K.  Cells were centrifuged again and AL buffer, without ethanol, was 
added to cell pellet.  Cells were mixed thoroughly and then incubated at 56°C for 10 
min.  100% ethanol was then added to each sample and mixed before being 
transferred to a DNeasy mini spin column which was placed in a micro-centrifuge 
tube.  Samples were centrifuged at 6000 x g for 1 min and the flow-through was 
discarded.  Each DNeasy mini spin column was placed in a new collection tube and 
AW1 buffer was added over the column.  Tubes were centrifuged for 1 min at 6000 x 
g after which the flow-through and collection tube were discarded.  DNeasy mini spin 
columns were placed in a new collection tube and AW2 buffer was added to each 
sample which were subsequently centrifuged for 3 min at 20,000 x g to dry the 
DNeasy membrane. The DNeasy mini spin columns were placed in a clean collection 
tube and nuclease free water was dispensed directly onto the DNeasy membrane. 
Incubated at room temperature for 1 min, and then centrifuged for 1 min at 6000 x g 
to elute the genomic DNA.  DNA purity and concentration was determined with UV 
spectrophotometry using a BioTek® Synergy™ H4 plate reader (BioTek Instruments, 
Inc, Winooski, VT, USA). 
Two sets of polymerase chain reaction (PCR) primers were designed for each gene 
using the known expression vector flanking sequences (Integrated DNA Technologies, 
Coralville, IA, USA).  Forward and reverse primers were diluted to 100 nmol/mL in 
nuclease free dH2O, diluted 1:2 with each other and added to the KOD hot start 
master mix (Sigma-Alrdich Cat. 71842-4) to achieve 100 pmol of each primer pair.  
300 ng of each DNA template was added separately to each primer set, transferred 
to a thermal cycler and DNA amplification was achieved using 40 cycles of a protocol 
consisting of a 15 second 95oC denaturing step, 15 second 55oC annealing step and 
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25 second 68oC elongation step.  Final elongation was achieved at 68oC for 10 
minutes. 
Samples were de-salted using spin columns and sent to Wyzer Biosciences 
(www.wyzerbio.com) for sequencing.  DNA sequence analysis and alignment to NCBI 
nucleotide reference sequences were confirmed using Vector NTi data analysis 
software.  Coding sequences were translated and aligned to NCBI protein reference 
sequences. 
 
2.4. Quantitation of receptor gene expression 
 
C5a1 CHO-K1 cells (2 x 10
6), C5a2 U2OS cells (2 x 10
6) or neutrophils (2 x 107)  were 
harvested and lysed using QIAshredder columns (Qiagen, Cat. 79656) and total RNA 
was prepared using the RNeasy Plus Mini Kit (Qiagen, Cat. 74136). RNA purity (ratio 
of absorbance at 260 and 280 nm) and concentration was determined using a 
BioTek® Synergy™ H4 plate reader. 
The RT-PCR reactions were performed using TaqMan® RNA-to-CT™ 1-Step Kit (Life 
Technologies Cat. 4392938) and the QuantStudio™ 12K Flex Real-Time PCR System 
(Life Technologies). Assay was performed in a 384 well plate using Taqman®, Assay 
on DemandTM primer probe sets for each protein of interest (see table 2.1) and 100 
ng total RNA per reaction.  Samples were tested in quadruplicate.  RT-PCR was 
performed using the following protocol; 30 minutes at 48oC, 1 minute at 95oC, 
followed by 40 cycles of 15 seconds 95oC, 1 minute at 60oC.  The fluorescence signal 
was measured at the annealing step of 60oC. The cycle thresholds (Ct) were manually 
set and the baseline was set automatically to obtain the Ct values for each target.  
Human or rodent GAPDH was used as an endogenous housekeeping control gene for 
normalization to determine a ΔCt for each target. The analysis of gene expression 
was performed using the Comparative Ct method (2–ΔΔCt) of relative quantification, 
according to ABI/Life Technologies recommended protocols. Results were expressed 
as the mean difference in relative expression. 
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Gene target Species Primer probe exon 
mapping 
Life Technologies Taqman® 
reagent Catalogue number 
C5a1 receptor Human Within a single exon Hs00704891_s1 
C5a1 receptor Human Probe spans exons Hs00383718_m1 
C5a2 receptor Human Within a single exon Hs01933768_s1 
C5a2 receptor Human Probe spans exons Hs00218495_m1 
C3a receptor Human Probe spans exons hs00377780_m1 
FPR1 Human Probe spans exons hs00181830_m1 
CXCR1 Human Probe spans exons hs00174146_m1 
CCR2 Human Probe spans exons hs00356601_m1 
CCR5 Human Probe spans exons hs00152917_m1 
-arrestin1 Human Probe spans exons Hs00244527_m1 
-arrestin2 Human Probe spans exons Hs01034132_m1 
GAPDH Human Probe spans exons Hs02758991_g1 
GAPDH Rodent Probe spans exons 4308313 
 
Table 2.1. Taqman® primer probe sets used to quantify gene expression 
 
2.5. Detection of protein expression using gel electrophoresis 
and immunoblotting 
 
C5a1 CHO-K1 cells (2 x 10
6), C5a2 U2OS cells (2 x 10
6) were lysed at 4oC for 30 minutes 
in RIPA buffer (Sigma-Aldrich, Cat. R0278) supplemented with 1x protease inhibitor 
cocktail (Sigma-Aldrich, Cat. P8340) and 1mM PMSF (Sigma Aldrich Cat. P7626) at a 
concentration of 20,000 cells per µL.  Lysate was then centrifuged at 15,000 x g for 15 
minutes at 4oC.  Supernatants were harvested and protein concentrations were 
quantified using a BCA protein detection kit (Thermo Fisher Scientific, Cat. 23225).  
Protein lysates were then diluted to the appropriate concentration in the 
supplemented RIPA buffer and then prepared in sample loading buffer (70% (v/v) 
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NuPAGE LDS Sample Buffer (Life Technologies, Cat. NP0008) and 30% (v/v) NuPAGE 
Sample Reducing Agent (Life Technologies, Cat. NP0004)) so that 20 µL of sample 
contained between 5 and 10 µg of protein.  The SeeBlue Plus2 pre-stained standard 
protein ladder (Life Technologies, Cat. LC5925) was diluted 1:10 in loading buffer.  
Protein samples and protein ladder were incubated at room temperature for 30 
minutes.  High denaturing temperatures were avoided to minimize protein 
aggregation.  20 µL of each protein sample was loaded to separate lanes of a 10% 
Bis-Tris polyacrylamide NuPAGE mini-gel (Life Technologies, Cat NP0301).  Proteins 
were resolved by electrophoresis using a XCell SureLock™ Mini-Cell Electrophoresis 
System and NuPAGE MOPS SDS running buffer (Life Technologies, Cat. NP000102) at 
80V for 5 minutes, 100V for 5 minutes followed by 160V for 80 minutes.  The 
resolved proteins were transferred to a 0.45 µm pore size nitrocellulose membrane 
(Life Technologies, Cat. 88014) using the XCell™ Blot Module and NuPAGE Transfer 
Buffer (Life Technologies, Cat. NP0006) containing 10% methanol and 0.1% (v/v) 
NuPAGE antioxidant (Life Technologies, Cat. NP0005).  Proteins were transferred at 
230mA for 70 minutes.  Nitrocellulose membranes were then blocked in neat 
Odyssey® PBS blocking buffer (Li-COR, Cat. 927-40000) for one hour.  Block solution 
was removed and membranes were then incubated with antibody block solution 
(50% (v/v) PBS/Odyssey® PBS blocking Buffer), supplemented with 0.1% Tween 20 
(Thermo Fisher Scientific, Cat. 28360) containing both C5a receptor and GAPDH 
specific detection antibodies (either 1:500 dilution of mouse anti-C5a1 clone S5/1 
(Thermo Fisher Scientific, Cat. MA5-16937) plus 1:2000 dilution rabbit anti-GAPDH 
Clone 14C10 (Cell Signaling Technology, Cat. 2118) or 1:500 rabbit anti-C5a2 clone 
N1-50 (Thermo Fisher Scientific, Cat. PA1-41397) plus 1:2000 dilution of mouse anti-
GAPDH clone ZG003 (Thermo Fisher Scientific Cat. 39-8600) for 16 hours at 4oC.  
Membranes were rinsed for 5 minutes, 5 times with 10 mLs of TBS containing 0.1% 
Tween 20.  Membranes were then incubated with antibody block solution containing 
1:10,000 dilution of both Alexa Fluor® 680 conjugated donkey anti-mouse IgG 
(Thermo Fisher Scientific, Cat. A10038) and IRDye 800CW conjugated goat anti-rabbit 
IgG secondary antibodies (LI-COR. Cat. 827-08365) for one hour at room 
temperature.  Membranes were washed again and fluorescent antibody detection 
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was performed using an ODYSSEY® CLx Infrared Imaging System (LI-COR 
Biotechnology, Lincoln, NE, USA). 
 
2.6. Characterization of human serum derived C5a and C5a 
des Arg 
 
Native human C5a and C5a des Arg, prepared from human derived C5 were obtained 
from Complement Technology Inc.  C5a, Lot 17 (Cat. A144) was supplied at a 
concentration of 50 µM and C5a des Arg, Lot 15, (Cat. A145) was supplied at a 
concentration of 54 µM.  Both peptides were reported to have an endotoxin level 
below < 0.1 EU/µg.  Purity and characterization of each anaphylatoxin was 
determined by mass spectrometry as follows: 40 µL of 50 µM sample solution in 
HEPES buffer was injected into an LC-MS system for MS and UV analysis. After 
injection, analytes were separated by reversed-phase liquid chromatography with an 
online ACQUITY H Class UPLC (Waters, Milford, MA, USA) system coupled with MS 
(SQ2)/UV. The system was equipped with a 5 μm Waters XBridge C4 Protein BEH (4.6 
μm × 50 mm; Waters), separation of the Proteins/peptides was conducted at room 
temperature and a flow rate of 2 mL/min. A linear gradient from 5% A (0.05% formic 
acid in water) to 25% B (0.05% formic acid in acetonitrile) was applied over 4.1min, 
with a wash at 100% B to 5 min.  UV monitoring was conducted at 280nm.  MS 
analysis was performed on an SQ2 (Waters) mass spectrometer equipped with an 
electrospray ionization source controlled by MassLynx 4.1 software (Waters). The 
capillary voltage was set to 3.5 kV, the cone voltage to 50 V and the source 
temperature to 150 °C. Mass spectra were acquired in positive ionization mode over 
an m/z range of 200–3000 Da at scan rate of 1.3s.  Deconvoluted spectra were 
generated by MaxEnt1 (Waters) over the full range of scanned raw data (200-
3000Da) with an output range of 10000:11000 Da, a resolution of 1Da and a 
minimum intensity ratio of 10%. 
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2.7. 125I-C5a receptor-ligand binding studies 
 
Whole cell receptor-ligand binding assays using 125I human recombinant C5a 
(PerkinElmer, Cat. NEX250) were performed to assess the expression level of each 
C5a receptor, the specificity of pharmacological tools, or kinetics of C5a for each C5a 
receptor.  Assays used use of the previously described engineered cells (C5a1 CHO-K1 
2500 cells/well, C5a2 U2OS 1000 cells/well) or human isolated neutrophils (200,000 
cells/well).   
The following pharmacological reagents were tested in competition mode to assess 
their affinity and specificity for each C5a receptor: Anaphylatoxins (obtained from 
Complement Technology Inc) C3a (Cat. A118), C3a des Arg (Cat. A119), C5a (Cat. 
A144) and C5a des Arg (Cat. A145) anti C5a1 receptor antibody clones (Thermo Fisher 
Scientific, P12/1 (Cat. MA1-35971), S5/1 (Cat. MA5-16937), 8D6 (Cat. MA5-17740), 
W17/1 (Cat. MA1-40174)), C5a1 receptor antagonists PMX53 (Pfizer laboratories) and 
NDT9513727 (Tocris, Cat. 3333), C5a2 receptor antibody clones 1D9-M12 (BioLegend, 
Cat. 342402), N1-50 (Thermo Fisher Scientific, Cat. PA1-41397), N1-23 (Hycult 
Biotech, Cat. HP9036) and species specific isotype controls (Thermo Fisher Scientific). 
Cells were incubated with 10 different concentrations of each test agent and a fixed 
concentration of 125I-C5a (approximately 25 pM for C5a1 receptor and 50 pM C5a2 
receptor) for four hours at room temperature.    
To characterize the binding kinetics of 125I-C5a to both C5a receptors and determine 
assay viability at extended incubation times, association receptor ligand binding 
experiments using two separate concentrations of 125I-C5a (C5a1 = 20 and 60 pM, 
C5a2 = 40 and 120 pM) were performed at time points ranging from 1 to 240 minutes 
at room temperature.  Specific 125I-C5a receptor binding for each time point was 
calculated from duplicate total binding (assay buffer) and non-specific binding (C5a1 
receptor 1 µM PMX53, C5a2 receptor 15µg/mL antibody clone 1D9-M12) controls. 
To obtain affinity estimates (Kd values) for 
125I-C5a and quantify the expression of 
each C5a receptor in either CHO-K1, U2OS or human isolated neutrophils, saturation 
receptor ligand binding experiments were performed. Each cell line was incubated 
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with 12 different concentrations of 125I-C5a, ranging from 1 nM to 1 pM, for four 
hours at room temperature.  For each 125I-C5a concentration, specific receptor ligand 
binding was calculated using both total binding and non-specific binding controls as 
described above. 
All receptor ligand binding reactions were performed in assay buffer in a total 
volume of 200µL (160 µL cells, 20 µL test agent or control and 20 µL 125I-C5a).  
Experiments were terminated via rapid vacuum filtration over GF/C Unifilter plates 
(PerkinElmer, Cat. 6005174) pre-soaked in 0.5% PEI (Sigma-Aldrich, Cat. 764647) 
using a Brandel Harvester (Brandel Inc. Gaithersburg, MD, USA).  Filters were washed 
four times with 1 mL of assay buffer and then dried at 40oC for two hours prior to the 
addition of 50 µL MicroScint™-O cocktail (PerkinElmer, Cat. 6013611) to each well.  
Plates were counted on a TopCount NXT™ Microplate Scintillation Counter 
(PerkinElmer, Waltham, MA, USA).  To quantify the concentration of each diluted 
125I-C5a sample, 10 µL of each sample was diluted in 6 mL of Ultima Gold™ 
scintillation cocktail (PerkinElmer, Cat. 6013680) and counted on a Tri-Carb® liquid 
scintillation counter (PerkinElmer, Waltham, MA, USA) using and a 125I quench curve.  
Radioactivity in DPM was converted to molar concentration using the constant 1 Ci = 
2.2212 DPM and a specific activity for 125I of 2200 Ci/mmol. 
 
2.8. Isolation of neutrophils from human whole blood 
 
Blood was collected at the Pfizer phlebotomy unit from healthy volunteers who had 
previously provided informed consent. 
Neutrophils were rapidly isolated from human whole blood using the negative 
selection MACSxpress® human neutrophil isolation kit (Miltenyi Biotec, Cat. 130-104-
434).  Blood was collected in K2EDTA spray-coated Vacutainer™ tubes (BD 
Biosciences, Cat. 366643).  The lyophilized neutrophil isolation cocktail pellet was 
reconstituted in 2 mL of the provided buffer A and mixed gently with repeat 
pipetting.  The final cocktail was then prepared with the addition of 2 mL of the 
provided buffer B.  The final 4 mL of neutrophil isolation cocktail was then added to a 
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15 mL conical centrifuge tube containing 8 mL of human whole blood. The tube was 
gently inverted three times and mixed for five minutes at room temperature using 
the MACSmix™ Tube Rotator (Miltenyi Biotec, Auburn, CA, USA).  The tube was then 
placed in the MACSxpress® Separator magnet (Miltenyi Biotec) for 15 minutes. With 
the tube still inside the magnetic field, the supernatant, containing the enriched 
neutrophils, was collected and transferred to a new 15 mL tube. Magnetically 
labelled non-target cells as well as aggregated erythrocytes are retained in the 
original tube.  The supernatant was then centrifuged at 300 x g for 5 minutes, the 
supernatant aspirated and discarded and the neutrophil pellet suspended in 15 mL of 
assay buffer.  Cells were centrifuged again and suspended in assay buffer to the 
desired concentration. 
 
2.9. Neutrophil purity and activation state 
 
To assess the purity of neutrophils isolated using the MACSxpress® human neutrophil 
isolation kit, a comparison of the percentage cells that stain for the granulocyte 
markers CD15 and CD16 before and after isolation from whole blood was performed.  
100 µL of human whole blood was added to 2.5 mL 1x BD Phosflow™ Lyse/Fix buffer 
(BD Biosciences, Cat. 558049) for 10 minutes at 37oC in order to lyse erythrocytes 
and fix leukocytes.  1 x 106 isolated neutrophils were fixed in 1 mL of BD Cytofix™ (BD 
Biosciences, Cat. 554655) for 20 minutes at 4oC.  Each fixed cell population was 
centrifuged at 500 x g for 5 minutes and suspended in sterile filtered BSA based stain 
buffer (BD Biosciences, Cat. 554657) supplemented with the Fc receptor blocking 
solution Human TruStain FcX™ (Biolegend Cat. 422302) to a concentration of 1 x 107 
cell/mL.  100 µL of each sample was stained with 20 µL APC mouse anti-human CD15 
clone HI98 (BD Biosciences, Cat. 561716) and 20 µL FITC mouse anti-human CD16 
clone 3G8 (BD Biosciences, Cat. 555406) for 20 minutes in dark conditions on ice.  
Samples were then centrifuged at 500 x g for 5 minutes and washed three times in 
200 µL of stain buffer.  Separate neutrophil samples were stained with individual 
antibodies for fluorochrome compensation controls.  Blank and stained samples 
 49 
 
were analysed for FITC and APC staining using the BD LSRFortessa™ flow cytometer 
(BD Biosciences, San Jose, CA, USA) 
To determine the activation state of the isolated neutrophils, a comparison of the 
expression of the cell surface adhesion molecule, CD11b, was performed between 
neutrophils fixed in whole blood and those isolated using the MACSxpress® isolation 
kit.  Procedures for erythrocyte lysis and cell fixation were the same as described 
above.  Prior to fixation, a sample of neutrophils was stimulated with 10 nM human 
purified C5a for 30 minutes at 37oC in assay buffer.  Samples were centrifuged at 300 
x g for 5 minutes, suspended in stain buffer containing 20 µL APC mouse anti-human 
CD11b/Mac-1 clone ICRF44 (BD Biosciences, Cat. 550019) or isotype matching 
control antibody clone X40 (BD Biosciences, Cat. 354818).  Staining intensity was 
assessed using BD LSRFortessa™ flow cytometer. 
 
2.10. Detection of cell surface C5a receptor expression using 
flow cytometry 
 
To determine the specificity and saturating concentrations of fluorophore conjugated 
antibodies for each C5a receptor and the presence of other immune system related 
receptors on the surface of the human isolated neutrophil, flow cytometry was 
employed. C5a1 CHO-K1 cells, C5a2 U2OS cells or neutrophils were suspended in stain 
buffer to a concentration of 1 x 107 cells/mL.  Individual cell samples were incubated 
with multiple or single concentrations of fluorophore conjugated antibodies for the 
following receptors; C5a1 receptor (Biolegend, Cat. 344305), C5a2 receptor 
(Biolegend, Cat. 342405), FPR1 (R&D Systems, Cat. FAB3744P), CD11b (BD 
biosciences, Cat. 562108), TNFR1 (R&D Systems, Cat. FAB225A), TNFR2 (R&D 
Systems, Cat. FAB226A) and TLR4 (R&D Systems, Cat. FAB6248A).  Cells were washed 
in stain buffer and fixed in BD CytofixTM as previously described.  Mean fluorescence 
intensity of each fluorophore was assessed using BD LSR Fortessa™ flow cytometer 
and compared to samples stained with equivalent concentrations of isotype matched 
control. 
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2.11. The impact of inflammatory agents on neutrophil 
receptor expression 
 
The effects of the sepsis associated inflammatory agents, LPS (InvivoGen Cat. tlrl-
ppglps), TNF (R&D Systems, Cat. 210-TA) C5a and C5a des Arg were individually 
assessed on the neutrophil surface expression of C5a1 receptor, C5a2 receptor, 
CD11b and the FPR-1.  Human isolated neutrophils we re-suspended in assay buffer 
to a concentration of 1 x 107 cells/mL and 90 µL of cell suspension was dispensed into 
wells of a 96 well polypropylene plate.  Neutrophils were then stimulated with either 
LPS (5 ng/mL), TNF (1 ng/mL), human purified C5a (5 nM) or human purified C5a 
des Arg (50 nM) at 37oC 5% CO2 for 60 minutes.   Cells were then centrifuged at 300 x 
g for 5 minutes, assay buffer removed and cells re-suspended in the previously 
described stain buffer.  Cells were transferred to a V-bottom polystyrene plate and 
further centrifuged as described above.  To each well, 100 µL of either receptor 
specific staining cocktail containing; FITC-anti C5a1 (Biolegend, Cat. 344306), APC-anti 
C5a2 (Biolegend, Cat. 342406), PE-anti FPR-1 (R&D Systems, Cat. FAB3744P) and 
V450-anti CD11b (BD Biosciences, Cat. 562108) or isotype control cocktail was added.  
All antibodies were used at the manufacturers recommended concentrations.  Cells 
were incubated with antibody cocktail for 20 minutes on ice in dark conditions.  Cells 
were centrifuged and washed three times in 200 µL of stain buffer.  Cells were re-
suspended in 200 µL CytofixTM (BD Biosciences, Cat. 554655) and incubated on ice in 
dark conditions for 20 minutes.  Cells were centrifuged and washed twice in stain 
buffer.  Each sample was filtered and the fluorescence intensity of each fluorophore 
was analysed using an LSR Fortessa™ flow cytometer (BD Biosciences).  Single stain 
controls were generated to determine the degree of compensation correction 
required for each emission channel.  Mean fluorescence intensity values of each 
fluorophore for each sample were expressed as a percentage of the no stimulation 
control. 
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2.12. Agonist induced intracellular calcium mobilization 
 
C5a1 CHO-K1 cells or human isolated neutrophils were suspended in assay buffer 
containing 1x Calcium 3 dye (Molecular Devices, Cat. R8091) to a concentration of 
200,000 cells/mL.  50 µL of cell suspension was added to each well of a black, clear 
bottom, 384 well assay plate and incubated for 1 hour at 37oC, 5% CO2.  For 
neutrophil experimentation, 10 µL of either assay buffer, C5a1 receptor antagonist 
PMX53 (assay concentration of 1 µM), C5a2 neutralizing antibody (clone 1D9-M12 
Biolegend – assay concentration of 15 ng/mL) or isotype control antibody (clone 
MG2a-53, BioLegend – assay concentration of 15 ng/mL) was added to control wells.  
Assay plate was then incubated for a further hour at 37oC, 5% CO2.  Assay plate was 
then stimulated with the addition of assay buffer or a concentration range of either 
C5a or C5a des Arg to wells that were previously treated with assay buffer.  To wells 
pre-treated with receptor antagonists, cells were stimulated with a sub-maximal 
concentration of either C5a (assay concentration of 1nM) or C5a des Arg (assay 
concentration 3nM).  Fluorescence of the Calcium 3 dye was measured from 0 
seconds to 3 minutes post agonist addition using the FDSS 7000 plate reader 
(Hamamatsu, Japan).  Maximum dye fluorescence in response to agonist addition 
was expressed as a ratio of dye fluorescence prior to agonist addition.  All 
fluorescence ratio data were expressed as a percentage of the assay window defined 
by the basal and maximum C5a response. 
 
2.13. Agonist induced neutrophil CD11b expression 
 
Human isolated neutrophils were diluted in assay buffer to a concentration of 1.2 x 
107 cells/mL.  To each well of a 96 x 1 mL polypropylene block, 70 µL of cell 
suspension was added and the assay block was then incubated at 37oC 5% CO2 for 1 
hour.  10 µL of either assay buffer, C5a1 receptor antagonist PMX53 (assay 
concentration of 1µM), C5a2 neutralizing antibody (clone 1D9-M12 Biolegend – assay 
concentration of 15 ng/mL) or isotype control antibody (clone MG2a-53, BioLegend – 
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assay concentration of 15 ng/mL) was added to respective wells.  This was followed 
by the addition of 10 µL of 1 mg/mL APC mouse anti-Human CD11b/Mac-1 clone 
ICRF44 (BD Biosciences, Cat. 550019) and the assay block was incubated for 60 
minutes at 37oC, 5% CO2.  To each assay well treated with assay buffer, either 10 µL 
assay buffer or 10 µL of a concentration range of either C5a or C5a desArg was 
added.  To wells pre-treated with antagonist, 10 µL of a sub maximal concentration 
of either C5a or C5a des Arg (assay concentration of 3 nM) was added.  The assay 
block was then incubated for 30 minutes at 37oC, 5% CO2.  After this time 500 µL of 
pre-warmed 1x BD Phosflow™ Lyse/Fix buffer (BD Biosciences) was added to each 
assay well and further incubated for 15 minutes at 37oC 5% CO2.  Assay block was 
then centrifuged at 500 x g for 5 minutes, supernatant aspirated and cell pellet was 
re-suspended in 800 µL of assay buffer.  Assay block was centrifuged again, assay 
buffer aspirated and cells pellets re-suspended in 200 µL of assay buffer and filtered 
prior to analysis.  CD11b expression was assessed using a BD LSR Fortessa™ flow 
cytometer (BD Biosciences) and APC mean fluorescence intensity was quantified for 
each sample. Fluorescence values were expressed as a percentage of the basal 
control and maximum C5a response. 
 
2.14. Agonist induced neutrophil respiratory burst 
 
Human isolated neutrophils were suspended in assay buffer to a concentration of 2 x 
107 cells/mL and 30 µL of cell suspension was added to each well of a 96 well 
polypropylene plate.  Cells were incubated with 10 µL of either assay buffer or C5a1 
receptor antagonist PMX53 (assay concentration of 1µM), C5a2 neutralizing antibody 
(clone 1D9-M12 Biolegend – assay concentration of 15 ng/mL) or isotype control 
antibody (clone MG2a-53, BioLegend – assay concentration of 15 ng/mL) for 45 
minutes at 37oC, 5% CO2.  10 µL of either assay buffer or TNF  (assay concentration 
1 ng/m, R&D Systems Cat. 210-TA) was added to each well and the assay plate was 
incubated for 15 minutes at 37oC.  Cells incubated with antagonist were stimulated 
with fixed concentrations of C5a (5 nM) or C5a des Arg (50 nM) and cells incubated 
with assay buffer were incubated with concentration ranges of either C5a or C5a des 
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Arg.  Each agonist concentration was diluted in 2x the reactive oxygen species 
indicator dye, Dihydrorhodamine (DHR) 123 (Sigma-Aldrich, Cat. D1054) to a 2x 
concentration.  Cells were stimulated with 50 µL of agonist for 15 minutes at 37oC 5% 
CO2.  Samples were then added to a 96 well x 1.2 mL polypropylene block containing 
400 µL pre-warmed Phosflow™ Lyse/Fix buffer (BD Biosciences) and incubated for 20 
minutes at 37oC 5% CO2.  A 200 µL sample from each well was filtered into a fresh 
assay plate and samples were analysed for mean fluorescence intensity on a BD LSR 
Fortessa™ flow cytometer (BD Biosciences).  Fluorescence values for each sample 
were expressed as a percentage the basal and maximal C5a induced response. 
 
2.15. Detection of intracellular ROS generation in the human 
isolated neutrophil 
 
To determine the role of TNF and C5a in the respiratory burst responses, the ability 
of each ligand to generate either hydrogen peroxide (H2O2) or hypochlorous acid 
(HOCl) in human isolated neutrophils was assessed.  Human isolated neutrophils 
were re-suspended in assay buffer to a concentration of 2 x 106 cell/mL.  For HOCl 
detection, experiment was performed as described above with DHR-123.  
Neutrophils were incubated with diluent or receptor antagonizing agents (PMX53, 
1D9-M12, TNFR1 antibody (R&D Systems, Cat. MAB225), TNFR2 antibody clone (R&D 
Systems, Cat. MAB726), MPO inhibitor PF-1355 (Pfizer) or isotype controls antibody) 
for 45 minutes at 37oC, 5% CO2.  Neutrophils were then incubated with TNF (1 
ng/mL R&D Systems) or diluent for 15 minutes at 37oC, 5% CO2 followed by 15 
minute stimulation with either C5a (5 nM),  C5a des Arg (50 nM) or diluent, all 
diluted in the HOCl indicator dye.  Samples were then processed as described above 
and the mean fluorescence intensity of each sample was detected using an LSR 
Fortessa™ flow cytometer.  Fluorescence values for each sample were expressed as a 
percentage of the maximal response to TNF plus highest concentration of C5a. 
For H2O2 detection, 30 µL cell suspension was added to wells of a 96 well 
polypropylene plate and incubated with the above receptor antagonizing agents for 
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45 minutes at 37oC, 5% CO2.  Cells were then stimulated with either TNF (1 ng/mL), 
C5a or C5a des Arg for 15 minutes before hypotonic lysis with 50 µL sterile dH2O for 
30 minutes at 37oC 5% CO2.  Cell lysates were transferred to a clear flat bottom assay 
plate containing 100 µL of 1x Amplex® Red (Thermo Fisher Scientific, Cat. A22188).  
After 30 minutes incubation at room temperature, the assay plate was read on a 
EnVision® Multilabel plate reader (PerkinElmer) using a fluorescence protocol with 
excitation and emission wavelengths of 570 and 585 nm respectively. 
 
2.16. Agonist induced human isolated neutrophil chemotaxis 
 
Human isolated neutrophils were suspended in assay buffer containing 1.5 µM 
Calcein AM (Corning, Cat. 354217) at a cell concentration of 2 x 106 cells/mL and 
incubated for 30 minutes at 37oC, 5% CO2.  Cells were then centrifuged at 300 x g for 
5 minutes and washed in assay buffer.  Cells were then centrifuged again and 
suspended in assay buffer to a concentration of 2.2 x 106 cells/mL.  Cells were then 
dispensed into wells of a 96 well polypropylene plate and incubated with either assay 
buffer, C5a1 receptor antagonist PMX53 (assay concentration of 1µM), C5a2 
neutralizing antibody (clone 1D9-M12 Biolegend – assay concentration of 15 ng/mL) 
or isotype control antibody (clone MG2a-53, BioLegend – assay concentration of 15 
ng/mL) for 60 minutes at 37oC, 5% CO2.  50 µL of each cell sample was then added to 
the top chamber of a FluoroBlok™ multiwell plate (Corning Life Sciences) containing 
3 µm polyethylene terephthalate membranes.  To the bottom chamber, 200 µL of 
either assay buffer or concentrations of C5a or C5a des Arg were added.  For cells 
pre-treated with antagonist a submaximal concentration of either C5a or C5a des Arg 
(1 nM) was added to the lower chamber.  Both top and bottom chambers were 
assembled together and the chemotaxis plate was incubated for 60 minutes at 37oC, 
5% CO2.  Chemotaxis plates were then read on an EnVision® Multilabel plate reader 
(PerkinElmer) using a bottom read protocol with excitation and emission 
wavelengths of 485 and 530 nm respectively.   
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2.17. Agonist induced cAMP accumulation in CHO cells 
expressing the C5a1 receptor 
 
CHO cells overexpressing the C5a1 receptor were suspended in growth media and 
seeded at 10,000 cell/well into a black, clear bottom 384 well polystyrene assay plate 
and incubated at 37oC, 5% CO2 overnight.  On the day of experimentation growth 
media was aspirated and replaced with 5 µL assay buffer.  After equilibration for an 
hour at 37oC, 5% CO2, 5 µL of water soluble forskolin, NKH 477 (Tocris, Cat. 1603) was 
added to all assay wells to achieve an assay concentration of 10 µM.  5 µL of assay 
buffer or a concentration range of either C5a or C5a des Arg was added to separate 
assay wells and the plate was then incubated for 3 hours at 37oC, 5% CO2.  
Intracellular cAMP concentrations were then detected using the DiscoverX 
HitHunter® cAMP detection kit (Cat. 90-0075SM25).   In brief, 5 µL of cAMP antibody 
reagent was added to all wells followed by 20 µL of cAMP working detection 
solution.  Assay plate was equilibrated for 1 hour at room temperature in the dark to 
allow the immunocompetition reaction to occur.  20 µL of cAMP solution A was then 
added to each well and the assay plate was then incubated in the dark overnight 
prior to reading on a PerkinElmer Envision® Multilabel plate reader using a 
luminescence protocol.  A cAMP standard curve was performed to ensure all cell 
generated cAMP was within the detection range of the assay kit. 
 
2.18. Agonist induced ERK 1/2 phosphorylation in CHO cells 
expressing the C5a1 receptor 
 
C5a and C5a des Arg induced intracellular phosphorylation of extracellular signal-
related kinase (ERK 1/2) was assessed using Cisbio’s cell based homogeneous HTRF® 
assay kit (Cisbio, Cat. 64AERPEG).  CHO cells overexpressing the C5a1 receptor were 
seeded into a white, clear bottom, 384 well assay plate at 15,000 cells/well in growth 
media.  Cells were incubated for 4 hours at 37oC, 5% CO2 to allow cells to attach.  
Growth media was then aspirated and replaced with growth media without FBS.  
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Assay plate was incubated at 37oC, 5% CO2 overnight to minimize basal levels of 
phosphorylated ERK 1/2.  On the day of experiment, cells were stimulated with 
concentration ranges of either C5a or C5a des Arg prepared in FBS deficient growth 
media supplemented with 0.05% BSA (Miltenyi Biotec Cat. 130-091-376).  The plate 
was incubated at 37oC, 5% CO2 for 5 minutes after which time the assay was 
terminated by the rapid removal of liquid from each well by a flicking action onto a 
paper towel, followed by the rapid administration of the cell lysis to all assay wells.  
After a 60 minute incubation on a shaker at room temperature, cell lysates were 
transferred to respective wells of a white, low volume 384 well detection plate 
containing 4 µL of pre-mixed pERK specific antibody detection reagent.  The assay 
plate as then sealed and incubated at room temperature overnight before being read 
on a PerkinElmer Envision® Multilabel plate reader using a 337 nm excitation and 
620/665 nm emission protocol.  Emission ratio values were expressed as a 
percentage of assay window defined by the no stimulation control and the maximum 
response achieved with C5a. 
 
2.19. Agonist induced C5a1 or C5a2 receptor internalization 
 
Agonist induced receptor internalization was assessed using the DiscoverX 
PathHunter® Activated GPCR Internalization Assay technology.  This technology 
monitors GPCR trafficking to the early endosome using -galactosidase (-gal) 
enzyme fragment complementation.  In this system a small fragment of -gal called 
the ProLink™ is localized to intracellular endosomes.  The larger fragment of -gal, 
called the Enzyme Acceptor is fused to -arrestin.  Receptor stimulation leads to -
arrestin recruitment to the activated GPCR followed by internalization of the 
receptor-arrestin complex to cellular endosomes.  This results in complementation of 
the two enzyme fragments and the formation of a functional enzyme that is able to 
hydrolyse a substrate to generate a chemiluminescent signal using the PathHunter® 
detection reagents. 
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U2OS cells over expressing either the C5a1 or the C5a2 receptor, enzyme acceptor 
tagged β-arrestin and a ProLink™ tag localized to the endosomes were plated at 5000 
cells per well in 20 µL in 384 well, black, clear bottom, tissue culture plates in 
DiscoverX proprietary cell plating media and left for 24 hours at 37oC, 5% CO2. Cell 
plating media was aspirated and replaced with 20 µL assay buffer. Cells were next 
incubated with 5 µL of either assay buffer, the C5a1 receptor antagonist PMX53 (1 
µM final assay concentration), mouse anti-human C5a2 receptor (15 µg/mL final 
assay concentration of clone 1D9-M12, BioLegend), or mouse IgG2a isotype antibody 
control (15 µg/mL final assay concentration of clone MG2a-53, BioLegend) for 60 
minutes at 37oC, 5% CO2.  Assay buffer pre-treated cells were then stimulated with 5 
µL of either assay buffer or concentrations of C5a or C5a des Arg.  Cells pre-treated 
with antagonist or isotype control were stimulated with 5 µL of either 3 nM or 30 nM 
final assay concentration of C5a or C5a des Arg.  Assay was incubated for 3 hours at 
37oC 5% CO2.  12 µL PathHunter® detection reagent was added to each experimental 
well and the assay plate was incubated for 60 minutes at room temperature.  Assay 
plates were then read on an EnVision® Multilabel plate reader (PerkinElmer) using 
luminescence protocol. 
 
2.20. Agonist induced C5a1 or C5a2 receptor -arrestin 
recruitment 
 
Agonist induced -arrestin recruitment to C5a receptors was assessed using the 
DiscoverX PathHunter® -arrestin recruitment assay technology.  The assay principle 
is similar to that described above for the internalization assay, with enzyme 
complementation occurring when receptor and -arrestin come together.   
CHO-K1 cells over expressing either ProLinkTM fused C5a1 receptor or the C5a2 
receptor and enzyme acceptor tagged β-arrestin were plated at 5000 cells per well in 
20 µL in 384 well, black, clear bottom, tissue culture plates in DiscoverX proprietary 
cell plating media and left for 24 hours at 37oC, 5% CO2.  The remainder of the assay 
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was performed in the same manner as described for the PathHunter® internalization 
assay. 
 
2.21. Expression of wild type and mutant C5a1 receptors in 
CHO cells 
 
To determine whether specific amino acid residues, located within the 
transmembrane region of the C5a1 receptor, contribute to either the affinity and 
functional potency of human purified C5a and C5a des Arg or antagonism produced 
by PMX53 and NDT9513727, either wild type or mutant C5a1 receptor constructs 
(E180A, E199A, D282A, R175A and R206A) were expressed in CHO cells.   pcDNA3.1 
plasmids containing each C5a1 receptor gene were generated by Blue Sky BioServices 
Inc, Worcester, MA, USA.  CHO cells transformed to stably over express the G16 G-
protein under Zeocin resistance were grown to 80% confluency in media described 
above with the exclusion of Geneticin®.  Cells were re-suspended in electroporation 
buffer (MaxCyte, Cat. EBR100) to a concentration of 1 x 108 cells/mL and 2 x 107 cells 
were mixed with 40 µg of a single plasmid.  Cells and plasmid were then transferred 
to a processing assembly (MaxCyte Cat. OC-400R10) and cells were transfected with 
the MaxCyte STX® electroporation transfection system using a CHO cell specific 
protocol.  Cells were then incubated at 37oC, 5% CO2 for 30 minutes in 
electroporation buffer before being re-suspended in previously described growth 
media and seeded into a 384 well, black, clear bottom assay plate at a density of 
10,000 cells/well.  Cells were incubated over night at 37oC, 5% CO2 before being 
investigated for agonist induced calcium mobilisation.  The expression of each 
receptor was assessed using the C5a1 receptor specific, FITC-S5/1 antibody 
(Biolegend) and flow cytometry as described above. 
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The characterization of reagents and 
pharmacological tools to enable accurate 
interrogation of C5a, C5a des Arg and their 
receptors, C5a1 and C5a2 
 
3.1. Abstract 
 
To elucidate the role of a protein macromolecule in a complex signalling pathway, 
scientists often use protein specific antibody, peptide and small molecule 
pharmacological tools to activate or neutralize the function of that protein.  
However, the specificity of a pharmacological tool for a single protein is 
concentration dependent, and using excessive amounts of that tool will invariably 
lead to the cross reactivity with other proteins.  Selection of pharmacological tools is 
usually achieved through data presented in peer reviewed scientific manuscripts, 
where details pertaining to the purity and protein specificity of that tool are often 
misleading or absent.  To enable the robust and accurate interrogation of the role of 
C5a and C5a des Arg in C5a1 and C5a2 signalling, here I have performed a thorough 
evaluation of the purity and receptor specificity of pharmacological tools that are 
reported to interact with the C5a receptors.  Through the use of receptor specific cell 
lines and competition binding experiments I have been able to select 
pharmacological tools and concentrations that will specifically perturb the 
interaction of C5a and C5a des Arg at either the C5a1 or C5a2 receptors.  These data 
will inform tool selection for research outlined in subsequent chapters of this thesis. 
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3.2. Introduction 
 
Small molecule, peptide ligands and specific protein antibodies are essential 
pharmacological tools to determine the role and function of protein macromolecules 
in biological systems.  Pharmacological tools, in conjunction with tailored 
experimental methods, not only enable the pharmacologist to determine the 
presence and abundance of a peptide or protein but also allow them to elucidate its 
role within a specific signalling pathway in the biological system of interest. 
In order for a pharmacologist to make an accurate claim regarding the role of a 
peptide or protein in a biological signalling pathway they must understand the 
quality and true protein specificity of the pharmacological tool that is being used.  No 
pharmacological tool is truly specific for any protein subtype and any claims 
regarding specificity of an agent will be related to a concentration used  (Ramage, 
2005). 
Pharmacological tool selection is generally achieved by gathering information from 
peer reviewed scientific manuscripts or from information provided by the supplier.  
The specificity of a pharmacological tool is often determined by biochemical or 
pharmacological experimentation using either purified or recombinant versions of 
the protein of interest.  However, in some instances, claims regarding the specificity 
of a pharmacological tool can be misleading. This can then lead the pharmacologist 
to make incorrect assumptions about the quality, specificity and subsequent utility of 
the research tool under consideration.  Lack of or misleading information can present 
in several forms: 
1. Minimal information concerning the amino acid sequence of a peptide ligand or a 
protein target to which the tool was designed. 
2. No information pertaining to the mode of the tools action.  Where on the protein 
target does the tool bind?  Is it competitive or non-competitive with the endogenous 
ligand for that protein? 
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3. Appropriate use of pharmacological endpoints to assess the selectivity of the 
pharmacological tool for the protein of interest over closely related protein 
homologues.  For instance, IC50 values can sometimes exaggerate the specificity of a 
competitive receptor antagonist for one protein over another if inappropriate 
concentrations stimulating agonist or tracer ligand are used. 
The main aim of this chapter is to perform a thorough characterization of the 
biological systems that specifically overexpress either the C5a1 or C5a2 receptor and 
determine the selectivity profile of the commercially available pharmacological 
agents that bind to these receptors. These agents include the peptide 
anaphylatoxins, C5a and C5a des Arg and the reported receptor specific tools which 
could be used to antagonize C5a and C5a des Arg at either the C5a1 or C5a2 receptor.  
These data will enable accurate interrogation of these ligands and receptors in 
subsequent chapters of this thesis. 
To address the concerns regarding the specificity of pharmacological tools that could 
be used to investigate the role of the fragment anaphylatoxin peptides C5a and C5a 
des Arg and the role of their receptors C5a1 and C5a2 in cell signalling this chapter 
includes the following aims: 
1. Confirm the sequence of the C5a1 and C5a2 receptor that are overexpressed 
in previously generated in-house cell lines (CHO-K1 expressing C5a1 receptor 
and the G16 G-protein, U2OS expressing the C5a2 receptor and GFP -arrestin 
2). 
2. Confirm that each cell line selectively expresses the relevant C5a receptor.  
3. Quantify the purity and molecular weight of commercially sourced human 
purified C5a and C5a des Arg by mass spectrometry.  
4. Develop receptor ligand binding assays for both the C5a1 and C5a2 receptor 
using the overexpressing cells and 125I-C5a to quantify the affinity and 
receptor specificity of reported pharmacological tools.  
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3.3. Chapter specific methods 
 
3.3.1. Data analysis and model fitting 
 
All non-linear regression models were fitted to data using GraphPad Prism version 
6.00 for Windows (GraphPad Software, La Jolla California USA, www.graphpad.com).   
Radioactive counts in CPM obtained from saturation binding experiments were 
converted to number of receptors in fmol/100,000 cells using a counter efficiency 
correction factor, the DPM/Ci constant  2.22 x 1012, ligand specific activity of 2200 
Ci/mmol and the number of cells per assay well.  Saturation data were fit to a one 
site specific binding model.  The Kd defined as the concentration of hot ligand that 
binds 50% of the receptor population and Bmax defined as the maximum number of 
binding sites per sample.  
Association kinetic data were globally fit to the association kinetic model using 
multiple concentrations of hot ligand to derive a single best-fit estimate for kon and 
for koff. 
Concentration response data from competition binding experiments were fit using 
the four parameter logistic equation (equation 3.1) to obtain IC50 values and an 
estimate of Hill slope. Affinity constants (Ki) for each competitive agent were 
calculated from IC50 values using the Cheng-Prusoff equation as described by Cheng 
et al. (1973) (equation 3.2). 
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Equation 3.1. Four parameter logistic equation 
 
 
 
 
 
Where, y = dependent variable, x = independent variable a = lower asymptote, b = Hill slope, c = IC50, d 
= upper asymptote. 
 
 
Equation 3.2. Cheng-Prusoff equation 
 
 
 
 
Where, Ki = equilibrium dissociation constant of a ligand for receptor, IC50 = concentration of 
pharmacological tool that inhibits 50% of tracer ligand binding to the receptor, [L] = free 
concentration of tracer ligand used in the experiment, Kd = equilibrium dissociation constant of the 
tracer ligand for receptor. 
 
 
 
 
 
Ki = 
IC50
[L]
Kd
1 + 
y  =  d  +
a  - d
x
c
1  + 
b
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3.4. Results 
 
3.4.1. Sequence analysis of recombinant C5a1 receptor and C5a2 
receptor overexpressed in CHO and U2OS cells 
 
To make accurate conclusions regarding the selectivity and specificity of 
pharmacological tools for each of the C5a receptors, the DNA sequence of the C5a1 
receptor over expressed in CHO cells and the C5a2 receptor over expressed in U2OS 
cells was determined.  Two sets of PCR primers were designed to the flanking 
sequences of the expression vectors for the C5a1 and C5a2 constructs.  The PCR 
products were purified and sent to Wyzer Biosciences Inc (Cambridge MA, US) for 
double stranded sequencing.   
The DNA nucleotide sequence for each recombinant gene from the initiating ‘ATG’ 
(Methionine) codon to the stop ‘TAG’ codon was aligned with the human DNA 
sequence for each gene published in the NCBI database (C5a1 receptor = 
NM_001736, C5a2 receptor = NM_018485).  The C5a1 receptor nucleotide sequence 
aligned 100% with the published nucleotide sequence.  The alignment of the C5a2 
receptor highlighted one nucleotide difference at position 754 with the recombinant 
C5a2 gene containing thymine and the published gene sequence containing cytosine.  
However the resultant nucleotide triplet (recombinant C5a2 receptor = TTG) encodes 
for the same amino acid, leucine, as reported in the published protein sequence 
(published C5a2 receptor = CTG), and therefore the difference is conserved.  This 
results in 100% identity for each recombinant receptor protein sequence to the 
published protein sequence (C5a1 receptor = NP_001727, C5a2 receptor = 
NP_060955).  Amino acid alignment of each receptor protein sequence is shown in 
appendix 1. 
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3.4.2. Quantifying the expression of each C5a receptor in the CHO and 
U2OS cells 
 
A range of methods were utilized to assess the extent and selectivity of expression of 
each C5a receptor at both the gene and protein level. 
Real-time qPCR was employed to assess the relative C5a1 and C5a2 receptor gene 
expression in each cell line compared to the endogenous control GAPDH.  For each 
gene in each sample ΔCT were calculated by subtracting the average CT of GAPDH 
control gene from CT of each replicate for the test gene.  Expression values were 
multiplied by a constant value such that genes with CT values of background (CT > 
35) had an expression value of ∼1. This allowed for easy determination of signals 
above background. Relative gene expression for the C5a1 and C5a2 can be seen in 
figure 3.1.  The stably transfected CHO cell express the C5a1 receptor gene to a high 
level with approximately 3 x 106 relative expression and as expected there was no 
detection of endogenous C5a2 receptor in this rodent cell line.  Similarly the U2OS 
cell line stably expressing the C5a2 receptor displays a high copy number of this gene 
with approximately 2 x 106 relative gene expression.  Using the primer probe set for 
the C5a1 receptor gene that maps within a single exon (highest gene coverage) it can 
be seen that this gene is expressed at a low level in the U2OS cell.  However, the 
expression of the C5a2 receptor is more than 300 time that of the C5a1 receptor 
which is sufficient to assess the specificity of agents towards the C5a2 receptor.  
Quantification of endogenous C5a2 gene expression with a primer probe set that 
spans an exon demonstrates that all of the C5a2 receptor expression in the U2OS cell 
comes from the stable transfection of this cell line. 
Whole cell protein expression of each receptor was next determined by resolving 
proteins from transformed CHO cell and U2OS cell lysates using gel electrophoresis 
followed by immunoblotting with specific receptor antibodies.  GAPDH detection was 
used as protein loading control and lysates from GM-CSF differentiated human 
monocyte-derived macrophages were used as a control lysate for both C5a 
receptors.  As can be seen in figure 3.2, a single protein band that corresponds to the 
approximate molecular weight of either the C5a1 or C5a2 receptor (45 kDa) appears 
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in each of the macrophage lysate lanes confirming the expression of both C5a 
receptors in human monocyte-derived macrophages.  The detection of a C5a1 
receptor protein band was only observed in the CHO cell lysate while the detection 
of a C5a2 receptor protein band was only observed in U2OS cell lysate.  Unlike the 
single C5a2 protein band identified in the macrophage lysate, two discrete bands 
appear in the U2OS lysate.  This double band probably reflects a post translational 
modification of the C5a2 receptor that has occurred in the U2OS cell line.  These data 
confirm the selective protein expression of the C5a1 and C5a2 in the CHO and U2OS 
cell lines respectively. 
Flow cytometry analysis was employed to ascertain the expression of each receptor 
at the surface of each cell line.  Separate samples of each cell line were stained with 
fluorophore conjugated antibodies that are specific for each C5a receptor. Mean 
fluorescence staining intensity was compared to samples stained with matching 
concentrations of isotype control antibodies.   
As can be seen from figure 3.3, the CHO cell line displays a high degree of staining 
intensity for the C5a1 receptor compared to isotype control (A) with no meaningful 
staining intensity of the C5a2 receptor (C).  Whereas the U2OS cell line displays a high 
degree of staining intensity for the C5a2 receptor (D) with no meaningful expression 
of the C5a1 receptor (B).  Saturated receptor staining was achieved with the 
manufactures recommended test concentration of 1 µg for the C5a1 specific S5/1 
antibody clone and 2 µg for the C5a2 specific 1D9-M12 antibody clone.   
Combined with the gene and whole cell protein expression results, these data 
confirm the selective cell surface expression of either the C5a1 or the C5a2 receptor 
in the CHO cells and U2OS cells respectively. 
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Figure 3.1. Selective gene expression of the C5a1 and C5a2 receptors in the transformed cell lines 
C5a1 and C5a2 receptor gene expression quantified from RNA isolated from either CHO or U2OS cells 
using Real-Time PCR.  Relative gene copy number was calculated using the endogenous control gene 
GAPDH and a comparative CT method (2
–ΔCt
).  The vertical axis represents mean + S.D. from 
quadruplicate wells.  Data obtained from a single experiment. 
 
 
 
 
 
 
 
Figure 3.2. Whole cell expression of the C5a1 and C5a2 receptors in CHO and U2OS cells 
Detection of the C5a1 and C5a2 receptor protein in lysates from CHO and U2OS cells by 
immunoblotting.  GAPDH was used as the sample loading control and lysate from human monocyte-
derived macrophage was used as a positive sample control.  Image representative of three separate 
experiments. 
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Figure 3.3. Cell line specific membrane expression of either the C5a1 and C5a2 receptor 
Cell surface staining of CHO cells with either the (A) C5a1 specific S5/1 antibody or (C) C5a2 specific 
1D9-M12 antibody and cell surface staining of U2OS cells with either (B) the C5a1 specific S5/1 
antibody or (D) the C5a2 specific 1D9-M12 antibody.  Receptor specific antibody staining is 
represented by the filled histogram and the isotype matched control staining by the open histogram.  
The horizontal axis represents mean fluorescence intensity.  The vertical axis represents cell count as a 
percentage peak height at the mode of the distribution. 
 
 
 
A 
C D 
B 
CHO cells U2OS cells 
C5a1 stain C5a1 stain 
C5a2 stain C5a2 stain 
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3.3.3. Characterisation of human purified C5a and C5a des Arg 
 
In order to verify the purity and mass of the purchased human purified C5a and C5a 
des Arg, each peptide fragment was analysed using mass spectrometry.  Peptide 
purity was assessed at an absorbance wavelength of 280 nm and revealed that C5a 
was 96% pure (figure 3.4A).  Maximum Entropy deconvolution was applied to the 
raw mass spectrometry data from peak 2 (B) to determine the peptide mass in the 
target molecular weight range (C).  The deconvoluted mass showed a parent 
ionization peak at 10,594 Da and a daughter peak at 10,476 Da with a molecular 
weight difference between these peaks of 118 Da.  Similar results were observed for 
C5a des Arg (figure 3.5).  Peptide purity was approximately 95% (A) and the 
devonvolution of the raw mass spectrometry peak (B) generated a parent ionizing 
peak at 10,438 Da and a daughter ionizing peak at 10,319 Da.  The difference 
between parent and daughter peak was 119 Da. 
The observed presence of parent and daughter ionization peaks split by a mass 
difference of 119 Da  can be explained by cysteinylated adduct formation.  C5a and 
C5a des Arg each contain a total of seven cysteine residues (figure 3.6 A).  Reis et al. 
(2012) comment that six of the these cysteines are engaged in disulphide bridges 
between residues 21-47, 22-54 and 34-55.  The cysteine at position 27 is therefore 
able to associate with free plasma cysteines in circulation forming a cysteinylated 
adduct via a disulphide bond.  This results in the parent ionizing peak, which contains 
the cysteinylated adduct, having a mass increase of 119 Da compared to the 
daughter ionizing peak which does not (figure 3.6 B). 
To determine the molecular weight difference between C5a and C5a des Arg the 
molecular weight of the parent ionization peak for C5a des Arg was subtracted from 
the molecular weight of the parent ionization peak for C5a.  This revealed a 
molecular weight difference of 156 Da.  Arginine is removed from the C-terminus of 
C5a via enzyme mediated hydrolysis by carboxypeptidases.  The molecular weight of 
Arginine is 174 Da and its removal followed by the addition of water (18 Da) results 
in a mass difference of 156 Da (figure 3.7). 
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The expected mass of each peptide based on the amino acid composition is 8274 and 
8117 Da for C5a and C5a des Arg respectively (determined using an online peptide 
mass calculator).  However both peptides have generated ionization peaks between 
10,600 and 10,300 Da.  This extra mass is can be explained by the glycosylation 
pattern of each peptide.  Fernandez et al. (1978b) demonstrated that the asparagine 
residue at position 64 in C5a is linked to a single oligosaccharide unit. Attachment 
occurs by a N-glycosidic linkage between N-acetylglucosamine and the amide 
nitrogen of an asparagine side chain which follows the empirical rule for N-
glycosylation at an asparagine residue in that the linkage occurs in glycoproteins only 
at an Asn-X-Ser/Thr sequence (Jackson et al., 1970). 
 
3.3.4. Determining the specificity of ligands and pharmacological tools 
for the C5a1 and C5a2 receptors 
 
Competition binding experiments using 125I-C5a were next employed to determine 
the affinity and selectivity of a set of pharmacological tools at the C5a1 and C5a2 
receptors.  All receptor ligand binding experiments were constructed in a way to 
prevent ligand depletion (< 10% of 125I-C5a or compound is bound to receptor or 
non-specific sites).  To ensure all affinity constants (K, the equilibrium dissociation 
constant) were determined at equilibrium, a set of association kinetic experiments 
using two concentrations of 125I-C5a were performed at each receptor.  As can be 
seen in figure 3.8, the binding of 125I-C5a to both C5a receptors is stable at the four 
hour extended incubation time.  Data for both ligand concentrations were fit to the 
association kinetic model to derive a single best-fit estimate for kon and for koff from 
which an estimate of the Kd could be derived.  
125I-C5a bound to C5a1 receptor with a 
mean average kon of 6.48E+08 M
-1 min-1, a koff of 0.011 min
-1 which generated a 
kinetically derived Kd of 18 pM.  
125I-C5a displayed an eight fold slower kon to the C5a2 
receptor (7.96E+07 M-1 min-1) but a comparable Koff (0.018 min
-1) which generated a 
kinetically derived Kd of 255 pM. 
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125I-C5a saturation analysis was next performed on each C5a receptor expressing cell 
line at the extended four hour incubation time.  This experiment allows the 
determination of the Kd, the concentration of ligand that binds to 50% of the 
receptor population at equilibrium, a value which is required for affinity constant 
calculation using the Cheng-Prusoff equation.  125I-C5a saturated both receptor 
populations in a monophasic manner (figure 3.9) with average Hill slopes of 0.85 and 
1.1 for C5a1 and C5a2 respectively and bound to C5a1 receptors expressed on CHO 
cells with a Kd of 35.2  7.41 pM (n=5) and to the C5a2 receptors expressed on U2OS 
cells with a Kd of 169.8   52.3 pM (n=4).  Both receptors were expressed at a high 
density in their respective cells lines with the C5a2 receptor expressed eight fold 
higher (Bmax = 98 fmol receptor/100,000 cells) than the C5a1 receptor (Bmax = 12 fmol 
receptor/100,000 cells). 
Eight of the pharmacological tools tested (table 3.1) bound to the C5a1 receptor in a 
competitive manner with 125I-C5a and displayed the following rank order of affinity: 
human purified C5a > human recombinant C5a > 8D6 > human purified C5a des Arg > 
P12/1 > S5/1 > NDT9513727 > PMX53.  Four of the tools bound the C5a2 receptor in a 
competitive manner with 125I-C5a with the following rank order of affinity: human 
purified C5a > human purified C5a des Arg > human recombinant C5a > 1D9-M12. 
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Figure 3.4. Purity assessment and mass determination of human purified C5a 
Analysis of C5a peptide purity as measured at an absorbance of 280 nm (A).  Raw mass spectrometry 
data for peak 2 (B) and deconvolution of peak 2 using MaxEnt in the anticipated molecular weight 
range of C5a (C). 
 Parent ionizing peak = 10594 m/z 
 
 Daughter ionizing peak = 10476 m/z 
 
 Difference in mass = 118 Da 
Raw MS spectra of peak 2 
Deconvoluted spectra of peak 2 
A 
B 
C 
Purity at 280nm 
P1 = 3.5% 
P2 = 95.7% 
5% 
P3 = 0.8% 
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Figure 3.5. Purity assessment and mass determination of human purified C5a des Arg 
Analysis of C5a des Arg peptide purity as measured at an absorbance of 280 nm (A).  Raw mass 
spectrometry data for peak 2 (B) and deconvolution of peak 2 using MaxEnt in the anticipated 
molecular weight range of C5a des Arg (C).  
 
A 
P2 = 94.9% 
5% 
P1 = 2.5% P3 = 3.2% 
Purity at 280nm 
 Parent ionizing peak = 10438 m/z 
 
 Daughter ionizing peak = 10319 m/z 
 
 Difference in mass = 119 Da 
Raw MS spectra of peak 2 B 
C Deconvoluted spectra of peak 2 
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Figure 3.6. Location of asparagine and cysteine residues in the peptide sequence of C5a and 
cysteinylation of cysteine
27
 
Location of the glycosylated asparagine
64
 (underlined) and cysteine residues in the amino acid 
sequence of C5a (A). Disulphide bridges form between cysteine residues 21-47 (red), 22-54 (blue) and 
34-55 (green) leaving a free cysteine residue at position 27 (orange).  Cysteinylation results in a mass 
increase of 119 Da (B). 
 
 
Figure 3.7. Removal of arginine via enzyme mediated hydrolysis 
Amino acid scheme detailing the molecular weight reduction in C5a when arginine is removed via 
enzyme mediated hydrolysis to form C5a des Arg.  This results in a molecular weight difference of 156 
Da between the two peptides. 
 
119 Da 
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Both the recombinant C5a and the 125I-C5a originate from the source (Sigma Aldrich 
Cat# C5788) and the affinity estimates for this ligand across the association kinetic, 
saturation and competition binding assays are highly comparable (18, 35, & 20 pM 
for C5a1 receptor and 255, 170 and 171 pM for the C5a2 receptor). 
Human purified C5a displayed very high affinity towards the overexpressed C5a1 
receptor in CHO cells and demonstrated a nine fold selectivity for C5a1 receptor over 
the C5a2 receptor. Similar results were obtained with human recombinant C5a.  In 
contrast C5a des Arg displayed marginally higher affinity (two fold) for the C5a2 
receptor.  Interestingly the competition response curves for C5a des Arg at the C5a1 
receptor were notably shallow (-0.54, n=4) and significantly different to the slopes at 
the C5a2 receptor (-1, n=4) (paired Students t-test; P=0.01) (figure 3.10 B).   
As expected the anaphylatoxin peptides C3a and C3a des Arg did not bind either C5a 
receptor in a competitive manner with 125I-C5a.  C3a and C3a des Arg have been 
reported to possess acylation-stimulation properties (Murray et al., 1997) and that 
C3a des Arg mediates this response via binding to and activation of the C5a2 receptor 
(Kalant et al., 2003).  The authors demonstrate that C3a des Arg interacts with the 
C5a2 receptor is at discrete binding sites to those used by C5a.  These data confirm 
that there is no competitive interaction between these two peptides at the C5a2 
receptor, and confirms the results obtained by Johswich et al. (2006).   
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Figure 3.8. Binding kinetics of 
125
I-C5a to the C5a1 and C5a2 receptors 
Association of 
125
I-C5a to (A) the C5a1 receptor and (B) the C5a2 receptor with two concentrations of 
hot ligand.  A global association kinetics model was fit to each data set to obtain Kon (M
-1
 min
-1
), Koff 
(min
-1
) and Kd (M).  Each data point is the mean average of two replicates  S.D.  Representative data 
from two separate experiments. 
 
 
 
 
 
 
 
 
Figure 3.9. Saturation analysis of C5a1 and C5a2 receptors using 
125
I-C5a 
Specific binding of 
125
I-C5a to (A) C5a1 receptors on CHO cells and (B) C5a2 receptors on U2OS cells.  
Plateau of the non-linear regression curve defined the maximal receptor expression (Bmax).  Affinity 
(Kd) was defined as the concentration of 
125
I-C5a that bound 50% of the receptor population.  Each 
data point is the mean average of two replicates. Data representative of four separate experiments. 
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The cyclic peptide antagonist PMX53 and small molecule antagonist NDT9513727 
displayed high affinity for the C5a1 receptor inhibiting the binding of 
125I-C5a to the 
C5a1 receptor in a concentration dependent manner.  Neither agent inhibited the 
binding of 125I-C5a to the C5a2 receptor.  Similar C5a1 receptor selective inhibition 
profiles were observed with the antibody clones P12/1, S5/1 and 8D6.  The P12/1 
and S5/1 mouse monoclonal antibodies were both generated through peptide 
immunization using a 31 amino acid peptide fragment of the N-terminus of the C5a1 
receptor (Met1-Asn31).  Vendors of this antibody (Abcam and Novus Biologicals) both 
claim in their product literature that clone P12/1 does not inhibit C5a binding to the 
C5a1 receptor.  However, data in this report clearly demonstrate this claim to be 
false.  Interestingly, unlike clone 8D6 which was raised using a rat basophilic 
leukemia cell line (RBL-2H3) transfected with the human C5a1 receptor, both P12/1 
and S5/1 cannot fully displace 125I-C5a from binding to the C5a1 receptor with 
approximately 15-20% residual 125I-C5a binding at receptor saturating concentrations 
of these two antibodies.  Antibody clone W17/1 demonstrated weak inhibition of 
125I-C5a at the C5a1 receptor with no apparent affinity for C5a2.   
Of all the antibody clones tested, only 1D9-M12 inhibited the binding of 125I-C5a to 
the C5a2 receptor.  As anticipated from the flow cytometry results this antibody does 
not bind the C5a1 receptor in a competitive manner with C5a. 
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Table 3.1. Affinity of pharmacological tools for the C5a1 and C5a2 receptors 
Affinity estimates for pharmacological tools that are reported to bind the C5a receptors. Affinity 
estimates (Ki) calculated from IC50 curves using the Cheng-Prusoff equation.  Mean Ki and 95% CI 
calculated from four separate experiments.  X = less than 50% inhibition achieved at highest 
concentration tested. 
 
 
 
 
 
 
 C5a1 receptor C5a2 receptor 
Agent Mean 
pKi 
95% CI Mean 
Ki (M) 
Mean 
pKi 
95% CI Mean 
Ki (M) 
Fold 
selectivity 
hp C5a 11.08 10.91 - 11.25 8.29E-12 10.11 9.90 – 10.32 7.75E-11 9.3 for C5a1 
hp C5a des Arg 9.47 9.25 - 9.70 3.35E-10 9.84 9.61 – 10.07 1.45E-10 2.3 for C5a2 
hrec C5a 10.68 10.51 - 10.85 2.08E-11 9.77 9.61 – 9.91 1.71E-10 8.2 for C5a1 
hp C3a X   X   X 
hp C3a des Arg X   X   X 
PMX53 8.02 7.94 - 8.11 9.46E-09 X   Specific for C5a1 
NDT9513727 8.37 8.18 - 8.57 4.25E-09 X   Specific for C5a1 
P12/1 8.89 8.74 - 9.03 1.30E-09 X   Specific for C5a1 
8D6 10.09 9.93 - 10.25 8.16E-11 X   Specific for C5a1 
S5/1 8.72 8.56 - 8.89 1.89E-09 X   Specific for C5a1 
W17/1 X   X   X 
1D9-M12 X   8.35 8.19 – 8.51 4.45E-09 Specific for C5a2 
N 1-50 X   X   X 
N 1-23 X   X   X 
Mouse Isotype X   X   X 
Rabbit Isotype X   X   X 
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Figure 3.10. Competition binding of pharmacological tools at the C5a1 and C5a2 receptors 
Inhibition of specific 
125
I-C5a binding to the human C5a1 receptor (blue) or human C5a2 receptor (red) 
by human purified C5a (A), human purified C5a des Arg (B), human recombinant C5a (C), human 
purified C3a (D), human purified C3a des Arg (E), small molecule receptor antagonists PMX53 (F), NDT-
9513727 (G) and antibody clones P12/1 (H), 8D6 (I), S5/1 (J), W17/1 (K), 1D9-M12 (L).  Data points 
represent mean  S.D. and are representative of four separate experiments. 
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Figure 3.10. Continued 
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3.5. Discussion 
 
The data generated in this research chapter have provided important information 
regarding the quality and specificity of pharmacological tools to enable the 
interrogation of C5a, C5a des Arg and their receptors, C5a1 and C5a2.   
Confirmation of the molecular mass and purity of human C5a and C5a des Arg has 
generated confidence that any similarities or differences observed in the 
pharmacology of these two peptides can be attributed to their molecular properties.  
Receptor-ligand binding assays enabled the quantification of the affinity of 
pharmacological tools for both C5a receptors which subsequently enabled the 
selection of agents that were both receptor specific and C5a competitive.  
The differences in affinity estimates for C5a and C5a des Arg for each of the C5a 
receptors reported here follow a similar trend to the affinity estimates generated by 
others.  However, the absolute estimates of affinity are quite different (table 3.2).  
Cain et al. (2002), Okinaga et al. (2003) and Scola et al. (2007) all report affinities in 
the nanomolar range whereas affinity estimates reported here are in the picomolar 
range.  This could be due to a number of reasons.  The cited reports all used 
recombinant versions of the peptide ligand which, as demonstrated here, are less 
potent that the human purified peptides.  Also, Cain and Okinaga report IC50 values 
which, unlike Ki values, are not affinity constants and are influenced by the 
concentration of competing ligand.  
The experimental factor that is probably contributing the most to the differences in 
absolute affinity estimates is that of the biological test system.  C5a and C5a des Arg 
are receptor agonists and there are four factors that make up receptor agonism 
(Kenakin, 2009a).  Two of these factors, affinity and intrinsic efficacy, are related to 
the agonist.  The other two factors, receptor density (Rt) and receptor-pathway 
coupling efficiency are related to the cell based system.   If an agonist possesses 
affinity for a receptor it will bind to the ligand binding-domain and induce a change in 
the receptor conformation.  This leads to a change in reactivity of the allosteric, 
cytosolic portion of the receptor resulting in intracellular pathway activation via G- 
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Table 3.2. A comparison of the affinity estimates for C5a and C5a des Arg at the C5a1 and C5a2 
receptors 
Mean estimates of affinity for C5a and C5a des Arg at wild type C5a1 and C5a2 receptors.  The table 
details the aspects of the experimental method employed for each data set namely competing ligand, 
cell background for receptor overexpression and source of C5a and C5a des Arg.  Mean affinity 
estimates were obtained from a minimum of four experiments. 
 
protein coupling and -arrestin recruitment.  This vectorial transfer of energy or 
information from allosteric sites is considered to be bi-directional (Kenakin, 2009b).  
As much as an agonist can promote an increase in the reactivity of a receptor with 
intracellular proteins and pathways, increasing the cellular components that make up 
these pathways can increase the likelihood that a receptor exists in an active 
conformation, a conformation that an agonist will display higher affinity for.  Both 
cell lines used in this research have a high degree of receptor expression and were 
both transformed to overexpress intracellular signalling pathway proteins.  The 
impact of G-protein overexpression on agonist affinity has been observed by others 
(Azzi et al., 2001). 
 
Cain (2002) 
IC50 nM 
Okinaga (2003) 
IC50 (nM) 
Scola (2007) 
EC50 (nM) 
Ramsey 
Ki (nM) 
 C5a1 C5a2 C5a1 C5a2 C5a1 C5a2 C5a1 C5a2 
C5a 19.0 9.50 3.4 2.5 5.52 6.92 0.008 0.075 
C5a des Arg 412 36.5 660 12 527 36 0.335 0.145 
Experimental 
details 
1. Competition binding 
with recombinant 
125I-C5a 
2. Transfected RBL 
cells 
3. Recombinant His6-
tagged peptides 
1. Competition binding 
with recombinant 
125I-C5a 
2. Transfected L1.2 cells 
3. Recombinant 
peptides 
 
1. Direct binding – 
antibody detection of 
peptides 
2. Transfected CHO cells 
3. Recombinant His6-
tagged peptides 
1. Competition 
binding with 
recombinant 125I-
C5a  
2. Transfected CHO & 
U2OS cells with 
intracellular 
proteins 
3. Human purified 
peptides 
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The clinically tested receptor antagonists PMX53 and NDT9513727 both displayed 
high affinity for the C5a1 receptor and complete specificity over the C5a2 receptor.  
Both of these antagonists, which bind to the transmembrane domain of the C5a1 
receptor (Waters et al., 2005), were able to antagonize the binding of 125I-C5a to the 
same degree as unlabelled C5a.  This observation was not consistent with the 
antibody clones P12/1 and S5/1 that were raised against the N-terminus of the C5a1 
receptor using a peptide sequence from Met1- Asn31 as the immunogen.  At receptor 
saturating concentrations, there is 10-20% residual 125I-C5a binding to the C5a1 
receptor.  This residual C5a binding is consistent with the multi binding-domain 
hypothesis by which C5a binds the C5a1 receptor (Mery et al., 1993).   Both Siciliano 
et al. (1994) and DeMartino et al. (1994) demonstrated that partial or complete 
truncation of the N-terminus of the C5a1 receptor resulted in a significant reduction 
in the affinity of C5a (~600 fold).  However, C5a and C-terminal peptides of C5a, are 
still able to bind the receptor through interactions with the transmembrane domain.   
These observations suggest that agents that interact with the transmembrane 
domain of the receptor bind in such a way that the full steric hindrance with C5a 
occurs.  However, agents that bind the N-terminus of the receptor only partially 
hinder the binding of C5a to the C5a1 receptor.  With that said, the antibody clone 
8D6, which was generated using the full length of the C5a1 receptor, is able to fully 
displace C5a binding.  These data suggest that this antibody achieves its antagonising 
effects through interactions with the transmembrane domain of the receptor. 
The only agent to inhibit the binding of C5a to the C5a2 receptor was the antibody 
clone 1D9-M12 that was generated using the full length receptor as the immunogen.  
This antibody was able to inhibit 125I-C5a binding to the C5a2 receptor to the same 
degree as unlabelled C5a, suggesting that this inhibition is achieved via interactions 
in the transmembrane region of the receptor.  This observation is consistent with 
data generated by Scola et al. (2007) who demonstrated using N-terminus targeting 
antibodies that C5a only interacts with the transmembrane domain of the C5a2 
receptor.   A scheme of the proposed mechanisms by which the different antibodies, 
cyclic peptides and small molecules antagonize the actions of C5a and C5a des Arg at 
the C5a1 and C5a2 receptors can be seen in figure 3.11.  
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In summary, the research outlined in this chapter has verified the molecular weight 
and purity of the complement system peptides C5a and C5a des Arg and enabled the 
selection of receptor specific agents that will antagonize the actions of C5a and C5a 
des Arg at the C5a1 or C5a2 receptor.  In subsequent research within this thesis 1µM 
of PMX53 or NDT9513727 will be used to antagonize the C5a1 receptor and 300nM 
(45 µg/mL) 1D9-M12 will be used to antagonize the C5a2 receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Inhibition of C5a binding to C5a receptors by pharmacological tools 
A sheme showing the machanism of A. C5a bindigng to C5a receptors, B. the antagonism of C5a at the 
C5a1 receptor by antibody clones P12/1 and S5/1 and C. the antagonism of C5a at the C5a1 receptor 
by PMX53 and NDT9513727 and C5a at the C5a2 receptor by antibody clone 1D9-M12.  
A 
B 
C 
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Characterization of a C5a sensitive biological test 
system, the human isolated neutrophil 
 
4.1. Abstract 
 
Biochemical and pharmacological assay systems employed to study the role of 
specific receptors on the surface of a neutrophil often require the use of purified 
neutrophils isolated from human whole blood.  Procedures to isolate human 
neutrophils are often lengthy and cumbersome involving many different reagents, 
some of which have the potential to activate this fragile population of myeloid cells.  
Using a range of molecular biology, biochemical and pharmacological assay 
techniques I have investigated the suitability of the new MACSxpress® neutrophil 
isolation kit offered by Miltenyi Biotec Inc to study the role of both the C5a1 and C5a2 
receptors in regulation of neutrophil function. The rapid, negative selection 
MACSxpress® kit yielded a uniform, quiescent population of neutrophils from human 
whole blood with minimal erythrocyte contamination.  Gene expression studies, 
receptor ligand binding experimentation and flow cytometry analysis all demonstrate 
that human neutrophils express both the C5a1 and C5a2 receptors on the surface of 
the neutrophil.  Neutrophil activation induced by C5a, C5a des Arg or TNF leads to a 
reduction or loss in surface expression of the two C5a receptors but enhances the 
expression of another innate immune system receptor, the formylpeptide receptor 1 
(FPR1).  This work demonstrates the high performance of the MACSxpress® human 
neutrophil isolation kit, which offers several advantages over more traditional 
neutrophil isolation methods, for the detection and investigation of the role of the 
C5a1 and C5a2 receptors in neutrophil function. 
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4.2. Introduction 
 
During pathogenic microbial infection, activation of the complement system leads to 
the rapid and localized generation of C5a which ligates receptors expressed on 
parenchymal cells and leukocytes (Haviland et al., 1995).  Activation of C5a receptors 
expressed on these myeloid cells leads to a series of cellular events that orchestrates 
their role in the inactivation and clearance of microbes.  These cellular events include 
selectin shedding, integrin up regulation (Jagels et al., 2000) and chemotaxis (Shin et 
al., 1968) promoting cellular margination and extravasation from the circulatory 
system to the site of infection.   Once myeloid cells have arrived at the site of 
infection, C5a facilitates the phagocytosis (Craddock et al., 1976) and destruction of 
pathogenic microbes via respiratory burst (Sacks et al., 1978a) and the release of 
antimicrobial proteins from intracellular granules.  High activation of C5a receptors 
on neutrophils can also lead to the generation of neutrophil extracellular traps 
(NETs), which are composed of nuclear chromatin, histones and granular 
antimicrobial proteins that are designed to trap and kill large scale microbial 
infections (Urban et al., 2009). 
Neutrophils are the most abundant leukocyte in human blood.  They represent 
approximately 60% of the total white blood cell population and are considered to be 
the fastest responding immune cell to infection (Kolaczkowska et al., 2013).  
Neutrophils are short-lived leukocytes that have a peripheral blood life span of 
approximately 6-10 hours (Tofts et al., 2011), after which they undergo apoptosis 
(Payne et al., 1994).  
The role of the C5a1 receptor in mediating anaphylatoxin induced neutrophil 
activation is well understood (Guo et al., 2005), however the role of C5a2 receptor is 
still largely enigmatic.  Scola et al. (2009) demonstrated that the C5a2 receptor 
primarily resides at an intracellular location when overexpressed in RBL and CHO 
cells.  They also showed that expression of the C5a2 receptor on the surface of the 
human isolated neutrophil, as identified by C5a binding capacity, is weak compared 
with the C5a1 receptor.  This low level of C5a2 receptor expression is capable of 
internalizing a small proportion of C5a, but is almost exclusively responsible for the 
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internalization and degradation of C5a des Arg.  Similar patterns of C5a receptor 
localization were observed by Bamberg et al. (2010) who showed that the C5a1 and 
C5a2 receptors were exclusively expressed in the human isolated neutrophil at 
surface and intracellular locations respectively.  Contrary to the anaphylatoxin 
internalization capacity of C5a2, Bamberg and co-workers demonstrated that the 
C5a2 receptor expressed in neutrophils did not contribute to the internalization of 
C5a from the extracellular space and that the main role of this receptor was to act as 
an intracellular regulator of the C5a activated C5a1 receptor. 
To investigate the role of receptors and other cellular proteins in neutrophil function, 
many biochemical and functional assay systems require the use of purified 
neutrophil preparations.  Traditional methods used in the isolation on neutrophils 
from human whole blood involve many reagents (dextran sedimentation 
erythrocytes, ficoll separation of mononuclear cells from neutrophils and lysis of 
residual erythrocytes) and rely on lengthy centrifugation steps.  These complex and 
lengthy procedures increase the potential for neutrophil activation, reduces the time 
a researcher has to investigate this short lived cell type and potentially leads to 
incorrect conclusions being made about the functional role of a cellular protein, 
(Glasser et al., 1990). 
With this in mind, the main focus of this research chapter is to investigate the 
performance of a MACSxpress®, rapid, negative selection, neutrophil isolation 
method offered by Miltenyi Biotec Inc.  This assessment will determine the suitability 
of this kit for the isolation of human neutrophils in subsequent chapters of this 
thesis.  The main objectives of this research chapter are: 
1. Determine the purity and activation state of neutrophils isolated from 
human whole blood using the Miltenyi Biotec Inc. MACSxpress® negative 
isolation kit. 
2. Assess the gene expression of C5a receptors in context to other innate 
immune system GPCRs, pattern recognition receptors, cytokine receptors 
and the intracellular pathway proteins -arrestin 1 and 2. 
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3. Using receptor specific, C5a competitive pharmacological tools, assess the 
contribution of each C5a receptor to the neutrophil surface binding 
capacity of C5a. 
4. Investigate whether sepsis associated inflammatory mediators (LPS, 
TNF, C5a and C5a des Arg) activate and alter the surface expression of 
each C5a receptor on human isolated neutrophil.  
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4.3. Chapter specific methods 
 
Concentration response data from competition binding experiments were fitted 
using the four parameter logistic equation outlined in chapter 3. 
4.3.1. Isolation of neutrophils from human whole blood using the 
Miltenyi Biotec MACSexpress® kit 
 
Figure 4.1 outlines the steps and apparatus used to isolate untouched neutrophils 
from human whole blood using the MACSxpress® protocol.  In brief, 8 mL of venous 
human whole blood, collected in EDTA coated BD Vacutainers, was added to 4 mL of 
reconstituted MACSxpress® neutrophil isolation cocktail in a 15 mL tube.  Tube was 
inverted three times and incubated for five minutes at room temperature using the 
MACSmix® Tube Rotator at a speed of 12 rpm.  Tube was then placed in the magnetic 
field of a MACSxpress® separator for 15 minutes with tube lid removed.  After this 
time, with the tube still in the magnetic separator, the supernatant containing the 
neutrophils was collected and placed in a fresh tube, leaving behind the magnetically 
labelled cells and aggregated erythrocytes settled at the bottom of the tube.  
Collected neutrophils were spun at 300 x g for five minutes, supernatant aspirated 
and cell pellet suspended in 10 mLs of assay buffer.  Cell concentration and viability 
was determined using a Beckman Vi-CELLTM  cell counter. 
4.3.2. Statistical analysis. 
 
Statistical significance differences between population means was assessed using 
either the Student’s t test or the one way analysis of variance (ANOVA) followed by a 
Tukey’s multiple comparison test.  All significance tests were performed using 
Graphpad Prism. 
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C       D  
 
 
 
 
 
 
 
Figure 4.1. Untouched isolation of neutrophils from human whole blood using the MACSxpress® 
neutrophil isolation kit 
EDTA collected human blood was added to the MACSxpress® neutrophil isolation cocktail (A) and 
mixed for 5 minutes on the MACSmix tube rotator for 5 minutes (B).  Tubes containing the 
blood/cocktail mix was then placed in MACSxpress magnetic separator with lid removed for 15 
minutes (C).  Supernatant containing untouched neutrophils was then collected and dispensed into a 
fresh tube, leaving behind the settled aggregated erythrocytes and magnetically labelled cells (D). 
Figure generated with images obtained from the Miltenyi Biotec Inc website. 
Tube containing 
blood and isolation 
cocktail 
MACSmix tube rotator 
MACSxpress 
magnetic separator 
Supernatant 
containing 
neutrophils 
Magnetically 
labelled cells 
Settled 
erythrocytes 
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4.4 Results. 
 
4.4.1. The MACSxpress® kit isolates a pure population of neutrophils 
from human whole blood with minimal erythrocyte 
contamination 
 
To assess the performance of the MACSxpress® neutrophil isolation method, the 
purity of isolated neutrophils was compared with the purity of neutrophils within 
human whole blood. Both lyse fixed whole blood and fixed isolated neutrophils were 
labelled with fluorophore conjugated antibodies for the granulocyte cell surface 
proteins CD15 and CD16.  Staining fluorescence intensity was assessed using flow 
cytometry.  Cells staining positive for both CD15 and CD16 were identified as 
neutrophils.  Figure 4.2 shows the different cell populations, based on forward (FSC) 
and side (SSC) scatter, found in either (A) human whole blood or (B) supernatant 
collected after neutrophil isolation.  As expected, whole blood generated a typical 
forward and side scatter plot, from which different cell populations (lymphocytes, 
monocytes and neutrophils) could be identified.  In comparison, the forward and side 
scatter plot of cells isolated using the MACSxpress® method appeared to only contain 
neutrophils and were devoid of monocytes and lymphocytes.  In human whole blood 
(C), approximately 57% of gated cells (lymphocytes, monocytes and neutrophils) 
showed positive staining for the two granulocyte markers.  After isolation (D), 
greater than 95% of cells stained positive for the two markers.  Interestingly, based 
on surface expression of a cell activation marker, the integrin receptor CD11b, 
isolated neutrophils display the same activation state as neutrophils in whole blood.  
Activation of isolated neutrophils with 10 nM human purified C5a increased CD11b 
surface expression, demonstrating the functional viability of neutrophils isolated 
using the MACSxpress® method.  From routine assessment of neutrophil yields, 
between 1.5 to 4 x 106 neutrophils were obtained per mL of human whole blood. 
MACSxpress® neutrophil isolation method was also assessed visually by microscopy.  
Isolated cells were mounted on to glass slides using a cytospin method followed by 
Wright-Giemsa staining.  Figure 4.3 shows an image of the isolated cells acquired on 
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a Zeiss Axio Imager microscope using a 20x objective.  Neutrophils, identified by their 
multi-lobed nucleus, are the only leukocyte isolated using the MACSxpress® method.  
Routine visual examination of isolated cell fraction revealed that there was between 
15-40% erythrocyte contamination.  This level of red blood cell contamination was 
considered acceptable and preferable over erythrocyte removal via hypotonic lysis 
which may cause neutrophil activation. 
 
4.4.2. Gene expression of neutrophil C5a receptors and other proteins 
associated with the innate immune system 
 
Next, gene expression analysis of the C5a receptors in conjunction with other innate 
G-protein coupled receptors (GPCR) was performed on purified RNA from the human 
isolated neutrophils using Real-Time, reverse transcription qPCR.  RNA purified from 
neutrophils was determined to be of high quality with absorbance ratios at 260/280 
nm being greater than 2.  Figure 4.4 shows the relative gene expression of the C5a1 
and C5a2 receptors compared with the C3aR, FPR1, CXCR1, CCR2 and CCR5 receptors 
determined from neutrophil RNA obtained from four different donors.  These data 
demonstrated that, at the gene level, human neutrophils express both the C5a1 and 
C5a2 receptors.  Assuming the efficiency of all primer-probe sets are the same it can 
be suggested that the C5a1 receptor appears to have twice the level of expression of 
the C5a2 receptor.  Expression of the C3aR, CCR2 and CCR5 receptors was barely 
detectable.  This was in contrast to the expression of FPR1 and the interleukin-8 
receptor, CXCR1, which display approximately 10 fold and 3 fold the expression of 
the C5a1 receptor respectively. 
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Figure 4.2. MACSxpress® Neutrophil Isolation Kit delivers a highly pure population of un-activated 
neutrophils from freshly drawn human blood 
Forward and side scatter of (A) lyse/fixed human whole blood and (B) fixed human isolated 
neutrophils separated from human whole blood using the MACSxpress® kit.  Neutrophil population 
identified by APC-CD15 and FITC-CD16 staining in (C) lyse/fixed human whole blood and (D) fixed 
human isolated neutrophils.  Activation state of neutrophils as identified by CD11b up-regulation 
before and after isolation (E).  Dotted histogram represents neutrophils in whole blood, solid 
histogram represents isolated neutrophils, filled histogram represents isolated neutrophils stimulated 
with 10 nM human purified C5a.  Data representative of three different experiments. 
A B 
C D 
E 
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Figure 4.3. MACSxpress® isolation method only isolates neutrophils from human whole blood 
Supernatant, collected from the MACSxpress® neutrophil isolation method, was cytospun onto a glass 
slide and stained with a Wright-Giemsa reagent.  Image, collected on Zeiss AxioImager with a Plan-
Apochromat 20x/0.8 objective with image capture on an AxioCam MRc digital camera, shows that the 
neutrophils, identified by their multi-lobed nucleus, are the only leukocyte to be isolated from human 
whole blood using this method.  Routine visual analysis shows that the collected supernatant contains 
a degree of erythrocyte contamination which represents between 15-40% of the total cells isolated. 
 
 
 
 
 
 
Neutrophils with 
typical multi-
lobed nuclei 
Erythrocytes 
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The relative gene expression of other proteins associated with the innate immune 
system and GPCR function was also assessed using the same purified neutrophil RNA 
used in the above experiment (figure 4.5A).  The toll-like receptor 4 protein (TLR-4), 
tumour necrosis factor receptor 1 (TNFR1), Interleukin-6 receptor (IL-6R) all 
displayed comparable levels of expression in the human isolated neutrophil.  The 
gene expression of two integrin proteins, integrin alpha M (ITGAM, CD11b) and 
integrin beta 2 (ITGB2) was also assessed.  Together these two proteins form the 
heterodimeric integrin alpha-M beta-2 (ITGAMB2) also known as complement 
receptor 3 (CR3), a pattern recognition receptor involved in the detection and 
clearance of pathogenic bacteria.  ITGB2 displayed approximately 10 fold greater 
expression than ITGAM.  This seemed appropriate as, unlike ITGAM which only forms 
a complex with ITGB2, ITGB2 complexes with many other integrin proteins including 
integrin alpha L (ITGAL), integrin alpha X (ITGAX) and integrin alpha D (ITGAD) 
forming important molecules for leukocyte migration and cellular interactions 
(Barczyk et al., 2010). 
To determine the suitability of the DiscoverX -arrestin PathHunter® assay system, 
which uses -arrestin-2, for functional assessment of C5a receptor pharmacology, 
the neutrophil, expression of two members of the -arrestin family of signalling 
proteins, -arrestin 1 and 2, was also assessed.  As can be seen from figure 4.5B the 
expression of -arrestin 2 was approximately 40 fold greater than -arrestin 1 (P < 
0.0001 determined by an unpaired Student’s t test).  These data are comparable with 
those obtained by Croker et al. (2014) who demonstrated that -arrestin 2 displays a 
significantly higher level of expression (17 fold) than -arrestin 1 in the human 
monocyte derived macrophage. 
The gene expression of TLR4 does not translate into detectable neutrophil surface 
expression (figure 4.6).  This is in contrast to the TNF receptors TNFR1 and TNFR2, 
which are both detected on the surface of a neutrophil by flow cytometry.  
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Figure 4.4. Gene expression of the C5a receptors and other innate G-protein coupled receptors in 
the human isolated neutrophil 
Gene expression of the C5a receptors and other innate immune system GPCRs determine by qRT-PCR 
on RNA isolated from neutrophils using the MACSxpress® isolation method.  Relative gene expression 
was calculated using the endogenous control gene GAPDH and a comparative CT method (2
–ΔCt
).  The 
vertical axis represents mean gene expression + S.D. from neutrophil RNA isolated from four healthy 
donors. 
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Figure 4.5. Gene expression of innate immune system receptors and intracellular signalling proteins 
in the human neutrophil 
Gene expression of (A) TLR-4, TNFRSF1, IL-6R, ITGAM and ITGB2 and (B) -arrestin 1 and 2 determined 
by qRT-PCR on RNA isolated from neutrophils using the MACSxpress® isolation method.  Relative gene 
expression was calculated using the endogenous control gene GAPDH and a comparative CT method 
(2
–ΔCt
).  The vertical axis represents mean gene expression + S.D. from neutrophil RNA isolated from 
four healthy donors. **** represents P < 0.0001 determined by an unpaired Student’s t test. 
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Figure 4.6. Neutrophil surface expression on the TLR4 and the TNF receptors TNFR1 and TNFR2 
Surface expression of (A) TLR4, (B) TNFR1 and (C) TNFR2 as detected by flow cytometry on the 
quiescent neutrophils isolated from human whole blood using the  MACSxpress® isolation method.  
Open histogram represents concentration matched isotype control antibody staining, shaded 
histogram represents receptor specific antibody staining.  Data representative of four separate 
donors. 
A 
B C 
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4.4.3. Both C5a receptors are expressed on the surface of the human 
isolated neutrophil 
 
To determine the relative surface expression of each C5a receptor on the human 
isolated neutrophil, the contribution of each C5a receptor to the cell surface binding 
capacity of 125I-C5a was investigated.  Neutrophils were incubated with 140 pM 125I-
C5a, a concentration of C5a expected to label both C5a receptors, at 4oC in the 
absence and presence of receptor specific, C5a competitive, inhibitors.  Specific 125I-
C5a receptor binding was determined using maximum (diluent) and minimum (100 
nM C5a) binding controls and all inhibitor treated wells were expressed as a 
percentage of the specific binding for each donor.  The C5a1 receptor specific 
antagonist, PMX53, significantly (P < 0.0001) reduced 125I-C5a specific binding to 
15.6% suggesting that the C5a1 receptor contributes to 84.4% of the surface C5a 
binding capacity of a neutrophil.  The C5a2 receptor specific antibody clone 1D9-M12 
significantly (P < 0.0001) reduced 125I-C5a specific binding to 87.1% suggesting that 
the C5a2 receptor contributes only 12.9% of the surface C5a binding capacity of a 
neutrophil.  The use of both receptor inhibitors together significantly (P < 0.001) 
reduced C5a binding over PMX53 alone but this dual receptor inhibition was not 
significantly different (P > 0.05) to the minimum 125I-C5a binding control (figure 4.7). 
To quantify the surface expression of C5a receptors on human neutrophils, 
saturation binding analysis was performed at 4oC using a concentration range of 125I-
C5a in the absence and presence of 100 nM unlabelled human purified C5a.  125I-C5a 
saturated neutrophils in a monophasic manner with an average Hill slope of 1.2 
(figure 4.8A).  The average maximum number of C5a binding sites (Bmax) was 0.58 
fmol/100,000 cells ( 0.24, 95% CI, n=4) and 125I-C5a bound to these receptors with a 
Kd of 150 pM ( 60, 95% CI, n=4).  In comparison with the expression of C5a 
receptors in the transformed cell lines described in chapter 3, C5a receptors are 
expressed at a low level in the human neutrophil, with 20 and 170 fold lower 
expression than the C5a1 (CHO) and C5a2 (U2OS) receptors respectively (figure 4.8B) . 
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Figure 4.7. Both C5a receptors contribute to the neutrophil surface binding capacity of 
125
I-C5a 
Neutrophils isolated from human whole blood using the MACSxpress® method were incubated with 
140 pM 
125
I-C5a in the absence or presence of receptor specific, C5a competitive inhibitors (C5a1 - 
PMX53, C5a2 - 1D9-M12, or dual receptor - C5a).  Specific 
125
I-C5a binding for each condition was 
represented as a percentage of the diluent and C5a controls for each donor.  Bars represent mean % 
specific 
125
I binding +/- S.D.  Statistical analysis was performed using one-way analysis of variance 
(ANOVA) and Tukey’s multiple comparison test (**** = P < 0.0001, *** = P < 0.001, ns = not significant 
P > 0.05).  Data obtained with neutrophils isolated from four healthy donors. 
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Figure 4.8. C5a receptor expression on the human isolated neutrophil compared with transformed 
cell lines 
125
I-C5a saturation binding of C5a receptors expressed on the surface of human isolated neutrophils 
(A). A nonlinear regression model was fit to the specific 
125
I-C5a receptor binding determined for each 
ligand concentration. The maximum C5a binding sites (Bmax) and 
125
I-C5a affinity (Kd) were 
extrapolated from the nonlinear fit.  Representative data from neutrophils isolated from four healthy 
donors (A).  Neutrophil C5a receptor expression compared with C5a1 and C5a2 receptor expression on 
the transformed cell lines described in chapter 3.  Bars represent mean Bmax values in fmol 
receptor/100,000 cells + S.D obtained from four separate experiments. 
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Next, competition binding experiments were employed to determine the affinity of 
human purified C5a and C5a des Arg for the receptors on the surface of human 
isolated neutrophils.  Both C5a and C5a des Arg fully inhibited a fixed concentration 
(190 pM) of 125I-C5a in a monophasic manner with Hill slopes close to unity (figure 
4.9).  IC50 values for each peptide ligand were extrapolated from the nonlinear 
regression fits and subsequently converted to system independent Ki values using 
the Cheng-Prusoff equation and the Kd for
 125I-C5a described above.    Table 4.1 
shows the calculated Ki values of both C5a and C5a des Arg for the C5a receptors 
expressed on the neutrophil compared with Ki for each ligand at the overexpressed 
receptors described in chapter 3. Human purified C5a displayed 150 fold greater 
affinity for neutrophil C5a receptors than C5a des Arg. This measured difference in 
affinity between the two peptide ligands was far greater than the fold difference that 
was observed at the overexpressed C5a1 (40 fold) or C5a2 receptor (2 fold).  
Interestingly, the absolute measures of affinity for each peptide agonist are 
noticeably weaker at the neutrophil C5a receptors than their overexpressed 
counterparts.  C5a, displayed a 25 and 3 fold increase in affinity for the 
overexpressed C5a1 and C5a2 receptors respectively compared with the neutrophil 
C5a receptors while C5a des Arg displayed an 87 and 200 fold increase in affinity for 
the two overexpressed receptors.  Due to the consistency in experimental 
parameters between neutrophil and overexpressed competition binding assay 
systems, such as probe ligand, assay incubation time and assay buffer, differences in 
peptide affinity are probably not due to experimental bias but due rather to 
differences in the cellular systems. 
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Figure 4.9. Characterizing the binding affinity of human purified C5a and C5a des Arg at neutrophil 
C5a receptors 
Competition binding experiment performed on human isolated neutrophils using a fixed 
concentration (190 pM) of 
125
I-C5a and increasing concentrations of human purified C5a or C5a des 
Arg.  Experiments were performed at 4
o
C and under equilibrium conditions.  IC50 values were 
extrapolated from the four parameter logistic equation fit of the data.  Points represent mean % 
specific 
125
I-C5a binding   S.D.  Data representative of four separate experiments.  
 
 
Table 4.1. Human purified C5a and C5a des Arg display a reduced affinity for neutrophil C5a 
receptors 
Mean average affinity estimates (Ki) of human purified C5a and C5a des Arg for C5a receptor 
expressed on the surface of the human isolated neutrophil determined by competition binding 
experiments using 
125
I-C5a.  Neutrophil C5a receptor affinity estimates compared with those derived 
at the overexpressed receptors in chapter 3. Mean values derived from at least 4 different 
experiments. 
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4.4.4. Regulation of C5a receptor expression on human isolated 
neutrophils 
 
To validate the 125I-C5a detection of both C5a1 and C5a2 receptors on the surface of 
the human isolated neutrophil, flow cytometry analysis was employed using 
saturating concentrations of the previously described receptor specific, fluorophore 
conjugated, antibody clones S5/1 and 1D9-M12.  As shown in figure 4.10, both C5a 
receptors are present on the surface on the human isolated neutrophil. The C5a1 
receptor antibody significantly (P < 0.01) stained the surface of neutrophils with 
approximately 25 fold the intensity of the isotype control antibody.  The staining of 
the C5a2 receptor, although significant (P < 0.001), was less pronounced with only a 
fourfold increase in staining over the isotype control.  Human neutrophils also 
stained positively for the formyl peptide receptor, FRP1, and the integrin molecule 
CD11b. 
To determine whether activation of neutrophils could lead to a change in the surface 
expression of C5a receptors, neutrophils were incubated with either LPS (3 ng/mL), 
TNF (1 ng/mL), C5a (5 nM) or C5a des Arg (50 nM) in the absence or presence of a 
C5/C5a neutralizing antibody.  To determine the degree of neutrophil activation 
induced by each inflammatory agent, changes in the surface CD11b expression were 
measured.  Changes in FPR1 expression were also measured to assess the impact of 
each inflammatory agent on a non-complement system neutrophil receptor.  From 
figure 4.11 it can be seen that LPS did not activate neutrophils with respect to 
changes in cell surface expression of CD11b or alter the expression of the three 
receptors.  In contrast, TNF induced profound activation of neutrophils as 
measured by an increase in CD11b expression (P < 0.0001) and significantly reduced 
(P < 0.0001) the expression of both the C5a1 and C5a2 receptors.  TNF induced 
activation of neutrophils caused an opposing effect on the FRP1 receptor, 
significantly increasing (P < 0.0001) its surface expression.   The C5/C5a neutralizing 
antibody had no effect on the neutrophil responses observed to TNF suggesting 
that TNF did not cause neutrophil activation and receptor regulation through the 
localized production of C5a.  As expected both C5a and C5a des Arg activated human 
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isolated neutrophils and significantly reduced (P < 0.0001) the cell surface detection 
of both the C5a1 and C5a2 receptors.  This reduced receptor detection was probably 
caused by receptor activation and internalization but it cannot be ruled out that the 
loss in receptor detection was cause by antibody displacement as a result of a 
competitive interaction with C5a.  Regardless of the reason for the reduced detection 
of each C5a receptor, these data demonstrate the presence of the C5a2 receptor on 
the surface of the human isolated neutrophil.  Comparable with TNF, C5a 
significantly increased (P < 0.01) the neutrophil surface expression of the FPR1 
receptor.  However, although C5a des Arg activated neutrophils to a comparable 
degree as C5a, it did not significantly regulate (P > 0.05) the expression of the FRP1 
receptor. 
Interestingly, the C5a neutralizing antibody was able to inhibit the actions of both 
C5a and C5a des Arg at the C5a1 receptor but not the C5a2 receptor. Although the 
neutralizing antibody was able to inhibit the ability of C5a to upregulate CD11b 
expression, it had no impact on ability of C5a des Arg to induce an increase in CD11b 
expression.  These data support the argument that the C5a2 receptor mediates C5a 
des Arg induced up-regulation of CD11b.  These data also suggest that both C5a and 
C5a des Arg bind the C5a2 receptor in a very different manner compared with how 
they bind the C5a1 receptor, involving peptide-receptor contact points which are not 
blocked by the C5a neutralizing antibody. 
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Figure 4.10. Both C5a receptors are expressed on the surface of the human isolated neutrophil 
Flow cytometry detection of fluorescence intensity staining of the (A) C5a1 receptor, (B) C5a2 receptor, 
(C) FRP1 receptor and (D) the integrin molecule CD11b on neutrophils isolated from human whole 
blood using the MACSxpress® isolation method.  Black open histogram represents concentration 
matched isotype control antibody staining, shaded histogram represents receptor specific antibody 
staining, red dotted histogram represents receptor specific antibody staining in the presence of the 
C5a neutralizing antibody.  Data representative of four separate donors.  
 
 
A B 
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Figure 4.11. TNF, C5a and C5a des Arg activate neutrophils and regulate surface receptor 
expression 
Flow cytometry detection of cell surface receptors (A – CD11b, B – C5a1, C – C5a2, D – FPR1) on the 
human isolated neutrophil after stimulation by either LPS (3 ng/mL), TNF (1 ng/mL), C5a (5 nM) or 
C5a des Arg in the absence or presence of a neutralizing antibody to C5/C5a.  Vertical axis represents 
% specific receptor staining.  Bars represent mean and S.D. using neutrophils isolated from four 
separate healthy donors.  Statistical analysis was performed using one-way analysis of variance 
(ANOVA) and Tukey’s multiple comparison test (**** = P < 0.0001, ** = P < 0.01).  All comparisons 
were made to no stimulation controls containing C5a or isotype antibody.  
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Figure 4.11. Continued 
 
 
Is
o
ty
p
e  
s t
a i
n
N
o
 s
t i
m
N
o
 S
t i
m
 +
 C
5 a
 m
A
b
N
o
 S
t i
m
 +
 C
5 a
 Is
o
LP
S  
+  
C 5
a  
m
A
b
LP
S  
+  
C 5
a  
Is
o
T N
F
 +
 C
5 a
 m
A
b
T N
F
 +
 C
5 a
 Is
o
C 5
a  
+  
C 5
a  
m
A
b
C 5
a  
+  
C 5
a  
Is
o
C 5
a  
d
e s
 A
rg
 +
 C
5 a
 m
A
b
C 5
a  
d
e s
 A
rg
 +
 C
5 a
 Is
o
0
5 0
1 0 0
1 5 0
2 0 0
C 5 a 2
%
 s
p
e
c
if
ic
 r
e
c
e
p
to
r 
s
ta
in
****
****
****
****
****
****
Is
o
ty
p
e  
s t
a i
n
N
o
 s
t i
m
N
o
 S
t i
m
 +
 C
5 a
 m
A
b
N
o
 S
t i
m
 +
 C
5 a
 Is
o
LP
S  
+  
C 5
a  
m
A
b
LP
S  
+  
C 5
a  
Is
o
T N
F
 +
 C
5 a
 m
A
b
T N
F
 +
 C
5 a
 Is
o
C 5
a  
+  
C 5
a  
m
A
b
C 5
a  
+  
C 5
a  
Is
o
C 5
a  
d
e s
 A
rg
 +
 C
5 a
 m
A
b
C 5
a  
d
e s
 A
rg
 +
 C
5 a
 Is
o
0
5 0
1 0 0
1 5 0
2 0 0
F P R 1
%
 s
p
e
c
if
ic
 r
e
c
e
p
to
r 
s
ta
in
****
****
**
C 
D 
 112 
 
4.5. Discussion 
 
The results described in this research chapter demonstrate the quality in 
performance of a new, negative selection, human neutrophil isolation kit offered by 
Miltenyi Biotec.  The MACSxpress® kit enabled the untouched isolation of a pure, 
high viability, non-activated population of neutrophils from human whole blood in 20 
minutes with minimal erythrocyte contamination.  This method offers several 
advantages over more traditional neutrophil isolation techniques that require 
multiple steps (ficoll density gradient centrifugation, dextran sedimentation of 
erythrocytes and lysis of residual erythrocytes with a hypotonic solution), all of which 
increase the likelihood of neutrophil activation (Bland et al., 2001; Maqbool et al., 
2011). 
The quantification of the relative gene expression level of each C5a receptor 
demonstrated that the C5a1 receptor is expressed at twice the level of the C5a2 
receptor in the human isolated neutrophil, a finding similar to those reported by 
others (Chen et al., 2007).  Both C5a receptors appear to have far greater neutrophil 
expression than the other complement system receptor, C3aR, but far reduced 
expression compared with the FPR1 and the CXCR1, GPCRs which control similar 
neutrophil functions to the C5a receptors (Sun et al., 2012).  The significant increase 
in -arrestin-2 gene expression over -arrestin-1 confirms the suitability of the 
DiscoverX PathHunter® platform for investigating interactions between the C5a 
receptors -arrestins. 
Gene expression translated into neutrophil surface protein expression of both C5a 
receptors as detected by both competition binding studies and flow cytometry 
analysis.   This is an important finding as it contrasts the observations made by 
Bamberg et al. (2010), who, using the same C5a2 specific antibody, clone 1D9-M12,  
were unable to detect expression of this receptor on the surface of a neutrophil. The 
presence of the C5a2 receptor on the surface of a neutrophil is further supported by 
the fact that this receptor can be desensitized, or its detection antagonized by both 
C5a and C5a des Arg.  In fact neutrophil activation, via TNF stimulation, leads to 
down regulation of both C5a receptors and in the case of the C5a2 receptor this 
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down regulation is close to the point of zero detection.   Minimal information is 
provided in the aforementioned manuscript as to how neutrophils were isolated 
from human whole blood.  Ficoll purification is mentioned which was presumably 
followed with a hypotonic lysis of erythrocytes.  As discussed above, these lengthy 
isolation procedures may lead to cellular activation which, as we have shown here, 
can result in loss of cell surface expression of C5a receptors. 
The neutrophil stimulation data described in this research chapter have highlighted a 
possible role for C5a2 and C5a des Arg in orchestrating the function of neutrophils.  
When bound by the C5a neutralizing antibody, both C5a and C5a des Arg are unable 
to bind, and presumably activate the C5a1 receptor.  However, even when bound by 
the C5a neutralizing antibody, C5a and C5a des Arg are still able to bind to the C5a2 
receptor.  Although antibody bound C5a is unable to activate neutrophils with 
respect to CD11b up-regulation, antibody bound C5a des Arg is still able to induce 
neutrophil activation.  These data suggest that C5a mediated neutrophil activation is 
via the C5a1 receptor and C5a des Arg activation is through C5a2. 
Unlike TNF and the isoforms of C5a, exposure to 3 ng/mL LPS did not induce 
neutrophil activation, as observed by changes in surface CD11b expression, or alter 
the expression of either of the three receptors that were measured.  This 
concentration of LPS is close to the range detected in clinical sepsis (Opal et al., 1999) 
and a concentration that I have shown to maximally induce IL-6 and TNF production 
in human whole blood (data not shown).  This lack of LPS induced neutrophil 
activation is perhaps not that surprising based on the negligible TLR4 expression on 
the surface of the non-activated neutrophil shown both here and by others (Hayashi 
et al., 2003). 
In contrast to the down regulation of C5a receptors, which presumably occurs to 
tightly regulate neutrophil activation once they have migrated along a C5a/C5a des 
Arg gradient to the site of microbial infection, TNF induced an increase in the 
expression of the formylpeptide receptor, FRP1.  These data corroborate the findings 
by O'Flaherty et al. (1991) who showed that specific binding of 3H-fMLP to human 
isolated neutrophils is increased in the presence of TNF.  Formylated peptide 
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ligands that bind and activate the FPR1 are secreted by invading pathogens and 
released from dying cells that are injured during inflammation (Dorward et al., 2015).  
Presumably this switching in neutrophil receptor emphasis orchestrates a more 
direct detection and clearance of pathogens and necrotic cells than the initial, 
indirect recruitment neutrophils to the site of infection that is orchestrated by toll-
like receptors and anaphylatoxins of the complement system. 
In summary, the research outlined in this chapter has demonstrated the high 
performance of the MACSxpress® kit to isolate a uniform population of non-activated 
neutrophils from human whole blood with minimal erythrocyte contamination.  
Based on the detection of both C5a receptors at the cell surface this isolation 
method appears to offer an advantage over more traditional neutrophil isolation 
methods for studying both C5a receptors.  The MACSxpress® method will be used to 
isolate neutrophils for functional assessment of the C5a1 and C5a2 in the next 
research chapter of this thesis.  
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Assessing the relative functional activity of the 
complement system peptides, C5a and C5a des 
Arg 
 
5.1. Abstract 
 
Activation of the complement system leads to the generation of the 74 amino acid 
peptide C5a which possesses potent anaphylactic and chemotactic properties.  C5a is 
rapidly metabolized to C5a des Arg by serum carboxypeptidases, a process 
considered to render this complement peptide inactive.  However many groups have 
demonstrated that C5a des Arg retains a strong capacity to induce the chemotaxis of 
leukocytes.  With the majority of, if not all, serum C5a thought to be the des 
arginated form, I decided to perform an in-depth characterization of the functional 
ability of C5a des Arg using a range of in vitro cell based assay systems.  From 
concentration responses to C5a and C5a des Arg in each experimental system, Emax 
and EC50 values were extrapolated.  A system independent expression of agonism 
was obtained for each peptide by taking the Log(Emax/EC50).  The relative activity of 
C5a des Arg to C5a was determined using Log(Emax/EC50).  C5a des Arg displayed 
biased agonism towards promoting a phenotype required for extravasation of 
neutrophils from the vasculature to sites of infection but away from an antimicrobial 
phenotype.  These results demonstrate that C5a des Arg retains potent cell adhesion 
and chemotactic properties required for migration of leukocytes from the blood to 
sites of infection.  However, the reduced capacity to induce a neutrophil respiratory 
burst response has possibly evolved to minimise the damage to blood vessels and 
surrounding tissue that can be caused by the highly reactive oxygen species 
generated during the respiratory burst response. 
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5.2. Introduction 
 
Activation of the complement system leads to the generation of the biologically 
active, 74 amino acid peptide, C5a.  Upon ligation of the C5a receptors, C5a induces a 
range of cellular responses in both immune and parenchymal cells including 
increased vascular permeability, selectin shedding, integrin upregulation, 
chemotaxis, phagocytosis, respiratory burst and cytokine release (Guo et al., 2005; 
Amara et al., 2008).  While the bulk of C5a, between amino acid residues 1-69, 
contributes to the majority of the binding affinity between C5a and the C5a 
receptors, all of the agonist properties of C5a are contained in the C-terminal 
between residues 69-74 (Monk et al., 2007).  C5a is rapidly metabolized by cell 
surface and serum carboxypeptidases that remove the C-terminal arginine, 
generating C5a des Arg (Bokisch et al., 1970; Skidgel et al., 2007).  Although the 
majority of analytical methods used to quantify concentrations of the peptide 
fragments of C5 are unable to distinguish between C5a and C5a des Arg, the vast 
majority of C5a in the circulation is considered to be that of the des arginated 
isoform (Fernandez et al., 1976; Mueller-Ortiz et al., 2009). 
C5a des Arg is often referred to as inactive C5a.  It has a greatly reduced affinity for 
the C5a1 receptor compared with C5a, as demonstrated by data in this thesis, and is 
devoid of anaphylactic properties.  Fernandez et al. (1978a) showed that when 
injected intradermally into guinea pigs, only C5a was able to increase vascular 
permeability whereas C5a des Arg was not.  Similarly, Gerard et al. (1981) showed 
that C5a des Arg exhibited 1/1000th of the activity of C5a at inducing both smooth 
muscle contraction of guinea pig ileum and vascular permeability of guinea pig skin.  
Interestingly these authors discovered that removal of the oligosaccharide unit from 
asparagine64 enhanced the activity of C5a des Arg in both of these assay endpoints.   
Workers at the New York University Medical Center identified a serum anionic 
polypeptide ‘helper factor’ that enhances the chemotactic activity of low 
concentrations C5a des Arg (Perez et al., 1980).  Originally referred to as 
cochemotaxin (Perez et al., 1986) and later identified as vitamin D-binding protein, 
this protein specifically enhances the actions of C5a des Arg and not C5a. 
 118 
 
There is a wealth of data in the literature highlighting the ability of C5a des Arg to 
induce a chemotactic response of leukocytes.  Fernandez et al. (1978b) determined 
that C5a des Arg, although approximately 10 fold weaker than C5a at inducing 
chemotactic response of human isolated neutrophils, was able promote the 
migration of a larger number of cells.  Similarly, Webster et al. (1980) demonstrated 
that human purified C5a des Arg was able to induce the same degree of chemotactic 
activity as C5a albeit at 50 times higher concentration.  Interestingly Marder et al. 
(1985) observed that human isolated monocytes exhibit identical chemotactic 
responses to C5a and C5a des Arg although their observation with human 
neutrophils were in line with those reported above.  Using a label-free technology to 
measure dynamic mass redistribution cellular responses, Reis et al. (2012) observed 
that C5a des Arg was 10 fold more potent than C5a at inducing morphological 
changes of RBL cells transformed to express the human C5a1 receptor.  Using the 
same technology they also observed that C5a des Arg was more potent than C5a at 
inducing cellular responses of human isolated neutrophils. 
There appears, therefore, to be a separation of biological activities between C5a and 
C5a des Arg and it has previously been postulated that anaphylatoxin and 
chemotactic properties of C5a reside in different regions of the peptide molecule 
(Muller-Eberhard, 1969).  Removal of the C-terminal arginine of C5a appears to 
generate an agonist that preferentially induces a chemotactic phenotype.  It is now 
widely accepted that agonists of G protein coupled receptors do not uniformly 
activate all cellular signalling pathways linked to a specific receptor and agonists can 
stabilize specific receptor conformation leading to the activation of different 
pathways (Kenakin, 2002).  Agonists that are able selectively activate a specific 
intracellular signalling pathway are often referred to as functionally selective or 
biased agonists (Kenakin et al., 2013).  
The response of an agonist is made up of two disparate parameters.  Efficacy or Emax, 
the maximal response induced by an agonist and potency or EC50, the concentration 
of agonist that produces 50% of its maximal response.  Methods to determine biased 
agonism rely on the quantification of the relative activity between agonists in a test 
system and require agonism be reduced to a single parameter (Ehlert, 2008; Kenakin 
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et al., 2012). The most commonly used method to quantify the relative agonist 
activity lends from operational model of agonism where a system independent 
expression of agonism can be obtained from values of Log(/KA) .  From explicit 
expressions of maximal response and EC50, it has also been shown that a surrogate of 
Log(/KA) value is provided by a value of Log(Emax/EC50) for dose-response curves with 
slopes not significantly different from unity (Black et al, 1985; Kenakin, 2012). 
As C5a des Arg, rather than C5a, appears to be the predominant form of the C5 
fragment isolated form in serum and displays signalling bias, I have decided to focus 
the research in this chapter on understanding the relative functional activity of 
human purified C5a des Arg and C5a in a range of cell based assay systems. The main 
objectives of are: 
1. Perform concentration response curves of both C5a and C5a des Arg in a 
range of functional assay systems using both neutrophils and transformed cell 
lines. 
2. For each agonist response curve fit the four parameter logistic equation and 
extrapolate both Emax and EC50 values. 
3. Using the Log(Emax/EC50) transformation, determine the relative efficacy of 
C5a des Arg compared with C5a. 
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5.3 Chapter specific methods 
 
5.3.1. Functional assays 
 
Concentration response curves were generated for both human purified C5a and C5a 
des Arg and tested in the following 12 functional cell based assay systems; neutrophil 
calcium mobilization, neutrophil chemotaxis, neutrophil integrin up regulation, 
neutrophil respiratory burst (with and without TNF prime), CHO C5a1 receptor 
calcium mobilization, CHO C5a1 receptor cAMP accumulation, CHO C5a1 receptor ERK 
phosphorylation, CHO C5a1 receptor -arrestin2 recruitment, CHO C5a2 receptor -
arrestin2 recruitment, U2OS C5a1 receptor internalization and U2OS C5a2 receptor 
internalization. 
 
5.3.2. Minimizing test system bias 
 
Test system bias is the impact a specific biological assay can have on the absolute 
potency of each agonist tested.  Undoubtedly each biological assay will impart a 
degree of system bias, either in the form of receptor sensitivity (via differential 
receptor expression and receptor pathway coupling efficiencies), kinetics of assay 
response and the temperature which the assay was performed at.  For this reason, 
the absolute potency of each agonist should not be solely used to determine 
pathway bias.  To minimize observational bias, the same assay buffer (Hanks 
Balanced Salt Solution with calcium and magnesium, supplemented with 20mM 
HEPES and 0.1% BSA, pH7.4) was used in all assay systems. 
 
5.3.3. Quantifying the relative efficacy of C5a and C5a des Arg 
 
The four parameter logistsic equation, described in chapter 3, was used to fit the 
concentration response data obtained for C5a and C5a des Arg in each experimental 
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endpoint. Data for each agonist were expressed as a percentage of the maximal 
response obtained in the test system to C5a.  Emax, EC50 and Hill slopes were 
extrapolated from each sigmoidal curve.    The activity of each agonist was reduced 
to a single parameter using the Log(Emax/EC50) ratio and the relative activity of C5 des 
Arg was compared with C5a by subtracting the ratio obtained for C5a des Arg from 
the ratio obtained for C5a to generate Log(Emax/EC50). The fold relative activity of 
C5a compared with C5a des Arg was calculated by taking the reciprocal of the 
inverse-Log of the Log(Emax/EC50) determined for each assay endpoint.  A minimum 
of four curves were performed for each agonist.  In experiments using human 
isolated neutrophils, cells were tested from a minimum of four healthy donors. 
 
5.3.4. Statistical analysis 
 
To determine statistical differences between treatment groups, data were initially 
assessed for normal distribution after which parametric one-way ANOVA followed by 
a Tukey’s multiple comparison test was performed.  All statistical tests were 
performed using Graphpad Prism 
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5.4. Results 
 
5.4.1. Assessing neutrophil functional responses to C5a and C5a des Arg 
 
Initial experiments investigating the relative activity of human purified C5a and C5a 
des Arg were focused on functional responses in the human isolated neutrophil.  
Neutrophils were isolated from human whole blood using the Miltenyi Biotec Inc 
MACSxpress® kit previously described in chapter 4. 
Both human purified C5a and C5a des Arg produced robust calcium mobilization in 
human neutrophils as detected with the Molecular Devices Calcium 3 indicator dye 
(figure 5.1A).  C5a was approximately 100 fold more potent than C5a des Arg 
producing an average EC50 value of 87 pM compared with 8.3 nM for C5a des Arg.  As 
calculated from the upper asymptote of the non-linear regression, C5a des Arg was 
less efficacious than C5a, generating an Emax value that was, on average 15% lower 
than the maximum response produced by C5a.  Using Log(Emax/EC50), the relative 
activity of C5a des Arg compared with C5a was -1.62 with C5a possessing 42 fold 
greater activity than C5a des Arg at inducing calcium mobilization in the human 
isolated neutrophil.  The selective antagonism of either the C5a1 receptor with 
PMX53 (P < 0.001) or the C5a2 receptor with the antibody clone 1D9-M12 
demonstrated that only the C5a1 receptor mediates C5a and C5a des Arg induced 
calcium mobilization in human neutrophils.  This finding is consistent with the 
reported inability of the C5a2 receptor to couple to G-proteins due to a sequence 
modification in the DRY motif at the end of the third transmembrane domain 
(Okinaga et al., 2003)  (figure 5.1B). 
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Figure 5.1. C5a and C5a des Arg induced calcium mobilization in the human isolated neutrophil 
Concentration response curves of human purified C5a and C5a des Arg at inducing calcium 
mobilization within human isolated neutrophils (A).  From the non-linear regression Emax and EC50 
values were extrapolated.  All data points were expressed as a percentage of the maximal response 
observed to C5a.  Each datum point represents the mean average S.D. of two replicates.  Data are 
representative of eight separate experiments.  Inhibition of neutrophil calcium mobilization induced 
by a fixed concentration of human purified C5a or C5a des Arg with either the C5a1 receptor 
antagonist PMX53 or the C5a2 receptor antagonist 1D9-M12 (B).  Data are expressed as a percentage 
of the C5a response.  Bars represent mean average S.D. of four replicates. Data are representative of 
two separate experiments. 
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Next, I investigated the ability of each peptide to induce chemotaxis of human 
isolated neutrophils (figure 5.2).  Both C5a and C5a des Arg induced a strong 
chemotactic response of human neutrophils at concentrations less than 1 nM.  
Interestingly, C5a des Arg, unlike C5a, did not produce the typical ‘bell shaped’ 
concentration response profile, often see with chemotactic agents (figure 5.2A). 
Instead of the typical concentration dependent desensitization of cellular migration, 
C5a des Arg produced a sustained response at concentrations greater than 1 nM.  
The degree of desensitization induced by C5a (comparing the response of each 
peptide at the top concentration tested, 100 nM, with the peak response at 1 nM) 
was significantly different to the same response produced by C5a des Arg (figure 
5.2B).  To determine whether the lack of desensitization response to C5a des Arg was 
due to agonist induced enhancement of the fluorescence intensity of the cell tracking 
dye Calcein-AM, cells were stimulated with a concentration range of each peptide 
(figure 5.2C).  Neither C5a or C5a des Arg, up to the maximal concentration of 100 
nM, enhanced the fluorescence intensity of the Calcein-AM loaded neutrophils. 
After removal of the assay points related to the desensitization response, a non-
linear regression was fit to the chemotaxis data.  Human purified C5a and C5a des 
Arg were equipotent at inducing chemotaxis of human neutrophils with average EC50 
values of 486 and 277 pM respectively (figure 5.3A).  Although C5a des Arg displayed 
a 15% reduced Emax compared with C5a (P < 0.01), the Log(Emax/EC50) comparison 
generated a value of 0.12.  This reveals that C5a des Arg possesses a slightly greater 
relative activity than C5a at inducing chemotaxis of human neutrophils.  As with 
calcium mobilization, the use of selective receptor antagonists demonstrated that all 
of the neutrophil chemotactic response induced by C5a and C5a des Arg is mediated 
via the C5a1 receptor (figure 5.3B). 
Fundamental to the extravasation of neutrophils from the blood to sites of infection 
is the up regulation of neutrophil cell surface adhesion molecules.   One such 
molecule is integrin alpha M or CD11b.  Both C5a and C5a des Arg potently induced 
an increase in cell surface expression of CD11b as detected by flow cytometry.  At 
the highest concentrations tested, both C5a and C5a des Arg appeared to desensitize  
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Figure 5.2. C5a and C5a des Arg induced chemotaxis of the human isolated neutrophil 
Human purified C5a and C5a des Arg mediated chemotaxis of human isolated neutrophils using the 
Corning Fluoroblok
TM
 system (A).  Data are expressed as a percentage of the maximum response 
observed to C5a and each point represents the mean average S.D. of two replicates, data are 
representative of eight separate donors.  Percentage desensitization of chemotaxis response between 
maximal response (at 1 nM) and top concentration tested (100nM) for all eight donors (B). Data were 
analysed using one-way ANOVA (**** = P < 0.0001).    The impact C5a and C5a des Arg stimulation on 
the fluorescence of human neutrophils loaded with the calcein-AM cell indicator dye used in 
chemotaxis experiments (C).  Data were expressed in relative fluorescence units and points represent 
mean average S.D. of two replicates. Data were obtained from a single experiment. 
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Figure 5.3. The neutrophil chemotactic response induced by C5a and C5a des Arg is mediated 
through the C5a1 receptor 
Non-linear regression fit to the human purified C5a and C5a des Arg neutrophil chemotaxis response 
data after desensitization point were removed (A).  Data are expressed as a percentage of the 
maximum response observed to C5a and each point represents the mean average S.D. of two 
replicates, data are representative of eight separate donors.  Inhibition of 1 nM C5a or C5a des Arg 
with saturating concentrations of either PMX53 or 1D9-M12 (B).  Data are expressed in relative 
fluorescence units and points are the average of two replicates per experiment.  Bars represent mean 
average S.D. from eight donor experiments.  Statistical significance was determined using one-way 
ANOVA (**** = P < 0.0001). 
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the integrin up regulation response.  Subsequent removal of the desensitization 
assay points allowed for a non-linear regression to be fit to the data which generated 
EC50 values of 244 pM and 357 pM for C5a and C5a des Arg respectively.  C5a des Arg 
was less efficacious than C5a and produced an average maximum response that was 
70% of that produced by the parent peptide (figure 5.4A).  The Log(Emax/EC50) 
produced a value of -0.35 which translates to C5a having a 2.2 fold greater relative 
activity than C5a des Arg at inducing CD11b up regulation in the human isolated 
neutrophil.  Again, the use of the selective C5a receptor inhibitors demonstrated that 
C5a and C5a des Arg mediate neutrophil CD11b up regulation via the C5a1 receptor.  
Activation of the C5a2 receptor by either peptide agonist does not appear to regulate 
the integrin response in either a positive or negative manner (figure 5.4B).   
The final neutrophil response I investigated was that of respiratory burst.  Upon 
bacterial infection, neutrophils engulf pathogenic microbes by phagocytosis and 
respiratorily destroy them by generating hypochlorous acid (HOCl).  The cell 
permeable reactive oxygen species (ROS) indicator, dihydrorhodamine 123, is rapidly 
oxidised to the fluorescent rhodamine 123 by HOCl and not by other ROS.  As 
detected by flow cytometry, activation of non-primed neutrophils by either C5a or 
C5a des Arg led to only a very small respiratory burst response with C5a des Arg 
being approximately 20% less efficacious than C5a (figure 5.5A).  The des arginated 
peptide also displayed a reduced potency to C5a, producing an average EC50 of 13 
nM compared with 2.4 nM.  A determination of the relative activity using 
Log(Emax/EC50) generated a value of -0.81, translating to C5a possessing a 6.5 fold 
greater relative activity than C5a des Arg at inducing respiratory burst in the non-
primed human neutrophil. 
To determine whether cytokines provide a priming role to enhance the respiratory 
burst response to C5a and C5a des Arg, neutrophils were pre-incubated for 15 
minutes prior to stimulation with a concentration of TNF (1 ng/mL).  TNF had a 
profound impact on the magnitude of the respiratory burst response to both C5a and 
C5a des Arg (figure 5.5B), significantly enhancing their actions by 8 and 5 fold 
respectively compared with their non-primed respiratory burst response (P < 0.001). 
 128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. C5a and C5a des Arg induced neutrophil integrin up regulation is mediated via the C5a1 
receptor 
Human purified C5a and C5a des Arg induced CD11b up regulation on human isolated neutrophils (A).  
Non-linear regression fit to the data after the removal of the desensitized response points (B).  Each 
point represents the mean average S.D of two replicates, data are representative of seven separate 
donors.  Inhibition of C5a or C5a des Arg induced CD11b up regulation by either the C5a1 receptor 
antagonist PMX53 or the C5a2 receptor antagonist 1D9-M12 (C).  Data are expressed as a percentage 
of the C5a response and each datum point reflect a test replicate.  Bars represent the mean average 
response S.D from seven separate experiments. 
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Figure 5.5. Neutrophils require a cytokine prime to generate a maximum respiratory burst response 
Concentration response of human purified C5a and C5a des Arg induced respiratory burst in the 
human isolated neutrophils, as detected by dihydrorhodamine-123 fluorescence using flow cytometry, 
in the absence and presence of 1 ng/mL TNF (A).  Data are expressed as a percentage of the 
maximum respiratory burst response achieved with C5a + TNF for each donor.  Each point represents 
the mean average S.D of two replicates, data are representative of four separate donor experiments.  
Maximal respiratory burst response achieved with C5a or C5a des Arg (100 nM) in the absence or 
presence of 1 ng/mL TNF.  Each datum point reflects a test replicate and bars represent mean 
average response S.D from four separate donor experiments. 
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As with the non-primed respiratory burst response, C5a des Arg was less efficacious, 
producing a maximal response that was only 40% of that produced by C5a.  EC50 
values were comparable with those generated in the non-primed neutrophil with 
values of 2.4 nM and 18 nM for C5a and C5a des Arg respectively.  The 
Log(Emax/EC50) comparison generated a value of -1.33 indicating that C5a has a 21 
fold greater relative activity than C5a des Arg at inducing respiratory burst in the 
TNF primed neutrophil. 
 
5.4.2. Activation of both the C5a1 receptor and TNFR1 is required for a 
complete neutrophil respiratory burst response 
 
With the data suggesting that activation of two cellular mechanisms is required to 
achieve maximal respiratory burst response, I next decided to focus my research on 
elucidating the contribution of TNF, C5a and their associated receptors to this 
neutrophil event.  To do this, I measured the effect of TNF (1 ng/mL) and or C5a (5 
nM) on the neutrophil production of HOCl and hydrogen peroxide (H2O2), a precursor 
to the formation of HOCl.  Experiments were performed in the absence and presence 
of TNF and C5a receptor specific, ligand competitive agents.  As can be seen in figure 
5.6A, only TNF was capable of inducing H2O2 production in the human neutrophil as 
measured by the H2O2 specific indicator Amplex® Red.  Selective antagonism of each 
TNF receptor (TNFR) demonstrated that only TNFR1 mediates TNF induced 
production of H2O2 in a human neutrophil.  C5a or its receptors do not appear to 
contribute to the H2O2 component of the neutrophil respiratory burst response.  As 
observed in the concentration response experiments, C5a was unable to induce a 
profound respiratory burst on its own.  This is also the case for TNF.  Not until the 
neutrophil is sequentially exposed to both agents, is a full HOCl respiratory burst 
response generated (figure 5.6B).  As expected, selective antagonism of either TNFR1 
or the C5a1 receptor resulted in complete inhibition of the HOCl response.  
Interestingly, whereas the TNFR2 did not contribute to the generation of H2O2, 
blockade of this receptor significantly inhibited (P < 0.001) the generation of HOCl.  
As observed with other neutrophil responses, antagonism of the C5a2 receptor did  
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Figure 5.6. Investigating the role of TNF and C5a in augmenting the neutrophil respiratory burst 
response 
Neutrophil generation of H2O2 as detected by Amplex Red in response to TNF and or C5a in the 
absence or presence of either TNFR1, TNFR2, C5a1 C5a2 receptor antagonists (A).  Data are expressed 
as a percentage of the maximum H2O2 response to TNF.  Neutrophil generation of HOCl as detected 
by dihydrorhodamine-123 in response to TNF and or C5a in the absence or presence of either TNFR1, 
TNFR2, C5a1 or C5a2 receptor antagonists or the MPO inhibitor PF-1355 (B).  Data are expressed as a 
percentage of the maximum HOCl response to TNF + C5a.  Each datum point represents a test 
replicate and bars represent the mean average response S.D from neutrophils isolated from four 
separate donors.  Statistical significance was determined using one-way ANOVA followed by Tukey’s 
multiple comparison test (*** = P < 0.001, **** = P < 0.0001) 
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not impact the ability of C5a to contribute to the respiratory burst response.  
Incubation of neutrophils with the selective myeloperoxidase inhibitor PF-1355 
significantly (P < 0.0001) but not completely inhibited the TNF/C5a respiratory burst 
response.  This is a surprising result as it is understood that peroxidase activity is 
required for production of HOCl from H2O2. 
 
5.4.3. Assessing the functional response of C5a and C5a des Arg in cell 
lines transformed to express the C5a receptors 
 
Next, my research focused on understanding the relative activity of C5a and C5a des 
Arg in activating intracellular pathways in cell lines transformed to express either the 
C5a1 or C5a2 receptor.  The C5a1 receptor expressing CHO cell line described in 
chapter 3 was used to investigate the action of each agonist on calcium mobilization, 
cAMP accumulation and ERK phosphorylation.  In both the calcium and cAMP 
endpoint assays, C5a des Arg was as efficacious as C5a.  A 7 fold increase in the EC50 
value was observed for C5a in the calcium assay compared with only a 3 fold increase 
in the cAMP assay (figure 5.7A and B).  Interestingly the absolute potencies for each 
agonist in the same cell line are far greater in the calcium endpoint compared with 
cAMP.  With receptor expression remaining constant, this suggests that there is a 
greater degree of pathway coupling efficiency to the calcium pathway.  Comparing 
agonist activity using Log(Emax/EC50), C5a has an 8 fold greater relative activity than 
C5a des Arg at inducing calcium mobilization and a 3.4 fold greater relative activity at 
inducing cAMP accumulation. 
Along with the CHO C5a1 receptor expressing cell line, ERK phosphorylation was also 
assessed in the U2OS C5a2 receptor cell line as it is thought that receptor--arrestin 
complex couples to ERK signalling.  Activation of the C5a2 receptor by either C5a of 
C5a des Arg resulted in no measurable phosphorylation of ERK (figure 5.8B).  This is 
in contrast to the responses observed at the C5a1 receptor.  C5a produced a very 
potent ERK phosphorylation response, generating an EC50 value of 26 pM while C5a 
des Arg was 7 fold weaker generating an EC50 value of 180 pM (figure 5.8A).  These 
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absolute potencies are identical to those generated in the calcium mobilization 
assay.  Naturally this leads to a comparable Log(Emax/EC50) value of -0.87 which 
translates to C5a displaying approximately an 8 fold greater relative activity at 
inducing ERK phosphorylation than C5a des Arg. 
The final two cellular endpoints I investigated to determine the relative activity of 
C5a des Arg to C5a, made use of DiscoverX’s PathHunter® assay platforms.  CHO cells 
expressing the receptor/-arrestin enzyme complementation technology and U2OS 
cells expressing the -arrestin/endosome enzyme complementation technology were 
engineered to selectively express either C5a receptor.   C5a des Arg was 9 fold less 
potent than C5a at promoting -arrestin recruitment to the C5a1 receptor but was 
equipotent to C5a at promoting -arrestin recruitment the C5a2 receptor (figure 5.9).   
 
Similar results were observed in the receptor internalization assays.  C5a des Arg was 
6 fold weaker than C5a at inducing internalization of the C5a1 receptor but 
equipotent to C5a at inducing C5a2 receptor internalization (figure 5.10).  Using the 
Log(Emax/EC50) to assess relative agonist activity, C5a possesses 11 fold greater 
activity at inducing -arrestin recruitment to the C5a1 receptor, 6 fold greater 
relative activity at internalizing the C5a1 receptor but is equiactive to C5a des Arg at 
inducing internalization of the C5a2 receptor.  C5a des Arg is marginally more active 
at promoting the recruitment of -arrestin to the C5a2 receptor. 
A summary of all EC50, Emax, Log(Emax/EC50) values and fold relative activities values 
can be found in table 5.1. 
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Figure 5.7. C5a and C5a des Arg induced calcium mobilization and cAMP via the C5a1 receptor 
Concentration response curves of human purified C5a and C5a des Arg at inducing calcium 
mobilization (A) and cAMP accumulation (B) in CHO cells transformed to express the C5a1 receptor.    
All data points were expressed as a percentage of the maximal response observed to C5a.  Each data 
point represents the mean average S.D. of two replicates.  Data representative of four separate 
experiments. 
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Figure 5.8. C5a and C5a des Arg induced phosphorylation of extracellular signal-regulated kinases 
Concentration response curves of human purified C5a and C5a des Arg at inducing phosphorylation of 
extracellular signal–regulated kinases (ERK) in CHO cells expressing the C5a1 receptor (A) and U2OS 
cells expressing the C5a2 receptor (B).    For responses in CHO cells all data points were expressed as a 
percentage of the maximal response observed to C5a.  For responses in U2OS cells all data points 
were expressed as a percentage of the maximal response observed to 1% heat inactivated foetal 
bovine serum.   Each data point represents the mean average S.D. of two replicates.  Data are 
representative of at least four separate experiments. 
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Figure 5.9. C5a and C5a des Arg promote the coupling of -arrestin to the C5a1 and C5a2 receptors 
Concentration response curves of human purified C5a and C5a des Arg at inducing the recruitment of 
-arrestin to the C5a1 receptor (A) or C5a2 receptor (B) expressed in CHO cells as detected with 
DiscoverX PathHunter® technology.  Data are expressed as a percentage of the maximum response 
observed to C5a and each point represents the mean average S.D of two replicates, data are 
representative of four separate experiments. 
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Figure 5.10. C5a and C5a des Arg promote internalization of the C5a1 and C5a2 receptors 
Concentration response curves of human purified C5a and C5a des Arg at inducing internalization of 
the C5a1 receptor (A) or C5a2 receptor (B) expressed in U2OS cells as detected with DiscoverX 
PathHunter® technology.  Data are expressed as a percentage of the maximum response observed to 
C5a and each point represents the mean average S.D of two replicates, data are representative of 
four separate experiments. 
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5.5. Discussion 
 
In this research chapter, I performed an extensive analysis of the relative activity of 
human purified C5a and C5a des Arg in range of functional cell based assays using 
both human isolated neutrophils and receptor transformed cell lines.  Using Emax and 
EC50 values from concentration response curves, I was able to determine a system 
independent expression of agonism for each peptide using Log(Emax/EC50) and a 
measure of relative agonist activity using Log(Emax/EC50).  By plotting all 
Log(Emax/EC50) scores together, I was able to generate a ‘web of relative activity’ for 
C5a and C5a des Arg which can be seen in figure 5.11.  From the presentation of all 
relative activities together, it becomes clear that C5a de Arg has a strong bias for 
activating certain functional responses compared with others.  This bias is towards 
promoting recruitment of -arrestin to the C5a2 receptor, internalization of the C5a2 
receptor and responses associated with neutrophil extravasation including 
chemotaxis and up regulation of cell surface adhesion molecules.  Alternatively, C5a 
des Arg shows a reduced relative activity at inducing the antimicrobial, neutrophil 
respiratory burst response, a response where the relative activity of C5a des Arg is 
further reduced in the presence of TNF.  This reduced relative activity is also 
observed in cellular responses downstream of the C5a1 receptor including calcium 
mobilization, cAMP accumulation and ERK phosphorylation. 
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Figure 5.11. The C5a, C5a des Arg ‘web of relative activity’ 
From quantification of the Emax and EC50 values from concentration response data, system 
independent expression of agonism for C5a and C5a des Arg was calculated for each in vitro cell based 
assay using Log(Emax/EC50).  The relative activity of C5a des Arg to C5a was determined using 
Log(Emax/EC50).  Along each in vitro assay axis the Log(Emax/EC50) of C5a to C5a (red) or C5a des Arg 
to C5a (blue) is plotted generating a C5a/C5a des Arg web of relative efficacy. 
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Table 5.1. The relative activity of human purified C5a des Arg to C5a in 12 in vitro cell based functional assays 
Emax and EC50 values were extrapolated from non-linear regression fits to concentration response data for human purified C5a and C5 des in a range of in vitro cell based 
functional assays.  A system independent expression of agonism was calculated using Log(Emax/EC50) and the relative activity of C5a des Arg to C5a was calculated using the 
Log(Emax/EC50).   Fold activity was calculated by determining the reciprocal of the inverse Log of Log(Emax/EC50). 
  C5a C5a des Arg   
Response n %Emax EC50 (M) 
Log 
(Emax/EC50) 
Log 
(Emax/EC50) 
%Emax EC50 (M) 
Log 
(Emax/EC50) 
Log 
(Emax/EC50) 
Inv-Log 
Fold 
activity 
Neutrophil Calcium 8 102.0 8.71E-11 12.2 0 85.2 8.33E-09 10.6 -1.63 0.024 42.3 
Neutrophil Chemotaxis 8 95.6 4.86E-10 11.5 0 84.3 2.77E-10 11.6 0.12 1.307 0.8 
Neutrophil CD11b 7 103.3 2.44E-10 11.7 0 72.6 3.57E-10 11.3 -0.35 0.452 2.2 
Neutrophil Respiratory 
Burst + TNFa 
4 97.3 2.40E-09 10.7 0 38.8 1.86E-08 9.3 -1.33 0.047 21.4 
Neutrophil Respiratory 
Burst - TNFa 
4 107.1 2.41E-09 10.7 0 80.8 1.26E-08 9.9 -0.81 0.154 6.5 
CHO C5a1 pERK 4 102.9 2.63E-11 12.6 0 95.0 1.80E-10 11.7 -0.87 0.134 7.5 
CHO C5a1 cAMP 4 101.3 1.00E-09 11.0 0 99.4 3.27E-09 10.5 -0.53 0.298 3.4 
CHO C5a1 Calcium 8 102.1 2.23E-11 12.7 0 100.0 1.63E-10 11.8 -0.90 0.127 7.9 
C5a1 B-arrestin2 4 103.3 1.39E-09 10.9 0 82.3 1.29E-08 9.8 -1.06 0.086 11.6 
C5a2 B-arrestin2 4 83.9 1.09E-09 10.9 0 89.9 8.24E-10 11.1 0.16 1.450 0.7 
C5a1 Internalization 4 108.9 2.40E-09 10.7 0 111.4 1.40E-08 9.9 -0.76 0.173 5.8 
C5a2 Internalization 4 101.3 3.56E-09 10.4 0 97.9 3.51E-09 10.3 -0.04 0.920 1.1 
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C5a des Arg also displayed a reduced relative activity at inducing the recruitment of 
-arrestin to and internalization of the C5a1 receptor, cellular processes that are 
considered to be important for desensitizing cellular responses during continual 
agonist exposure.  From receptor antagonism studies I demonstrated that the C5a1 
receptor is responsible for mediating the chemotactic responses of both peptide 
agonists, yet C5a des Arg did not promote the typical desensitization response often 
observed in cellular migration experiments.  This lack of desensitization was also 
observed by Yancey et al. (1989) who investigated the chemotactic effects of C5a and 
C5a des Arg on human monocytes and neutrophils.  The inability of C5a des Arg to 
desensitize the cell migratory response is probably due to its reduced activity to 
switch off the C5a1 receptor via -arrestin recruitment and subsequent receptor 
internalization. 
This apparent signalling bias of C5a des Arg towards an integrin up regulation and 
chemotactic phenotype and away from an antimicrobial phenotype could be 
considered mechanistically advantageous.  When a peripheral microbial infection is 
detected by the complement system and tissue resident macrophages, C5a and pro-
inflammatory cytokines are produced (figure 5.12).  As C5a diffuses away from the 
site of infection and towards blood vessels it is metabolized to C5a des Arg by 
carboxypeptidases.  With the majority of, if not all, serum C5a in the blood being C5a 
des Arg, this peptide needs to retain potent integrin and chemotactic activity to 
effectively extravasate immune cells from the blood to sites of infection.  On the 
other hand, it would be a disadvantage if neutrophils, while migrating to the site of 
infection, produced antimicrobial agents such as HOCl that could potentially damage 
the surrounding tissue.  Therefore, the fact that neutrophil generation of 
antimicrobial agents appears to be under the control of C5a and TNF, agents whose 
concentration are at their highest at the immediate site of infection, suggests that 
this microbial clearance response is tightly controlled to minimize damage to the 
surrounding tissue. 
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Figure 5.12. Schematic depiction of the role of C5a and C5a des Arg in elimination of a microbial 
infection 
Peripheral microbial infection results in activation of the complements system (1a) and production of 
proinflammatory cytokines, including TNF, by tissue resident macrophages (1b).  As C5a diffuses 
away from the site of infection towards blood vessels it is rapidly converted to C5a des Arg by 
carboxypeptidases (2).  C5a des Arg binds to C5a1 receptors expressed on the surface of neutrophils 
(3), resulting cell activation and adhesion to endothelial cells lining the vasculature (4 & 5).  
Neutrophils migrate from blood vessels along the C5a des Arg / C5a gradient by chemotaxis (6 & 7) to 
the site of infection.   Upon contact, neutrophils phagocytose pathogenic microbes, while non-
metabolized C5a and TNF ligate C5a1 and TNFR1 expressed on the neutrophil surface.  Dual receptor 
activation induces the respiratory burst response resulting in the production of the antimicrobial 
agent HOCl (8). 
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Lastly, my research in this chapter attempted to shed light on the mechanism 
through which TNF and C5a control the HOCl respiratory burst response.  It is well 
known that during respiratory burst, phagocytes generate HOCl, to destroy 
pathogenic microbes that have entered sterile compartments of the body (Albrich et 
al., 1982; Pullar et al., 2000).  My research has demonstrated that in order to achieve 
a full respiratory burst response, neutrophils require both a priming and activation 
stimuli.  This research demonstrates that TNF provides a priming role by increasing 
intracellular concentrations of the oxygen radical H2O2, which is mediated solely 
through the TNFR1.  Unlike TNFR2, which primarily couples to TNF receptor-
associating factors (TRAFs), TNFR1 contains a death domain motif towards the 
carboxy-terminal of the receptor which allows it to couple to other death domain 
containing proteins including TNF receptor-associated death domain (TRADD) and 
Fas-associated death domain (FADD)  (Tartaglia et al., 1993; MacEwan, 2002).  While 
FADD regulates cell death mechanisms, TRADD has been shown to recruit and 
activate riboflavin kinase (RFK) (Yazdanpanah et al., 2009).  RFK phosphorylates 
riboflavin to produce flavin mononucleotide (FMN) which is subsequently converted 
to flavin adenine dinucleotide (FAD) by FAD synthetase (Schramm et al., 2014). FAD 
acts as an essential cofactor of the NADPH oxidases 2 (NOX2), an oxidase abundant in 
phagocytic immune cells (Panday et al., 2015).  Upon activation, NOX2 generates 
superoxide (O2
-) inside the phagosome which is rapidly converted to H2O2 by 
superoxide dismutase (SOD).  However H2O2 is unable to rapidly oxidize the ROS 
indicator dihydrorhodamine123 and is not the ultimate oxygen species to effectively 
neutralize pathogenic microbes. 
It was not until neutrophils were exposed to C5a after being primed with TNF that 
HOCl was generated, the effects of which were solely mediated via the C5a1 
receptor.  C5a is known to induce neutrophil degranulation, causing release of 
myeloperoxidase (MPO) from azurophilic lysosomal granules (Chenoweth et al., 
1980).  The release of MPO results in the chlorination of H2O2 to generate the highly 
reactive HOCl (figure 5.13).  Although not directly measured here, there is an 
indication that C5a des Arg would show a bias away from inducing a degranulation-
MPO release response.  In fact this was observed by Chenoweth et al. (1983) who 
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showed that C5a des Arg is approximately 40 fold weaker than C5a at inducing MPO 
activity in neutrophils. 
I believe the results described here pertaining to the dual mechanism required to 
generate HOCl for complete respiratory burst (TNF inducing the intracellular 
production of H2O2 via TNFR1, and C5a promoting the release of MPO from 
azurophilic granules via the C5a1 receptor), shed light on the true role of C5a in the 
respiratory burst response.  C5a does not induce the production of H2O2, which it is 
often misrepresented in the literature as doing so (Lee et al., 2008). 
In summary, the work in this research chapter demonstrates that C5a des Arg 
displays a biased agonism profile.  This signalling bias is towards promoting a cell 
phenotype required for extravasation of neutrophils from the blood to peripheral 
sites of microbial infection and away from a phenotype required for microbial 
elimination.  Unfortunately the research described here was unable to shed further 
light as to the function of the C5a2 receptor, the role of which is still largely 
enigmatic. 
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Figure 5.13. Schematic depiction of the role C5a, TNF and their receptors in the neutrophil 
respiratory burst response 
TNF ligation of the TNFR1 expressed on the surface of neutrophils results in the recruitment of death 
domain adaptor proteins, including TNF-receptor associated death domain (TRADD) or Fas-associated 
death domain (FADD) to the death domain region of TNRF1 located at its carboxyl-terminal.  The 
TNFR2 is not capable of interacting with death domain containing adaptor proteins but couples to TNF 
receptor-associated factors (TRAFF).  TRADD recruits and activates riboflavin kinase (RFK) which 
phosphorylates riboflavin to produce flavin mononucleotide (FMN) which is then converted to flavin 
adenine dinucleotide (FAD) by FAD synthetase. FAD binds to NADPH oxidase 2 (NOX2) which further 
recruits the regulatory subunits p40
phox
, p47
phox
, p67
phox
 and Rac.  This leads to NOX2 activation which 
transfers electrons from cytosolic NADPH to oxygen (O2) on the luminal side of the phagosome 
generating superoxide (O2
-
).  O2
-
 is converted to hydrogen peroxide (H2O2) by superoxide dismutase 
(SOD).  Activation of the C5a1 receptors expressed on the surface of neutrophils by C5a results in 
degranulation of azurophilic lysosomal granules releasing myeloperoxidase (MPO) into the 
phagosome.  MPO chlorinates H2O2 resulting in the generation of the highly reactive antimicrobial 
agent hypochlorous acid (HOCl). 
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Defining the mechanism of C5a des Arg induced 
biased agonism 
 
6.1. Abstract 
The complement system fragment peptide, C5a des Arg, retains a significant degree 
of the activity displayed by its parent isoform, C5a, at the C5a1 receptor.  The 
functional responses induced by C5a des Arg promote a cellular phenotype linked to 
immune cell extravasation.  However, C5a des Arg is almost devoid of the ability to 
induce an immune cell response involved in the removal of a microbial infection.  The 
work performed in this chapter attempted to elucidate the mechanism by which C5a 
des Arg produces its biased agonism profile. 
Receptor mutagenesis and cell based functional assays were performed to 
understand whether there are differences in how C5a and C5a des Arg bind the 
transmembrane domain of the C5a1 receptor.  The BioSens-All
TM platform, offered by 
Domain Therapeutics, was subsequently employed to determine whether C5a des 
Arg produces a different G-protein and -arrestin activation profile compared with 
C5a. 
Both C5a and C5a des Arg electrostatically interact with the transmembrane region 
of the C5a1 receptor.  To achieve its superior affinity, C5a interacts with amino acid 
residue D282.  C5a des Arg relies on a cluster of amino acids at the top of the fourth 
and fifth transmembrane domains.  This difference in binding does not translate into 
a different G-protein activation signature but it does appear to alter the ability of C5a 
des Arg to promote the recruitment of -arrestin.  The lack of -arrestin recruitment 
induced by C5a des Arg may be responsible for its biased agonism profile at the C5a1 
receptor. 
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6.2. Introduction 
 
As demonstrated by the work in the previous chapter, C5a des Arg displays a biased 
agonism profile compared with C5a.  The C-terminal arginine of C5a allows it to 
induce neutrophil responses, especially respiratory burst which appears to be tied to 
calcium mobilization and/or -arrestin recruitment.  However, the removal of the 
arginine appears to focus the ligand’s functional activity towards neutrophil 
phenotypes that contribute to cellular extravasation, including integrin upregulation 
and chemotaxis which appear to be tied to the regulation of intracellular cAMP 
concentrations and possibly its actions at the C5a2 receptor.  Although only 
characterized using monoclonal antibodies, due to the lack of cell permeable 
reagents, results from the previous chapter suggest that the C5a2 does not 
contribute the actions of C5a des Arg in mediating neutrophil responses.  With this in 
mind, it is possible that C5a des Arg produces its biased agonism profile by inducing a 
specific conformation of the C5a1 receptor that only allows activation of specific 
intracellular pathways. 
For an agonist to produce a cellular response it must first bind to its cognate GPCR 
and then provide a stimulus.  This stimulus leads to a change in the receptors tertiary 
structure resulting in an active receptor conformation.  The active receptor 
conformation is typified by a contraction of the agonist binding pocket (orthosteric 
site), movement of transmembrane (TM) domains, including the shift of TM6 away 
from the core of the receptor, which reveals intracellular binding sites to which 
intracellular proteins, including G-proteins and -arrestins, bind (Rasmussen et al., 
2011; Cooke et al., 2016).  Rather than promoting a single active receptor 
conformation, agonists can induce an ensemble of receptor conformations that 
promote the recruitment of multiple types of G-proteins, leading to the activation of 
several intracellular pathways (Li et al., 2004).  It is therefore possible that C5a des 
Arg, in contrast to C5a, induces a different receptor conformation that leads to the 
activation of only select pathways.  If so, what are the mechanisms by which C5a des 
Arg drives conformational selectivity of the C5a1 receptor and how does this 
influence pathway activation? 
 149 
 
There is also a possibility that the biased agonism profile generated by C5a des Arg is 
due to receptor-ligand binding kinetics.  From results generated earlier in this thesis, 
which are similar to those observed by others, C5a des Arg has a significantly 
reduced affinity at the C5a1 receptor compared with C5a.  A ligand’s affinity for a 
receptor is a function of its association and dissociation binding kinetics, with faster 
association and slower dissociation kinetics increasing the affinity of a ligand for a 
receptor.  Interestingly, the functional endpoints that C5a des Arg is biased towards 
have extended assay incubations times, whereas, the functional endpoints which C5a 
des Arg is biased away from have short experimental incubation times.  However, 
there is an exception to this trend which is observed with the recruitment of -
arrestin 2 to the C5a1 receptor.  Of all experimental endpoints investigated, this assay 
experienced the longest assay incubation time, yet C5a des Arg failed to display 
comparable potency to C5a. 
Numerous research groups have attempted to define the specific amino acids 
residues within the TM domain of the C5a1 receptor that contribute to the binding 
affinity and efficacy of C5a and C5a des Arg (DeMartino et al., 1995; Cain et al., 2001; 
Higginbottom et al., 2005).  Using receptor mutagenesis, researchers discovered that 
a strong electrostatic interaction exists between the terminal arginine of C5a and the 
Asp-282 amino acid residue that lies within TM seven in the C5a1 receptor.  This 
interaction contributes to the binding affinity of C5a and helps explain the reduced 
affinity of C5a des Arg at the C5a1 receptor.  Interestingly, a cluster of charged 
residues at the top of TM 4 and 5 (Arg 175, Glu-199 and Arg 206) contribute heavily 
to the affinity and efficacy of C5a des Arg but have no impact on C5a. 
With the uncertainty as to whether selective receptor conformations or receptor-
ligand binding kinetics contribute to the biased agonism profile of C5a des Arg, I have 
decided to focus the research in this chapter on understanding the mechanism by 
which C5a des Arg achieves its biased agonism profile.  The main objectives of are: 
1. Using site directed mutagenesis, investigate the contribution of the charged 
amino acid residues Arg-175, Glu-180, Glu-199, Arg-206 and Asp-282 within 
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the transmembrane region of the C5a1 receptor to the potency and efficacy 
of C5a and C5a des Arg. 
 
2. Using both C5a and C5a des Arg, perform pA2 analyses with the competitive 
antagonist, PMX53 and the inverse agonist, NDT9513727 (figure 6.1), to 
determine whether each agonist is proportionally antagonized by each 
antagonist and how each charged residue impacts antagonist affinity. 
 
3. Using the BioSens-All platform offered by Domain Therapeutics, assess the G-
protein and -arrestin signalling signatures induced by C5a and C5a des Arg at 
the wild type C5a1 receptor.  Assess the impact of assay kinetics on the 
signalling signature of each peptide agonist. 
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Figure 6.1. Structures of C5a, C5a des Arg, PMX53 and NDT9513727 
The last six amino acids that form the C-terminus of C5a (Asp-Met-Gln-Leu-Gly-Arg) (A).  The removal 
of the terminal arginine by carboxypeptidases generates C5a des Arg (B).  The cyclic peptide C5a1 
receptor antagonist PMX53, (Ace-Phe-[Orn-Pro-dCha-Trp-Arg]) which resembles the C-terminus of C5a 
(C) and the C5a1 receptor inverse agonist NDT9513727 (D). 
 
A B 
C D 
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6.3. Chapter specific methods 
 
6.3.1. Wild type and mutant C5a1 receptor expression 
 
Codon optimized wild type and mutant C5a1 receptor constructs were generated by 
Blue Sky BioServices Inc, Worcester, MA, USA, and expressed in pcDNA3.1 plasmid 
vectors.  CHO cells transformed to stably overexpress the G16 G-protein were grown 
to 80% confluency and separately transfected with each plasmid DNA using the 
MaxCyte STX electroporation apparatus.  Cells from each transfection were 
resuspended in growth medium and either seeded into a T75 flask for assessment of 
receptor expression (2 x 106 cells/flask), or into black, clear bottom plates (10,000 
cells/well) for functional assay assessment.  Cells were left in culture for 24 hours 
before experimentation. 
6.3.2. Flow cytometry assessment of receptor expression 
 
On the day of experimentation, cells were harvested from the flasks and stained in 
FACS buffer with either the C5a1 receptor specific FITC conjugated monoclonal 
antibody S5/1, or an equivalent concentration of IgG matched isotype control.  
Samples were assessed for mean fluorescence intensity in the FITC channel using 
flow cytometry. 
6.3.3. Functional assessment of the wild type and mutant C5a1 receptor 
constructs using pA2 analyses 
 
The impact of each receptor mutation on the potency and efficacy of C5a and C5a 
des Arg as well as the affinity of two C5a1 receptor antagonists, PMX53 and 
NDT9513727, was assessed using calcium mobilization as described in detail in the 
main methods section.  Concentration ranges of either C5a or C5a des Arg were 
tested in the absence or presence of increasing concentrations of each antagonist.  
To obtain estimates of potency and efficacy for each agonist condition, the four 
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parameter logistic equation was fit to each concentration response data set.  To 
determine an estimate of the affinity constant for each antagonist at each receptor 
construct using either C5a or C5a des Arg as the agonist, equiactive agonist 
concentrations were extrapolated from agonist curves in the absence and presence 
of antagonist to calculate dose ratios (DR).  Using the Schild regression (plotting the 
antagonist concentration (Log[B]) vs Log(DR-1)), and the pA2 equation (equation 6.1), 
the concentration of antagonist that produces a 2 fold shift in agonist concentration 
response curve (pA2) was calculated. 
 
pA2   =   Log(DR-1) – Log[B] 
Equation 6.1. The pA2 equation 
 
6.3.4. The G-protein coupling signature of C5a and C5a des Arg at the 
C5a1 receptor 
 
To determine the G-protein/-arrestin signalling signature of C5a and C5a des Arg at 
the wild type C5a1 receptor, the Domain Therapeutics BioSens-All
TM platform was 
used.  The BioSens-AllTM platform uses bioluminescence resonance energy transfer 
(BRET) technology to determine specific G-protein subunit activation by measuring 
its proximity to a G-protein complex.  At rest, in its GDP bound state, the 
bioluminescent, luciferase conjugated G subunit is in close proximity to the green 
fluorescent protein tagged G-protein complex, and a fluorescent signal is 
generated.  If a particular G-protein is activated upon agonist induced receptor 
activation, GDP-GTP exchange occurs leading to its dissociation from its G-protein 
counterpart resulting in a diminished fluorescence signal.  A similar BRET 
arrangement can also detect the receptor recruitment of -arrestin. 
C5a1 receptor interactions with the Gi2, GoB, and G15/16 as well as -arrestin 2 
biosensors were investigated in the BioSens-All platform.   The potency and efficacy 
of both C5a and C5a des Arg were assessed using 22 point concentration response 
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curves.  The impact of agonist kinetics on each biosensor response was assessed by 
reading each biosensor assay at multiple time points.  The relative activity of C5 des 
Arg at each biosensor was compared to C5a using the previously described 
Log(Emax/EC50) transformation. 
 
6.3.5. Characterizing the receptor binding arrangement of the two C5a1 
receptor antagonists PMX53 and NDT9513727 
 
To determine whether NDT9513727 binds to the same site on the C5a1 receptor as 
PMX53, a competition binding study using a tritiated analogue of PMX53 was 
employed.  CHO cells expressing the C5a1 receptor were incubated with a Kd 
concentration of the tritiated cyclic peptide in the presence of a concentration range 
of either NDT9513727, PMX53 or human purified C5a or C5a des Arg.  Assay was 
incubated for 3 hours at room temperature prior to termination via rapid filtration 
through PEI soaked GF/C filter plates using a Brandel Harvester.  Concentration 
response data were expressed as a percentage of total and non-specific binding 
controls (defined with 1 µM PMX53) and IC50 values were generated using the four 
parameter logistic equation described earlier. 
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6.4. Results 
 
6.4.1. Functionally viable expression of wild type and mutant C5a1 
receptors 
 
To determine the contribution of electrostatic interactions between the C5a1 
receptor and C5a and C5a des Arg in driving agonist induced responses, charged 
residues within the transmembrane region and extracellular loops of the receptor 
were mutated.  Single point mutations were performed at positions R175, E180, 
E199, R206 and D282, substituting each amino acid for a chemically inert alanine.   
Wild type and mutant C5a1 receptors were expressed in CHO cells over-expressing 
the G16-protein and receptor expression was quantified by flow cytometry.  Using 40 
µg of DNA, each receptor construct expressed at a comparable level in CHO cells and 
to within two fold of the wild type receptor.  There was no detection of endogenous 
C5a1 receptor in CHO cells using the S5/1 antibody clone.  However the cross 
reactivity of this reagent with hamster C5a1 receptor is not known (figure 6.2). 
To assess the consequence of each receptor mutation on the functional activity of 
C5a and C5a des Arg and on the affinity of the two antagonists PMX53 and 
NDT9513727, a calcium mobilization assay was used.  To ensure cells expressing each 
receptor were functionally viable and loaded with an equivalent amount of the 
calcium dye, plated cells were stimulated with either 100 nM of the calcium 
ionophore, A23187, or with a high concentration (3 µM) of human purified C5a 
(figure 6.3).  All cells expressing C5a1 receptor constructs produced robust and 
reproducible responses to the calcium ionophore which, were within 20% of the 
response produced by the parent CHO cells.  Similarly, all cells expressing C5a1 
receptor constructs produced robust responses to C5a which were within 25% of the 
response produced by cells expressing the wild type receptor.  Interestingly, the 
parent CHO cells produced a response to C5a that was approximately 15% that of the 
wild type receptor response.  Although reproducible, this response was not 
considered to be large enough to impact the interpretation of agonist concentration 
response data. 
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Figure 6.2. Expression of the different C5a1 receptor constructs in CHO cells 
Surface expression of wild type and mutant constructs of the human C5a1 receptor expressed in CHO 
cells.  Relative receptor expression was determined using flow cytometry and the FITC conjugated 
C5a1 receptor specific antibody clone S5/1.  Parent CHO cell (A), wild type C5a1 receptor (B), R175A 
(C), E180A (D), E199A (E), R206A (F) and R282A (G).  Open histogram represents concentration 
matched isotype control antibody staining, shaded histogram represents receptor specific antibody 
staining. 
Parent Wild Type 
E180A 
D282A 
E199A 
R175A 
R206A 
A B C 
D E F 
G 
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  A 
 
 
 
 
 
 
 
  B 
 
 
 
 
 
 
Figure 6.3. Functional responsiveness of CHO cells expressing wild type and mutant C5a1 receptor 
constructs 
Viability and functional expression of human C5a1 receptor constructs in CHO cells measured by 
calcium mobilization using the fluorescence imaging.  CHO cells loaded with calcium 3 indicator dye 
were stimulated with the calcium ionophore A23187 (100 nM) (A), or human purified C5a (3 µM) (B).  
Response is plotted as ratio of the maximum-minimum fluorescence response.  Bars represent mean 
and S.D. from between 4-24 different replicates. 
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6.4.2. Charged residues within the transmembrane domain of the C5a1 
receptor contribute to the affinity of C5a and C5a des Arg 
 
The impact of mutating the charged amino acid residues on the potency (EC50) and 
efficacy (Emax) of C5a and C5a des Arg assessed using calcium mobilization assays.  At 
the wild type receptor both C5a and C5a des Arg were as efficacious as each other 
and displayed EC50 values of 11 and 64 pM respectively (figure 6.4).  The mutant C5a1 
receptor R175A, had a small impact on the EC50 of C5a, (3.4 fold increase) but a 
profound effect on the potency of C5a des Arg, reducing its EC50 by 170 fold to 11 nM 
(table 6.1).  This was in contrast to the mutant E180A, a charged amino acid residue 
present within the second extracellular loop of the C5a1 receptor.  This mutation had 
no impact on the potency of C5a and a minor impact on the potency of C5a des Arg 
(2.2 fold increase in EC50).  Mutant E199A, located at the top to TM 5, produced a 
mild reduction in the EC50 of C5a but produced a 10 fold reduction in the EC50 of C5a 
des Arg.  When mutating the C5a1 receptor at position R206A, an amino acid residue 
also within the fifth TM, minimal impact was observed on the EC50 of C5a.  However 
the mutation of this residue had the most profound effect on the EC50 of C5a des Arg, 
reducing its potency by approximately 550 fold to 35 nM.  Finally, mutation D282A 
within the seventh TM of the C5a1 receptor had no impact on the EC50 of C5a des Arg 
but had a substantial effect on the EC50 of C5a, reducing its EC50 by 6 fold to 70 pM.  
Using the Log(Emax/EC50) conversion, a web of efficacy for C5a and C5a des Arg at 
the wild type and mutant C5a1 receptors was generated (figure 6.5).  These data 
confirm the electrostatic interaction between the positively charged arginine at the 
C-terminal of C5a and the negatively charged Asp-282 within the seventh TM of the 
C5a1 receptor.  They also highlight the importance of the cluster of amino acids at 
the top of TM 5 and 6 in controlling the affinity of C5a des Arg. 
Next, the effects of receptor mutagenesis were assessed on the affinity of the two 
C5a1 receptor antagonists PMX53 and NDT9513727 using pA2 analysis.  Analyses 
were performed using both C5a and C5a des Arg to determine whether antagonism 
of each agonist was comparable.  Due the lack of equilibrium achieved in calcium 
mobilization assays, pA2 values were only used to compare antagonist affinity  
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Figure 6.4. The effect of C5a1 receptor mutagenesis on potency and efficacy of C5a and C5a des Arg 
Calcium mobilization responses induced by concentrations of human purified C5a or C5a des Arg at 
human wild type and mutant C5a1 receptors expressed in CHO cells.  Wild type C5a1 receptor (A), 
R175A (B), E180A (C), E199A (D), R206A (E) and R282A (F).  Responses for each C5a1 receptor 
construct were expressed as a percentage of the maximum response induced by C5a.  Data points 
represent mean and S.D. from eight replicates.  
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 C5a 
EC50 (M) 
C5a des Arg 
EC50 (M) 
Fold difference  
C5a to C5a des Arg 
Wild type 1.14E-11 6.46E-11 5.7 
R175A 3.89E-11 1.10E-08 282.0 
E180A 1.00E-11 1.41E-10 14.1 
E199A 7.81E-12 6.52E-10 83.5 
R206A 9.72E-12 3.54E-08 3641.2 
D282A 7.08E-11 8.71E-11 1.2 
 
 Fold difference to wild 
type 
Fold difference to wild 
type 
Wild type 1.0 1.0 
R175A 3.4 169.9 
E180A 0.9 2.2 
E199A 0.7 10.1 
R206A 0.9 547.9 
D282A 6.2 1.3 
 
Table 6.1. Potency of C5a and C5a des Arg at the wild type and mutant C5a1 receptors 
EC50 values of human purified C5a and C5a des Arg at the human wild type and mutant C5a1 receptors 
expressed in CHO cells.  Upper table shows EC50 values extrapolated from the four parameter logistic 
equation and the fold difference between C5a and C5a des Arg at the different C5a1 receptor 
constructs.  Lower table shows the fold difference in EC50 for either C5a or C5a des Arg at each mutant 
construct compared with wild type receptor. 
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Figure 6.5. Relative agonism of C5a and C5a des Arg at each C5a1 receptor construct 
A radar plot showing the relative agonism of C5a des Arg (blue line) to C5a (red line) at the human 
wild type and mutant C5a1 receptor constructs.  Relative agonist activity was calculated using the 
Log(Emax/EC50) transformation. 
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between receptor constructs and were not considered to be system independent 
measures of antagonist affinity. 
Against C5a, both PMX53 and NDT9513727 produced dextral displacement of the 
agonist concentration response curve at the wild type C5a1 receptor which were 
surmountable at each antagonist concentration (figure 6.6 A and C).  The pA2 values 
for NDT9513727 and PMX53 were comparable at 7 and 6.7 respectively (table 6.2).  
A very interesting observation was made from the pA2 analyses using C5a des Arg.  
The dextral shifts of the C5a des Arg concentration response curves induced by both 
antagonists were much larger than those observed against C5a (figure 6.6 B and D).  
This translated into an increased affinity of both NDT9513727 and PMX53 with pA2 
values of 7.7 and 7.8 respectively.  This apparent probe dependence in receptor 
antagonism suggests that both PMX53 and NDT9513727 bind the C5a1 receptor 
allosterically to either one or both C5a peptides.  Interestingly, at high 
concentrations, NDT9513727 displayed profound degree of insurmountable 
antagonism compared with PMX53, again further indicating an allosteric mode of 
action for this C5a1 receptor antagonist. 
At the R175A mutant receptor, both NDT9513727 and PMX53 produced greater 
dextral shifts in C5a concentration response curves than were seen at the wild type 
receptor with pA2 values of 8.4 and 8.1 respectively (figure 6.6 E and G).  In addition, 
NDT9513727 displayed insurmountable antagonism at the highest concentrations 
tested, again possibly alluding to an allosteric model of action for this antagonist.  
Both antagonists displayed similar antagonism profiles at C5a des Arg, with the 
agonist concentration response curves starting much further down the concentration 
range. These data confirm the observations from the agonist alone experiments, 
demonstrating the role of the R175 residue in controlling the affinity of C5a and C5a 
des Arg at the C5a1 receptor.  Interestingly, the addition of PMX53 to cells expressing 
the R175A construct, prior to the addition of agonist, resulted partial agonist 
response which plateaued at 50% of the response induced by C5a and with an EC50 
400nM.  These data highlight that R175 probably forms an important electrostatic 
interaction with PMX53 which locks the receptor in an inactive conformation.  When 
this interaction is absent, the cyclic peptide antagonist is able to activate the  
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Figure 6.6. Antagonism of C5a and C5a des Arg at C5a1 receptor constructs by PMX53 and 
NDT9513727 
Concentration response curves for C5a and C5a des Arg in the absence or presence of increasing 
concentrations of either the cyclic peptide antagonist PMX53 or the inverse agonist NDT9513727.  
Wild type C5a1 receptor (A-D), and mutant constructs R175A (E-H), E180A (I-L), E199A (M-P), R206A 
(Q-T) and D282 (U-X).  All agonist responses were expressed as a percentage of the maximum agonist 
response.  Data points are represent mean and S.D. from two replicates. 
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Figure 6.6. Continued 
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Figure 6.6. continued 
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Figure 6.6. Continued 
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Figure 6.6. Continued 
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Figure 6.6. Continued 
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Table 6.2. pA2 values for NDT9513727 and PMX53 at the human wild type and mutant C5a1 
receptors 
pA2 values for PMX53 and NDT9513727 at each C5a1 receptor construct obtained from Schild 
analyses.  pA2 values were generated using either human purified C5a or C5a des Arg. 
 
 
 
 
 
 
 
  pA2 [M] A2 [M]  
C5a1 receptor Antagonist C5a C5a des Arg C5a C5a des Arg Fold A2 
C5a/C5a des Arg 
Wild Type NDT 7.0 7.7 1.0E-07 1.9E-08 5.3 
R175A NDT 8.4 8.1 4.3E-09 8.6E-09 0.5 
E180A NDT 7.4 7.8 3.7E-08 1.7E-08 2.2 
E199A NDT 7.4 7.7 3.6E-08 2.1E-08 1.7 
R206A NDT 8.3 6.8 5.2E-09 1.5E-07 0.04 
D282A NDT 8.0 8.0 1.1E-08 9.2E-09 1.1 
Wild Type PMX53 6.7 7.8 1.9E-07 1.7E-08 11.4 
R175A PMX53 8.0 8.5 1.0E-08 3.4E-9 3 
E180A PMX53 7.3 8.3 5.5E-08 4.7E-09 11.8 
E199A PMX53 7.4 7.8 4.2E-08 1.5E-08 2.8 
R206A PMX53 8.5 7.8 3.4E-09 1.7E-08 0.2 
D282A PMX53 7.0 6.8 9.5E-08 1.4E-07 0.7 
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receptor.  Neither NDT9513727 nor PMX53 produced an agonist response at the 
other C5a1 receptor constructs. 
Mutating the C5a1 receptor at position E180 within the second extracellular loop, 
enhanced the affinity of both antagonists when profiled against C5a and C5a des Arg 
(figure 6.6 I-L).  This was apparent by the greater dextral shifts in each agonist 
response curve and highlights a possible interaction between C5a and C5a des Arg at 
this point on the receptor.  Similar concentration response curve displacement 
profiles were observed at the E199A mutant receptor (figure 6.6 M-P).  The increase 
in affinity estimate for both antagonists against both agonists when compared with 
the wild type receptor suggest that this receptor residue contributes to the affinity of 
both peptides at the C5a1 receptor. 
As observed in the agonist alone experiment, residue R206 profoundly contributed to 
the affinity of C5a des Arg at the C5a1 receptor but appeared to have minimal impact 
on C5a.  However, the mutant R206A receptor caused both antagonists to produce 
larger dextral shifts in the concentration response curves of C5a compared with the 
wild type receptor and resulted in pA2 values of 8.3 and 8.5 for NDT9513727 and 
PMX53 respectively (figure 6.6 Q-T). 
The impact of each antagonist on the response induced by C5a des Arg was difficult 
to assess due to the weak potency of this agonist at the R206A mutant receptor.  
Although quoted in table 6.2, the pA2 values for both antagonists against C5a des Arg 
at this receptor construct are probably incorrect due to the high degree of 
insurmountable antagonism and very few points on the Schild regression.  
Nevertheless, these data highlight that R206, located within the fifth TM of the C5a1 
contributes to the binding of both C5a and C5a des Arg.  
Finally, the mutant C5a1 receptor D282A, had a very interesting effect on both 
antagonists (figure 6.6 U-X).  NDT9513727 produced much greater dextral shifts in 
the concentration curves produced by C5a (pA2 of 8), which were almost identical to 
those generated against C5a des Arg (pA2 of 8) and by C5a des Arg at the wild type 
construct (pA2 of 7.7).  This was in contrast to the shifts in concentration response 
curves induced by PMX53 at the R282A construct.  PMX53 produced an identical 
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antagonism profile against C5a (pA2 of 7) compared with C5a des Arg (pA2 of 6.8) 
which was identical to that observed against C5a at the wild type receptor (pA2 of 
6.7), albeit with a change in the location of the C5a concentration response curve 
along the x-axis.  The effect of mutating residue D282 therefore had the opposite 
effect on each antagonist.  This mutation increased the apparent affinity of 
NDT9513727 yet reduced the affinity of PMX53.  These data suggest that PMX53, 
unlike NDT9513727, uses the D282 residue for affinity, further suggesting that these 
two antagonists bind different sites on the C5a1 receptor.  
 
6.4.3. PMX53 and NDT9513727 bind the C5a1 receptor in a non-
competitive manner 
 
The data from the pA2 analyses suggest that cyclic peptide, PMX53, and the inverse 
agonist, NDT9513727 bind to different locations on the C5a1 receptor.  To test this 
hypothesis, a C5a1 receptor competition binding assay using a tritiated analogue of 
PMX53 as the tracer ligand was employed.   PMX53 displaced a Kd concentration 
3H-
cyclic peptide analogue from the C5a1 receptor in a monophasic manner with an IC50 
of 12 nM (figure 6.7).  This was in complete contrast to NDT9513727 which failed to 
inhibit the binding of the 3H-cyclic peptide to the C5a1 receptor at concentrations up 
to 10 µM.  Although C5a displayed a greater affinity than PMX53 for the C5a1 
receptor (IC50 of 5 nM), at plateau, it was only able to able to inhibit the binding of 
the 3H-cyclic peptide by 50%.  A similar observation was made with C5a des Arg.  As 
well as a reduced affinity (IC50 of 300 nM), C5a des Arg also displayed a shallow 
binding slope. 
 
6.4.4. C5a des Arg does not induce G-protein bias of the C5a1 receptor 
 
To understand whether the different interactions of C5a and C5a des Arg at the C5a1 
receptor leads to a differences in receptor conformation and selective pathway 
stimulation, agonist induced G-protein activation was assessed using the BioSens-
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AllTM platform offered by Domain Therapeutics.  Using the wild type C5a1 receptor, 
initial experiments investigated the ability of C5a and C5a des Arg to activate the 
Gi2, Go, G16 or -arrestin 2 biosensors at 10 and 60 minutes.  At both time points, 
C5a des Arg was as efficacious as C5a at each of the G-protein biosensors (figure 6.8 
A-F).  At the shorter assay time point, C5a produced EC50 values of between 50-100 
pM at each of the G-protein biosensor which was approximately five fold more 
potent than C5a des Arg in each assay.  However, at the longer assay incubation 
time, C5a displayed a reduced EC50 at each G-protein biosensor, becoming only two 
fold more potent than C5a des Arg (figure 6.9).   
These data are in substantial contrast to those obtained with the -arrestin 2 
biosensor (figure 6.8 G&H).  At both early and late time points, C5a des Arg achieved 
a maximal response that was only 50% of the maximal response produced by C5a.  In 
addition, C5a des Arg displayed a reduced potency (10-20 fold) compared with C5a 
(figure 6.9).  These data are in accordance with those generated in CHO cells using 
the DiscoverX PathHunter® assay technology and demonstrate that C5a des Arg 
displays a consistent bias away from recruiting -arrestin to the C5a1 receptor which 
is not due to assay kinetics. 
In response to these data, a further experiment using the BioSens-AllTM platform was 
performed to investigate the contribution of -arrestins to the G-protein responses.  
As can be seen in figure 6.10, both Gi2 and G16 responses, induced by an EC50 
concentration of C5a in wild type cells expressing both -arrestin 1 and 2, decline 
over time.  This decline in biosensor response diminishes with the double knock out 
of both -arrestins.  Interestingly C5a des Arg produces stable Gi2 and G16 response 
in both the presence and absence of -arrestins.  These data further confirm the 
reduced ability of C5a des Arg to promote -arrestin recruitment to the C5a1 
receptor. 
 
 
 
 173 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 PMX53 and NDT9513727 bind separate sites on the C5a1 receptor 
Competition binding between human purified C5a, C5a des Arg, PMX53 or NDT9513727 and a 
3
H-
analogue of PMX53.  Each ligand was tested against a Kd concentration of the 
3
H-analogue of PMX53.  
Data points represent mean and S.D. from two replicates.  Data are representative of two separate 
experiments. 
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Figure 6.8. G-protein and -arrestin signalling signatures of C5a and C5a des Arg 
Activation and recruitment of G-protein and -arrestin biosensors at the human wild type C5a1 
receptor by human purified C5a and C5a des Arg using the BioSens-All
TM
 platform offered by Domain 
Therapeutics.  Activation of Gi2 (A-B), Go (C-D), G16 (E-F) and recruitment of -arrestin (G-H) was 
assessed at 10 and 60 minutes.  Data points are single replicates.  Data are representative of two 
experiments. 
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Figure 6.9. The relative G-protein and -arrestin activity of C5a and C5a des Arg 
A radar plot showing the relative activity of C5a des Arg (blue line) to C5a (red line) at inducing G-
protein activation or -arrestin recruitment via the human wild type C5a1 receptor.  Solid line 
represents response at 10 minutes, dashed line represents response at 60 minutes. Relative agonist 
activity was calculated using the Log(Emax/EC50) transformation.  All agonist responses were 
compared to C5a at 10 minutes.   
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Figure 6.10. C5a induced desensitization of the G-protein biosensor response is -arrestin 
dependent 
Time dependent activation of the Gi2 (A) and Gi16 (B) biosensors by human purified C5a and C5a des 
Arg using the BioSens-All
TM
 platform.  Response assessed in cells expressing the human wild type C5a1 
receptor with or without endogenous -arrestin 1 and 2.  Each agonist was tested at an EC50 
concentration defined at 10 minutes.  Data points represent mean and S.D. from two replicates.  Data 
are representative of two separate experiments. 
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6.5. Discussion 
 
The main objective of the research outlined in this chapter was to elucidate the 
mechanism by which C5a des Arg produces its biased agonism response at the C5a1 
receptor.  Two potential mechanisms were proposed.  1). C5a des Arg binds to the 
C5a1 receptor in such a way that it induces a conformation that only allows the 
recruitment of certain intracellular proteins and specific pathway activation, or 2). 
loss of key electrostatic interactions between C5a des Arg and the C5a1 receptor 
reduces its affinity and alters the kinetics of the C5a des Arg induced response.  
By performing receptor mutagenesis coupled with a cell based calcium mobilization 
assay, key electrostatic interactions between charged amino acid residues within the 
TM region of the C5a1 receptor and the two agonist peptides were detected.  It was 
observed that the C-terminal arginine of C5a, which is missing from C5a des Arg, 
forms a strong electrostatic interaction with D282 on the C5a1 receptor, a finding 
originally discovered by Cain et al. (2001).  Receptor mutagenesis also highlighted the 
importance of a cluster of residues at the top of TM4 and 5, specifically R175, E199 
and R206.  When mutated to alanine, these residues appeared to have a mild to 
moderate impact on the potency of C5a but had a profound impact of the potency of 
C5a des Arg.  Although similar to the results observed by Higginbottom et al. (2005), 
who demonstrated that mutation of these residues prevented any RBL cell 
degranulation induced by C5a des Arg, they observed that mutation of these residues 
did have a noticeable impact on the potency  of C5a.  These differences could in part 
be due to the probable high receptor reserve in the CHO cells that were used in this 
research, brought about by the over expression of both receptor and calcium 
mobilization promoting G-proteins.  It could also be due to the differences in cellular 
endpoints that were investigated.  
Subsequent pA2 analyses using the cyclic peptide antagonist PMX53 and the inverse 
agonist NDT9513727 confirmed the importance of the electrostatic interaction 
between the arginine of C5a and D282 on the C5a1 receptor.  These analyses also 
highlighted that the C5a does in fact depend on the R175, E199 and R206 cluster of 
residues for affinity but not to the same degree as C5a des Arg (figure 6.11).   
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Figure 6.11. Apparent electrostatic interactions between the C5a peptide agonists and the C5a1 
receptor 
Both C5a and C5a des Arg rely on electrostatic interactions with specific charged amino acid residues 
within the transmembrane (TM) region of the C5a1 receptor for affinity and efficacy.  The arginine of 
C5a interacts with aspartic acid 282 (Asp282), within the seventh TM domain (A).  Both C5a and C5a 
des Arg interact with arginine 175 (Arg175) arginine 206 (Arg206) and glutamic acid 199 (Glu199 – 
residue not shown) (B). 
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Figure 6.12. Snake plot of the C5a1 receptor 
Snake plot detailing the 350 amino acids that form the human C5a1 receptor.  Image highlights the 
residues that are critical for G-protein binding (pink), residues that were mutated in this thesis (blue), 
the serine and threonine residues that are candidates for phosphorylation by G-protein coupled 
receptor kinases (red) and the tryptophan residue essential for small molecule antagonist affinity 
(green).  Image taken from www.gpcrdb.org (Isberg et al., 2016). 
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Surprisingly, the pA2 analyses also demonstrated that each antagonist displayed a 
differential capability of antagonizing either C5a or C5a des Arg, essentially giving 
each antagonist two different affinities depending on which agonist was used to 
characterize it. 
With C5a and C5a des Arg relying on different receptor residues for affinity to varying 
degrees, it seemed plausible that each agonist may promote a different receptor 
conformation resulting in the differential activation of intracellular proteins, 
particularly G-proteins.  Using the BioSens-AllTM platform it was observed that C5a 
des Arg could induce the activation of the same set of G- proteins as C5a, with similar 
magnitude and potency.  However, this was not the case with -arrestin.  C5a des 
Arg displayed weak partial agonism at promoting the recruitment of this protein to 
the C5a1 receptor compared with C5a.  The reduced ability of C5a des Arg to 
promote receptor recruitment of -arrestin was further demonstrated in time course 
studies using cells where the arrestin proteins were knocked out.   Unlike C5a, which 
induced a -arrestin dependent desensitization of the G-protein biosensor response, 
the G-protein responses produced by C5a des were stable over time, in either the 
absence or presence of -arrestin.   
GPCRs recruit -arrestin proteins upon phosphorylation of their intracellular domains 
by G-protein coupled receptor kinases (GRKs).  This family of kinases, which includes 
seven members (GRK 1-7), specifically phosphorylate serine and threonine residues 
within the C-terminus of the receptor after activation.   Different GRKs are thought to 
phosphorylate different serine and threonine residues on a receptor, which, is in 
part, considered to be regulated by the active conformational state of the receptor.  
This can therefore result in unique phosphorylation patterns, or barcodes, of the 
receptors C-terminus (Nobles et al., 2011).  The C5a1 receptor contains 11 serine and 
threonine residues within its C-terminus (figure 6.12).  It is, therefore, possible that 
the conformation of the C5a1 receptor, induced by C5a des Arg, results in either the 
recruitment of certain GRKs that produce a different phosphorylation barcode to the 
one induced by C5a, or fails to recruit GRKs to the receptor at all.  This latter 
hypothesis seems plausible, especially considering C5a des Arg does not interact with 
TM 7, at the tail end of which are the sites to which -arrestin is recruited.  In either 
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case, the actions of C5a des Arg do not lead to -arrestin recruitment to the C5a1 
receptor. 
Finally, using the 3H-cyclic peptide competition binding assay, it was discovered that 
the two antagonists, PMX53 and NDT9513727, used in the pA2 analyses bind to 
different locations on the C5a1 receptor.  This finding is in accordance with the 
observation set out by Waters et al. (2005), who demonstrated that traditional small 
molecules of the C5a1 receptor, rely of a tryptophan residue at position 213.  Based 
on the high lipophilicity of these small molecules, it is probable that this residue and 
associated binding pocket are orientated away from the hydrophilic binding pocket 
of C5a, where PMX53 binds, and towards the lipophilic cell membrane. 
In summary, the data presented in this chapter demonstrate that key electrostatic 
interactions with amino acid residues in the TM region of the C5a1 receptor control 
the affinity and efficacy of C5a and C5a des Arg.  Although both peptide agonists 
display the same G-protein activation signature, C5a des Arg does not promote the 
recruitment of -arrestin to the C5a1 receptor or subsequently induce receptor 
desensitization.  Therefore the biased agonism profile induced by C5a des Arg is 
probably due to both its reduced affinity for the C5a1 receptor and its ability to 
promote a different receptor conformation to the one induced by C5a. 
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7.1. Final discussion 
 
The complement system forms an essential component of the immune system that 
protects multicellular organisms from microbial invasion.  This complex network of 
soluble and membrane bound proteins orchestrates a fast and localized immune 
response, that is able to distinguish between host and pathogenic surfaces.  
However, dysregulation of the complement system can lead to it actions being 
directed towards the host, resulting in disease.  For this reason, numerous attempts 
have been made to therapeutically target the effector functions of the complement 
system.  More specifically, a great deal of effort has focused on preventing the 
actions of the anaphylatoxin, C5a, via the C5a1 receptor.  However, to date no agent 
targeting this axis has delivered clinical efficacy in diseases associated with over 
activation of the complement system. 
The main objective of the research conducted in this thesis was to provide a better 
understanding as to functions of C5a and its cleaved isoform C5a des Arg and the 
precise role of their two C5a receptors in controlling neutrophil function.  Such 
information would support future research efforts to develop therapies that target 
this component of the complement system to treat disease. 
An important observation from the results generated early on in this thesis, is that 
both C5a and C5a des Arg appear to have vastly different affinities for the C5a1 
receptor depending on the cell in which the receptor is expressed.  Both peptide 
agonists displayed a much greater affinity for the C5a1 receptor when overexpressed 
in immortalized cells compared with neutrophils.  Having a robust understanding of 
the true affinity of a peptide agonist for its receptor is of paramount importance, 
especially when designing a competitive receptor antagonist for the receptor to 
which it binds.  This increase in agonist affinity is probably due to the overexpressed 
receptors existing in a conformation which is more energetically favourable for C5a 
and C5a des Arg binding.  The concept of receptor conformational states and their 
impact on agonist binding can be explained using the two-state model of agonist-
receptor interaction and an understanding that G-protein coupled receptors act as 
allosteric vectors that transmit signals across a cell membrane.  According to the law 
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of mass action, an agonist (A) with affinity will bind to a receptor existing in an 
inactive state (R) at a rate defined by an affinity constant (KA).  Once bound, the 
agonist will induce a change in receptor conformation, promoting a 
thermodynamically distinct receptor state or active receptor state (AR*).  This active 
receptor will now interact with intracellular G-proteins and -arrestins subsequently 
activating intracellular signalling pathways (figure 4.11A) (Bridges et al., 2008; 
Kenakin, 2012).  This change in reactivity at the intracellular site of the receptor 
caused by energy imparted by an agonist binding to the extracellular site of the 
receptor is referred to as protein allosterism (Kenakin, 2009b).  In this case, the 
receptor acts as a conduit, allowing the transfer of energy between a modulator 
(agonist) and a guest (G-protein or -arrestin).  This allosteric transfer of energy is 
considered to be bi-directional where the intracellular proteins that interact with the 
receptor become the modulator and the agonist becomes the guest (figure 7.1).  
Both the CHO cell expressing the C5a1 receptor and the U2OS cell expressing the 
C5a2 receptor were also engineered to over-express intracellular signalling proteins, 
G16 and -arrestin-2 respectively.  It is therefore probable that the overexpression of 
these intracellular proteins, coupled with over-expression of each receptor, 
artificially enhanced the active state of each receptor, a conformational state that 
C5a and C5a des Arg promote and one that they have increased affinity for. 
One of the key objectives of this research was to shed light on the precise function of 
the C5a2 receptor.  This receptor has received much attention since its discovery 15 
years ago but the role it plays in controlling the actions of C5a and C5a des Arg still 
remains largely enigmatic.  In contrast to the observations made by Bamberg et al. 
(2010), I demonstrated that the C5a2 receptor is expressed on the surface of the non-
activated human neutrophils.  However, although the role of this receptor in C5a and 
C5a des Arg mediated neutrophil responses was assessed using a validated receptor 
neutralizing antibody, it did not appear to contribute directly to any of the functional 
responses investigated.  The only significant finding that was made regarding this 
receptor was that it appears to be removed from the surface of a neutrophil upon 
activation by inflammatory agents including TNF, C5a and C5a des Arg.   
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Figure 7.1. Intracellular pathway proteins and their impact on the affinity of receptor agonists 
According to the ‘two-state’ model of agonist-receptor interactions, an agonist (A) will bind to an 
inactive state receptor (R) at a rate defined by an affinity constant (KA).   Once bound, the agonist will 
induce and conformational change in the receptor promoting an active state (AR*), which will interact 
with G-proteins and other proteins which subsequently activate intracellular signalling pathways (A).  
This flow of energy from the agonist (modulator) through the receptor (conduit) to the intracellular G-
proteins (guest) is bi-directional (B).  The intracellular proteins can act as the modulator, transferring 
energy through the conduit and inducing an active-state receptor, a state to which the guest agonist 
displays higher affinity for (C). 
A 
C B 
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This observation may support the hypothesis set out by Scola et al. (2009) who 
claimed that the C5a2 receptor serves as a recycling decoy receptor to remove 
extracellular C5a des Arg. 
A significant amount of the research within this thesis focused on understanding how 
much of the functional activity of C5a is retained by C5a des Arg.  By testing both 
peptide agonists in a range of functional cell based assays, it became apparent that 
C5a des Arg displays biased agonism in the favour of promoting cellular phenotypes 
that enhance immune cell extravasation toward sites of infection.  However, its 
ability to induce cellular responses associated with microbial clearance and 
destruction, such as neutrophil respiratory burst, are significantly impaired.  
Although the biased response induced by C5a des Arg does not appear to be caused 
by the selective activation of specific G-proteins downstream of the C5a1 receptor, it 
may in part, be due to its inability to promote the recruitment of -arrestins to the 
C5a1 receptor.  Failure to recruit -arrestins prevents these proteins from fulfilling 
their receptor desensitizing function which was observed using the BioSens-AllTM 
platform.  This result supports the observations from neutrophil chemotaxis 
experiments where, unlike C5a, C5a des Arg failed to produce the typical, ‘bell-
shaped’, chemotactic response, a response often observed to chemokines.  Instead, 
C5a des Arg’s neutrophil chemotaxis profile is sustained and supports earlier 
observations made by Fernandez et al. (1978b)  who demonstrated that C5a des Arg 
is able to recruit a greater number of human neutrophils compared with C5a. 
Although C5a des Arg does not appear to induce a selective conformation of the C5a1 
receptor with respect to G-protein activation, it is possible that it does so with 
respect to the recruitment of -arrestins.  The only difference between C5a and C5a 
des Arg is a C-terminal arginine which was shown to electrostatically interact with 
Asp-282 that lies within the seventh TM domain of the C5a1 receptor.  It is therefore 
reasonable to suggest that the lack of interaction between C5a des Arg and this 
amino acid residue minimizes the movement of this part of the receptor.  This in turn 
may prevent the exposure of the receptors C-terminus, that lies at the bottom of this 
TM domain, to GRKs which would normally phosphorylate it and promote the 
recruitment of -arrestins.  Further work is required to test this hypothesis. 
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Another objective of this research was to understand the precise contribution of C5a 
to the neutrophil respiratory burst response.  It is often cited that C5a mediates this 
neutrophil response via the C5a1 receptor, which serves to destroy pathogenic 
microbes via the generation of HOCl.  Data presented here strongly suggest that C5a 
alone cannot produce the complete HOCl mediated respiratory response.  For this to 
occur, neutrophils require a prime to generate the precursor to HOCl, H2O2.  In the 
case of experiments described here, this prime was induced by TNF which, via the 
TNFR1 presumably activates NOX2 to generate O2
•–, which is converted to H2O2 by 
SOD.  The contribution of C5a to the respiratory burst response is therefore needed 
to promote the release of MPO from intracellular vesicles which, in a chlorine 
dependent manner, generates the powerful oxidizing agent HOCl from H2O2. 
Taken together, the results presented in this thesis suggests that a host protective 
mechanism has been evolutionary designed into the chemotactic capacity of the 
complement system.    C5a, which is continually produced by complement activation 
at the site of infection, permeates toward blood vessels where quiescent cells of the 
innate immune system circulate the body.  Due to the rapid actions of 
carboxypeptidases, the majority of this permeating trail of complement ligand is in 
the form of C5a des Arg.  Retaining immune cell extravasation properties, but devoid 
of respiratory burst activity, C5a des Arg induces the long range chemotaxis of 
neutrophils along its gradient without promoting the release of bactericide agents.  
Upon approaching the epicentre of the infection, newly produced C5a hones the 
accuracy of cellular migration by desensitizing the chemotaxis response.  Once 
primed with the local production of TNF by resident macrophages, C5a promotes 
the destruction of the microbial infection by stimulating the neutrophil respiratory 
burst response.  This dual mechanism required for respiratory burst focuses the 
release of bactericide agents at the site of infection and not along the migratory 
path, which if allowed to do so, would lead to tissue damage and disease.  
Furthermore, the apparent switching of receptor emphasis from C5a1 to FPR1 by 
locally produced TNF and C5a, may promote neutrophils to focus their efforts on 
removing host cells which have been damaged by local inflammation.  Upon 
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inflammation induced necrosis, host cells can release DAMPs in the form of N-formyl 
peptides which activate the FPR1. 
An overarching goal of this project was to improve the understanding of the function 
of the C5a/C5a des Arg-C5a1 receptor axis.  This in turn will support future drug 
discovery efforts that target this axis to treat complement associated diseases.  
Similar to the attempt made by Teva Pharmaceuticals Ltd, who tested the C5a1 
receptor cyclic peptide antagonist PMX53 in a clinical trial for RA.  Unfortunately 
PMX53 did not show any benefit in this patient population and the sponsors of this 
study concluded that antagonism of the C5a1 receptor does not result in reduced 
synovial inflammation in RA patients (Vergunst et al., 2007).  However, on closer 
inspection of the reported clinical data, it appears that this study did not adequately 
test the hypothesis that antagonizing the C5a1 receptor would ameliorate joint 
inflammation associated with RA.  In the published report of the findings from this 
study (Vergunst et al., 2007), pharmacokinetic analysis of the once daily dose of 
PMX53 (8 mg/kg) produced a mean AUC of 40.8 nmol h/L.  This concentration is four 
times higher than the 10 nmol h/L that they determined from in vitro 
experimentation would be sufficient to antagonise C5a at the C5a1 receptor.  
However, the mean AUC value relates to the total exposure achieved over the 24 
hour dosing interval and not the drug exposure at any one moment in time.  From a 
crude conversion of the AUC to average exposure, the total plasma concentration of 
PMX53 equates to 1.7 nmol/L which is approximately 6 fold lower than the 
concentration required to sufficiently antagonise C5a at the C5a1 receptor.  The poor 
systemic exposure from such a dose of PMX53 was probably due to the low oral 
bioavailability, which from rat pharmacokinetic analysis appears to be less than 1% 
(Morgan et al., 2008).  
It therefore appears that the PMX53 clinical trial failed because fundamental 
pharmacokinetic and pharmacodynamic principles were not met; that is, sufficient 
exposure at target site of action, sufficient target binding and evidence of functional 
pharmacological activity (Morgan et al., 2012).  It is often stated that greater than 
80% antagonist receptor occupancy is required to sufficiently block the effects of an 
agonist at a receptor (Bot et al., 2017).  As stated by the law of mass action, the 
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occupancy of a receptor by a ligand is proportional to the concentration and affinity 
of that ligand and can be calculated using equation 7.1.  For example, using the 
concentration of C5a that was detected in the joints of RA patients by (Jose et al., 
1990) of 2 nM and the affinity of C5a at the human neutrophil C5a1 receptor 
determined in Chapter 4 of 0.2 nM, the percentage of C5a1 receptors occupied by 
C5a is 90%. 
To determine the concentration of a competitive receptor antagonist, such as 
PMX53, required to reduce this agonist occupancy to 10%, the equation first 
described by Sir John Henry Gaddum can be used (Gaddum et al., 1955) (equation 
7.2).  Taking the estimate of affinity for PMX53 derived in chapter 3 of 10 nM, it is 
not until a concentration of 1 µM PMX53 is achieved that the C5a1 receptor 
occupancy by C5a is reduced to approximately 10%.  This concentration is 
approximately 600 fold greater than that achieved in the PMX53 clinical trial. 
The above equations assume that the functional response induced by C5a is 
proportional to its receptor occupancy.  However, for most agonist-receptor 
interactions this is not the case. In fact, agonists often achieve their maximal 
response when they occupy only a small proportion of the receptor population.  This 
phenomenon is known as receptor reserve (Grimwood et al., 2009) and is brought 
about by both attributes of the agonist ligand and the system in which the agonist is 
tested.  As well as affinity for a receptor, agonists also possess intrinsic efficacy, a 
property which describes the degree of stimulus that an agonist provides to a 
receptor.  The cellular expression of that receptor and the efficiency with which the 
receptor couples to intracellular signalling pathways determine the proportion of 
receptors that need to be occupied and activated to induce a maximal response.  
These components of intrinsic efficacy, receptor expression and receptor pathway 
coupling efficiency all relate to the signal transduction capacity of the agonist and 
receptor system and is often described by the arbitrary factor of Tau (), originally 
described by Black et al. (1983).  
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Equation 7.1. Quantifying agonist receptor occupancy. 
According to mass action, agonist receptor occupancy is proportional to its concentration and affinity.  
PAR = proportion of receptors occupied by agonist, [A] = concentration of agonist, KA = affinity of 
agonist. 
 
 
 
  
 
 
 
Equation 7.2. Quantifying competitive receptor antagonism. 
Competitive antagonism described by the Gaddum equation.  PAR = proportion of receptors occupied 
by agonist in presence of antagonist.  [A] = concentration of agonist, KA = affinity of agonist, [B] = 
concentration of antagonist, KB = affinity of antagonist [B]. 
 
 
 
[A]/KA 
PAR    = 
[A]/KA + [B]/KB + 1 
   [A]/KA 
PAR     =      
[A]/KA + 1 
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Therefore with the knowledge obtained from the results presented in this thesis 
regarding the signalling capacity of C5a des Arg and the differential affinity of a 
competitive receptor antagonist, with assistance from Dr Terry Kenakin, I have 
developed a model to predict the composite response of C5a and C5a des Arg in the 
absence and presence of a competitive receptor antagonist (equation 7.3).  Using 
values of agonist affinity (KA) and efficacy () derived from the fitting of the 
operational model of agonism to the neutrophils functional data (appendix 2), and 
estimates of antagonist affinity against the two agonists, the effect of different 
concentrations of antagonist on the composite agonist response can be simulated. 
A simulation using the composite agonist response model can be seen in figure 7.3.  
In this simulation, values of KA and  were derived for both C5a and C5a des Arg from 
the operational model of agonism fit to the human isolated neutrophil chemotaxis 
data generated in chapter 5.  Affinity values of a competitive receptor antagonist 
were chosen so that the antagonist affinity was 10 fold greater against C5a des Arg 
than C5a (1 and 10 nM respectively), as observed in chapter 6.  Concentrations of 
C5a and C5a des Arg were set at 1 and 4 nM respectively so that C5a equated to 20% 
of the total peptide ligand concentration.  The simulations predict that C5a and C5a 
des Arg will produce a fractional composite chemotaxis response of 0.76 in the 
absence of a competitive antagonist.  In the presence of 10 nM of a competitive 
receptor antagonist, the fractional composite chemotaxis response is only reduced to 
0.75.  Increasing the antagonist concentration to 100 nM further reduced the 
composite response to 0.53, but it is not until a concentration of 1 µM of antagonist 
is used, which is 100 and 1000 fold the C5a and C5a des Arg affinity respectively, that 
the composite chemotaxis response is reduced to approximately 0.1.  These 
simulations, using the composite agonist response model, further suggest that the 
clinical exposures of PMX53 in the RA trial were not high enough to sufficiently 
antagonise the actions of C5a and C5a des Arg at the C5a1 receptor. 
 
 
 192 
 
The main aim of the research outlined in this thesis was to improve the 
understanding of the precise role of the Complement System peptide ligands C5a 
and C5a des Arg and their receptors, C5a1 and C5a2, in orchestrating neutrophil 
responses.  Although this research was unable to shed further light on the precise 
function of the C5a2 receptor, it did demonstrate that this receptor does not appear 
to regulate C5a mediated adhesion molecule expression, chemotaxis or respiratory 
burst responses in the human isolated neutrophil.  This research did determine the 
precise contribution of C5a-C5a1 receptor axis to the neutrophil respiratory burst 
response and the requirement of a neutrophil prime via the TNFR1 to induce a full 
respiratory burst response.   It also demonstrated that the cleaved C5a peptide 
fragment, C5a des Arg, retains a significant degree of functional activity which 
appears to be aligned to the orchestration of immune cell extravasation.  The biased 
agonist profile of C5a des Arg is due to its lack of interaction with the seventh 
transmembrane domain of the C5a1 receptor, which promotes a receptor 
conformation that displays a reduced interaction with -arrestin 2.  Lastly, the results 
presented in this thesis have supported the development of a composite agonist 
model, that will enable the selection of more appropriate doses of competitive C5a1 
receptor antagonists to treat diseases associated with over activation of the 
complement system.  
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Equation 7.3. Model to predict a composite agonist response 
[C5a] = concentration of C5a, KC5a = KA of C5a, C5a = efficacy of C5a in a test system, [C5a-dA] = 
concentration of C5a des Arg, KC5a-dA = KA of C5a, C5a-dA = efficacy of C5a des Arg in a test system, [B] = 
concentration of antagonist, KB-C5a = affinity of antagonist for blocking C5a response, KB-C5a-dA = affinity 
of antagonist for blocking C5a des Arg response. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. Composite agonist response model simulations 
Simulation of the composite agonist response induced by C5a and C5a des Arg in the absence and 
presence of a competitive C5a1 receptor antagonist as defined by equation 7.3.  Simulations of the 
C5a and C5a des Arg composite response using the parameters obtained from the fitting of the 
operational model of agonism to the neutrophil chemotaxis data (appendix 2).  All concentrations in 
nM. 
C5a 8 taua
C5a-dA 3
KC5a= 0.80 kay
KC5a-dA= 0.20
KB-C5a= 10.00 kaybe1
KB-C5a-dA= 1.00
C5a C5a-dA
[C5a] [C5a-dA] [B]
Fraction 
composite 
response
1 1 4 0 0.759
2 1 4 10 0.752
3 1 4 100 0.534
4 1 4 1000 0.133
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Appendix 
 
Appendix 1 
C5a receptor sequence confirmation. 
Translated amino acid sequence for the recombinant C5a1 receptor (A), C5a2 receptor (B) and their 
alignment to published amino acid sequences.  Amino acid sequence alignment was performed using 
the Life Technologies Vector NTi application. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A)     
                       1                                               50 
C5a1_PCR  (1) MNSFNYTTPDYGHYDDKDTLDLNTPVDKTSNTLRVPDILALVIFAVVFLV 
Human C5a1 NP_001727  (1) MNSFNYTTPDYGHYDDKDTLDLNTPVDKTSNTLRVPDILALVIFAVVFLV 
Consensus  (1) MNSFNYTTPDYGHYDDKDTLDLNTPVDKTSNTLRVPDILALVIFAVVFLV 
                           51                                             100 
C5a1_PCR (51) GVLGNALVVWVTAFEAKRTINAIWFLNLAVADFLSCLALPILFTSIVQHH 
Human C5a1 NP_001727 (51) GVLGNALVVWVTAFEAKRTINAIWFLNLAVADFLSCLALPILFTSIVQHH 
            Consensus (51) GVLGNALVVWVTAFEAKRTINAIWFLNLAVADFLSCLALPILFTSIVQHH 
                           101                                            150 
C5a1_PCR (101)HWPFGGAACSILPSLILLNMYASILLLATISADRFLLVFKPIWCQNFRGA 
Human C5a1 NP_001727 (101)HWPFGGAACSILPSLILLNMYASILLLATISADRFLLVFKPIWCQNFRGA 
            Consensus (101)HWPFGGAACSILPSLILLNMYASILLLATISADRFLLVFKPIWCQNFRGA 
                           151                                            200 
C5a1_PCR (151)GLAWIACAVAWGLALLLTIPSFLYRVVREEYFPPKVLCGVDYSHDKRRER 
Human C5a1 NP_001727 (151)GLAWIACAVAWGLALLLTIPSFLYRVVREEYFPPKVLCGVDYSHDKRRER 
           Consensus (151)GLAWIACAVAWGLALLLTIPSFLYRVVREEYFPPKVLCGVDYSHDKRRER 
                           201                                            250 
C5a1_PCR (201)AVAIVRLVLGFLWPLLTLTICYTFILLRTWSRRATRSTKTLKVVVAVVAS 
Human C5a1 NP_001727 (201)AVAIVRLVLGFLWPLLTLTICYTFILLRTWSRRATRSTKTLKVVVAVVAS 
            Consensus (201)AVAIVRLVLGFLWPLLTLTICYTFILLRTWSRRATRSTKTLKVVVAVVAS 
                           251                                            300 
C5a1_PCR (251)FFIFWLPYQVTGIMMSFLEPSSPTFLLLNKLDSLCVSFAYINCCINPIIY 
Human C5a1 NP_001727 (251)FFIFWLPYQVTGIMMSFLEPSSPTFLLLNKLDSLCVSFAYINCCINPIIY 
            Consensus (251)FFIFWLPYQVTGIMMSFLEPSSPTFLLLNKLDSLCVSFAYINCCINPIIY 
301                                            350 
C5a1_PCR (301)VVAGQGFQGRLRKSLPSLLRNVLTEESVVRESKSFTRSTVDTMAQKTQAV 
Human C5a1 NP_001727 (301)VVAGQGFQGRLRKSLPSLLRNVLTEESVVRESKSFTRSTVDTMAQKTQAV 
   Consensus (301)VVAGQGFQGRLRKSLPSLLRNVLTEESVVRESKSFTRSTVDTMAQKTQAV 
 
(B) 
 1                                               50 
C5a2_PCR   (1)MGNDSVSYEYGDYSDLSDRPVDCLDGACLAIDPLRVAPLPLYAAIFLVGV 
Human C5a2 NP_060955   (1)MGNDSVSYEYGDYSDLSDRPVDCLDGACLAIDPLRVAPLPLYAAIFLVGV 
 Consensus   (1)MGNDSVSYEYGDYSDLSDRPVDCLDGACLAIDPLRVAPLPLYAAIFLVGV 
                           51                                             100 
 C5a2_PCR  (51)PGNAMVAWVAGKVARRRVGATWLLHLAVADLLCCLSLPILAVPIARGGHW 
 Human C5a2 NP_060955  (51)PGNAMVAWVAGKVARRRVGATWLLHLAVADLLCCLSLPILAVPIARGGHW 
Consensus  (51)PGNAMVAWVAGKVARRRVGATWLLHLAVADLLCCLSLPILAVPIARGGHW 
          101                                            150 
C5a2_PCR (101)PYGAVGCRALPSIILLTMYASVLLLAALSADLCFLALGPAWWSTVQRACG 
 Human C5a2 NP_060955 (101)PYGAVGCRALPSIILLTMYASVLLLAALSADLCFLALGPAWWSTVQRACG 
        Consensus (101)PYGAVGCRALPSIILLTMYASVLLLAALSADLCFLALGPAWWSTVQRACG 
                   151                                            200 
C5a2_PCR (151)VQVACGAAWTLALLLTVPSAIYRRLHQEHFPARLQCVVDYGGSSSTENAV 
 Human C5a2 NP_060955 (151)VQVACGAAWTLALLLTVPSAIYRRLHQEHFPARLQCVVDYGGSSSTENAV 
          Consensus (151)VQVACGAAWTLALLLTVPSAIYRRLHQEHFPARLQCVVDYGGSSSTENAV 
                  201                                            250 
C5a2_PCR (201)TAIRFLFGFLGPLVAVASCHSALLCWAARRCRPLGTAIVVGFFVCWAPYH 
Human C5a2 NP_060955 (201)TAIRFLFGFLGPLVAVASCHSALLCWAARRCRPLGTAIVVGFFVCWAPYH 
          Consensus (201)TAIRFLFGFLGPLVAVASCHSALLCWAARRCRPLGTAIVVGFFVCWAPYH   
251                                            300 
C5a2_PCR (251)LLGLVLTVAAPNSALLARALRAEPLIVGLALAHSCLNPMLFLYFGRAQLR 
 Human C5a2 NP_060955 (251)LLGLVLTVAAPNSALLARALRAEPLIVGLALAHSCLNPMLFLYFGRAQLR 
          Consensus (251)LLGLVLTVAAPNSALLARALRAEPLIVGLALAHSCLNPMLFLYFGRAQLR 
                            301                               337 
         C5a2_PCR (301)RSLPAACHWALRESQGQDESVDSKKSTSHDLVSEMEVXXXXXXXXXXXXX 
Human C5a2 NP_060955 (301)RSLPAACHWALRESQGQDESVDSKKSTSHDLVSEMEVXXXXXXXXXXXXX 
         Consensus (301)RSLPAACHWALRESQGQDESVDSKKSTSHDLVSEMEVXXXXXXXXXXXXX 
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Appendix 2 
Using a Microsoft Excel tool developed by Dr Terry Kenakin, the Operational Model 
of Agonism was fit to the neutrophil functional data from chapter 5.  Estimates of 
affinity (KA) agonist efficacy () were obtained for both C5a and C5a des Arg in each 
neutrophil assay system.  These parameters were used in the modified Gaddum 
equation, described in the final discussion, to understand the composite neutrophil 
response induced by combinations of C5a and C5a des Arg in the absence and 
presence of a competitive C5a1 receptor antagonist. 
The Black & Leff Operational Model of Agonism: 
 
 
 
 
Where: 
[A] = Agonist concentration 
 (tau) = Efficacy of an agonist which is made up of both the intrinsic efficacy of the 
agonist and the sensitivity of the biological system.  
Emax = Maximal response capability of the system 
KA = The equilibrium dissociation constant for the agonist (affinity) 
 
 
 
 
Response  =  
[A]E
max
 
[A]( + 1) + K
A
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The Operational Model of Agonism fit to the neutrophil functional data to obtain 
estimates of KA and . 
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